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Abstract  
Epstein-Barr virus (EBV) and human herpesvirus-6 (HHV-6) are ubiquitous herpesviruses 
that cause infection in immunocompetent and immunocompromised individuals. Following 
initial infection, the viruses persist life-long in various cells in the host, only to reactivate 
during periods of immunosuppression. In healthy individuals, primary infection is 
controlled by the host immune system and produces either subclinical or self-limiting and 
mild disease. However, in those with impaired cellular immunity (e.g. HIV/AIDS and 
transplant recipients), the viruses cause acute diseases associated with high morbidity and 
mortality. Sensitive and accurate diagnostic tests are therefore essential in the detection 
and quantification of EBV and HHV-6 infection. Serological detection of virus-specific 
serum antibodies is performed to determine the infection status of an individual (e.g. 
current versus past infection), but is less reliable in those with immune system 
derangements and malignancies. Nucleic acid testing using polymerase chain reaction 
(PCR) is suitable for testing immunocompetent and immunocompromised populations, and 
has become gold standard for the detection of most viruses including EBV and HHV-6.  
 
In asymptomatic healthy individuals, the burden of virus (viral load) is often undetectable 
or present at low levels. However, in those with symptomatic disease, viral load often 
correlates with the clinical status of the patient. A surge in viral load is associated with 
worsening of symptoms, while a decline in viral load usually reflects clinical improvement. 
Quantitative PCR (qPCR) using the standard curve method is useful for diagnosing and 
monitoring viral infections (e.g. HIV, hepatitis B and C infections) by enabling the 
absolute measurement of viral nucleic acid in a given sample. For EBV and HHV-6, 
commercial qPCR assays that incorporate fluorogenic probes are available, but are 
expensive and less suitable for large-scale studies. Non-sequence-specific detection 
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formats such as the use of the double-stranded DNA binding dye, SYBR Green I, are 
equally as sensitive, inexpensive, and may be easily incorporated into any assay design. As 
such, SYBR Green I dyes are often used for in-house quantification for EBV and HHV-6. 
 
This thesis describes the development of three separate in-house qPCR assays for the 
detection and quantification of EBV and HHV-6 DNA in various specimen types from 
both clinical and research cohorts. This involved PCR amplification of two EBV and one 
HHV-6 DNA target, plus the reference control gene, β-globin. The clinical group tested 
included hospitalised individuals with EBV- or HHV-6-related diseases and at-risk 
populations (e.g. HIV-infected individuals and transplant recipients). The research group 
consisted of case-control participants from a sub-study of the Ausimmune Study that 
investigated the role of EBV and HHV-6 infection in individuals with a first clinical 
diagnosis of central nervous system demyelination, a precursor to multiple sclerosis (MS); 
and a subset of MS subjects from the Southern Tasmanian MS Longitudinal Study.  
 
Results showed that the qPCR assays were sensitive and accurate at detecting and 
quantifying EBV and HHV-6 DNA. This was evident by our performance in external 
quality assurance programs and the generation of viral DNA loads that were comparable 
with those reported in the literature for similar diseases. Application of these methods to 
The Ausimmune Study found no significant differences in EBV detection (positivity) and 
quantification (viral load) between cases with a first clinical diagnosis of CNS 
demyelination (FCD) versus case-matched (by age, sex and region) controls. EBV 
quantitative serology was also performed and showed significantly higher antibody titres 
(for EBNA-1, VCA and EA-R IgG) for the FCD cases compared with the controls, and a 
28% increase in the odds of being a FCD case with a doubling of EBNA-1 IgG antibody 
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titres. In general, markers of past EBV infection (EBV-specific IgG antibodies and a 
history of infectious mononucleosis) rather than markers of current infection (DNA 
positivity and load) were associated with an increased risk of being an FCD case. In 
preliminary investigations, HHV-6 DNA positivity and load were shown to be twice as 
high in FCD cases compared with controls, but the data was not adjusted for possible 
confounders and were driven entirely by a small proportion of cases that had extremely 
high HHV-6 viral loads.  
 
EBV and HHV-6 DNA positive samples in this thesis were also sequenced with the aim of 
identifying the genotype and strains circulating within these groups. Two EBV genotypes 
represented by four EBV strains were identified at different frequencies, genotype A 
(98.2%: GD1, B95-1, M-ABA) and genotype B (1.8%: AG876). Of the two HHV-6 
species, HHV-6B, strain HST was the most frequently detected in all groups at 96.6%; and 
HHV-6A, strain U1102 was the least common at 3.6%. There was no evidence of disease-
specific EBV or HHV-6 genotypes or strains in the groups examined. 
 
Overall, the work described herein demonstrates sensitive and accurate SYBR Green I-
based qPCR assays that were suitable for EBV and HHV-6 detection and quantification in 
both immunocompetent and immunocompromised individuals. The molecular work 
showed mixed associations with initial diagnosis of CNS demyelination: EBV 
investigations at the onset of clinical disease indicated that EBV DNA might not be of 
major diagnostic importance as previously hypothesised, whereas raw HHV-6 DNA data 
suggested possible associations. The identification of EBV and HHV-6 genotypes and 
strains has provided insights into the molecular epidemiology and diversity of EBV and 
HHV-6 infection in Australia.  
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XXIII 
 
A guide to the thesis  
This thesis contains published and unpublished works. The first chapter comprises a 
literature review that provides a detailed summation of the current research into Epstein-
Barr virus (EBV) and human herpesvirus-6 (HHV-6) in the context of the central nervous 
system (CNS) demyelinating disease, multiple sclerosis (MS). This chapter contributes to a 
review article examining the role of EBV in MS (Publication 1; Lucas et al, 2011). Chapter 
2 outlines the materials and methods employed in this thesis with the assay design, 
development and optimisation process following in Chapter 3. Chapter 4 describes the 
development and assessment of an in-house quantitative polymerase chain reaction (qPCR) 
assay for the detection and quantification of EBV DNA. This qPCR assay was applied to 
research and clinical groups, consisting of individuals with and without initial CNS 
demyelination and EBV-related disease to investigate the DNA activity (presence or 
positivity, and viral load) in these subjects. This work led to two separate publications 
(Publication 2; Lay et al, 2010 and Publication 3; Lucas, 2011). Chapter 5 describes the 
development of an in-house qPCR assay for the detection and quantification of HHV-6 
DNA in the same research samples and a clinical group with HHV-6-related disease. The 
research samples in Chapters 4 and 5 originated from the viral infection sub-study of The 
Ausimmune Study, a national project established to investigate the role of the environment 
in respect to immune diseases. Chapter 6, partly published as an original article 
(Publication 4; Lay et al, 2012) and presented in chapter form (manuscript in preparation), 
explores the EBV and HHV-6 genotypes and strains in the above-mentioned populations. 
Chapter 7 discusses the findings from Chapters 4, 5 and 6, highlights the key strengths, 
acknowledges the project limitations and considers the possible future research directions. 
The thesis concludes with Chapter 8, which contains general appendices covering other 
relevant data. A list of references is included at the end of each chapter and/or manuscript. 
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Chapter 1 
Literature Review 
 
Contains 
(Publication 1) 
Lucas RM, Hughes AM, Lay ML, Ponsonby AL, Dwyer DE, Taylor BV, et al. Epstein-
Barr Virus and Multiple Sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 
2011;82(10):1142-1148. 
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 The Herpesviridae family 1.1
The Herpesviridae family is a diverse group of double stranded DNA (dsDNA) viruses 
that colonise all vertebrates from birds, fish and reptiles to mammals (1, 2). In the current 
International Committee for Taxonomy of Viruses (ICTV) report (2012) (3), the 
Herpesviridae family is divided into three subfamilies based on genetic and biologic 
similarities (1, 4). These are:  
 α-herpesvirinae (including the assigned genera: Iltovirus, Mardivirus, Scutavirus, 
Simplexvirus and Varicellovirus); 
 β-herpesvirinae (genera: Cytomegalovirus, Muromegalovirus, Proboscivirus and 
Roseolovirus);  
 γ-herpesvirinae (genera: Lymphocryptovirus, Macavirus, Percavirus and 
Rhadinovirus)  
 
It has been estimated that these subfamilies evolved between 180 and 220 million years 
ago, with subdivisions into genera occurring in the last 80 million years (1). To date, 
eight herpesviruses are known to infect humans: herpes simplex virus-1 (HSV-1) and 
herpes simplex virus-2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), 
human cytomegalovirus (CMV), human herpesvirus-6 (HHV-6), human herpesvirus-7 
(HHV-7) and Kaposi sarcoma-associated herpesvirus (KSHV or HHV-8) (Table 1) (4, 5). 
 
Table 1. ICTV Herpesvirus classification 
 
Subfamily Genus Species Common name 
    
α-herpesvirinae Simplexvirus  HHV-1 Herpes simplex virus-1 
HHV-2 Herpes simplex virus-2 
Varicellovirus HHV-3 Varicella zoster virus 
β-herpesvirinae  
 
Cytomegalovirus HHV-5 Cytomegalovirus 
Roseolovirus HHV-6* Human herpesvirus-6 
HHV-7 Human herpesvirus-7 
γ-herpesvirinae  
 
Lymphocriptovirus  HHV-4 Epstein-Barr virus 
Rhadinovirus  HHV-8 Kaposi sarcoma-associated herpesvirus 
Abbreviations: HHV, human herpesvirus. 
*HHV-6 recently further divided into species A and B (3); http://www.hhv-6foundation.org/featured/hhv-6a-
and-hhv-6b-to-be-recognized-as-two-distinct-viruses. 
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Herpesvirus identification is based on three classifications: structure, genome 
organisation and biology. All herpesviruses are architecturally identical. Each consists of 
four concentric layers of a core, capsid, tegument and an envelope (Figure 1) (6). The 
core contains a single copy of a linear dsDNA molecule that ranges from 100 to 225 kb in 
length, and encodes for 100 to 200 genes (2). Protecting the core is an icosahedral capsid 
made of 162 hollow-centered capsomeres about 100 nm in diameter. Together, the core 
and the capsid are called the nucleocapsid. Between the capsid and the lipid bilayer 
envelope is an amorphous layer of proteins known as the tegument. Protruding from the 
envelope are glycoprotein spikes.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of a typical herpesvirus virion  
All herpesviruses have a core with dsDNA, capsid, tegument and an envelope (with glycoproteins).  
Original image modified from: http://www.agefotostock.com/en/Stock-Images/Royalty-Free/MED-
MedRF-29139. 
 
The genome is organised into two main regions: unique short (US) and unique long (UL) 
segments. Within these regions are internal repeats that allow for genome 
rearrangements, and many repeated sequences that contribute to size variation between 
herpesvirus strains. 
Glycoprotein spike 
Envelope 
Tegument 
Double-stranded DNA core  
 
Capsid 
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Herpesviruses have four distinguishing biological features (7, 8): 
1. A large number of enzymes that are expressed for nucleic acid metabolism (e.g. 
thymidine kinase), replication (e.g. DNA polymerase), DNA synthesis (e.g. DNA 
helicase/primase) and protein processing (e.g. protein kinase)  
2. The synthesis of viral genomes and assembly of capsids occurs in the nucleus  
3. The productive infection is complemented by destruction of the host cell  
4. The ability to establish latency and reactivate during low cellular immunity 
 
Although biologically similar, each herpesvirus has tropism towards distinct cell types, 
has preferred sites of persistence and is associated with different disease conditions. The 
differences in clinical and biological characteristics are shown in Table 2. 
 
Table 2. Clinical and biological characteristics of the eight human herpesviruses 
Abbreviations: CMV, cytomegalovirus; EBV, Epstein-Barr virus; HSV-1, herpes simplex virus-1; HSV-2, herpes simplex virus-2; HHV-
6, human herpesvirus-6; HHV-7, human herpesvirus-7; VZV, varicella zoster virus. 
 
 
Human 
herpesvirus 
Disease 
associations 
Cellular tropism Latency site Seroprevalence 
% (adults) 
References 
HSV-1 
 
Gingivostomatitis, 
fevers, blisters, 
encephalitis 
Mucosal epithelium, 
neuronal cells 
Neurons 50-90% (5, 9) 
HSV-2 Genital sores, 
encephalitis 
Mucosal epithelium, 
neuronal cells 
Neurons 15-95% (5, 9) 
VZV Chicken pox, shingles, 
encephalitis 
Respiratory epithelium, 
T cells, squamous 
epithelium 
Neurons 90-100% (5, 9) 
EBV Mononucleosis, 
cancers 
Oral epithelium B cells, salivary 
glands 
90-100% (5, 9) 
CMV Mononucleosis, 
retinitis, pneumonia 
Mucosal epithelium Monocytes, 
epithelial cells, 
salivary glands, 
smooth muscle 
cells 
50-100% (5, 9) 
HHV-6 
 
Exanthem subitum, 
hepatitis, encephalitis 
Mucosal epithelium, 
neuronal cells 
Monocytes, T cells, 
salivary glands 
90-100% (5, 9) 
HHV-7 Exanthem subitum Mucosal epithelium Monocytes, T cells, 
salivary glands 
85-100% (5, 9) 
Kaposi 
sarcoma-
associated 
herpesvirus 
Kaposi sarcoma Unknown B cells, endothelial 
cells 
5-50% (5, 9) 
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 Epstein-Barr virus 1.2
First discovered by Epstein and Achong in 1964 in B cells from a patient with African 
Burkitt’s lymphoma (BL) (10-12), EBV is a ubiquitous γ-herpesvirus that causes 
infectious mononucleosis (IM), an acute but self-limiting disease of young adults. In the 
developing world, EBV seropositivity approaches 100% in the first decade of life (13); in 
developed regions, exposure to EBV occurs relatively late and between 50% and 70% of 
adolescents and young adults are EBV seropositive (14). Transmitted through saliva, 
EBV primarily infects B cells (15), but has also been shown to infect other cell types 
such as T cells (including various subpopulations), natural killer (NK) cells, plasma cells, 
squamous and glandular epithelial cells, monocytes/macrophages, smooth muscle cells, 
endothelial cells, and follicular dendritic cells (16-24). Replication occurs in the 
oropharyngeal epithelium, followed by infection of dormant B cells in the pharynx, 
where EBV is immortalised and persists lifelong (25). In immunocompetent individuals, 
EBV infection is often asymptomatic or causes minor clinical disease, but in the 
immunocompromised, EBV infection may reactivate to cause serious, and sometimes 
life-threatening diseases (26, 27).  
 
 1.2.1 The EBV genome 
The EBV genome spans approximately 170 kb in length and consists of 84 open reading 
frames (ORFs) and terminal repeats (TR) that flag both ends (28) (Figure 2). Internal 
repeats (IR) further divide the genome into four large unique regions, IR1-4. IR1 lies 
between the US and UL regions, while IR2, 3 and 4 lie within the UL region (29). Within 
the IR1 region are promoters, Cp or Wp, that control the latency genes and are important 
for the initial infection of B cells (28). EBV is unique from α-herpesvirus in that 
isomerization does not occur (i.e. EBV has a single arrangement only ‘US-IR1-UL’). The 
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number of IR and TR regions is stable for a given genotype, but varies between strains 
(e.g. B95.8 is 171.82 kb whereas AG876 is 172.76 kb) (29). 
 
                            
 
       
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. EBV genome arrangement in linearised and circularised forms  
A. (i) Linearized EBV genome showing the terminal repeats (TR), unique short (US), unique long (UL) and 
internal repeat 1 (IR1) region; (ii) Circularised EBV genome B. EBV genome arrangement based on 
prototype B95-8 strain: (i) Diagram showing the location and transcription of the EBV latent genes in a 
dsDNA episome; (ii) Diagram showing the location of open reading frames (ORFs) for EBV latent 
proteins on a BamHI restriction endonuclease map. Note: The BamHI fragments are named according to 
size, with ‘A’ being the largest, lowercase letters being the smallest fragments and Nhet denoting the 
heterogeneity region due to the variable number of TRs in different virus isolates and in different clones of 
EBV-infected cells. Image from: http://www.nature.com/nrc/journal/v4/n10/images/nrc1452-f1.jpg. 
 B. (i) 
    (ii) 
A. (i) 
(ii) 
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Epstein-Barr virus genes encode for nearly 100 viral proteins important for gene 
expression, replication, formation of structural components and modulation of the host 
immune response (30). Different sets of genes are expressed to establish different types 
of infection. For example, in lytic infection, about 70 proteins are expressed (31). These 
are classified into immediate-early, early and late lytic proteins (32). In latent infection, 
12 genes are expressed in four distinct latency patterns, 0, I, II and III (31, 33). Latency 
patterns I, II and III are found in EBV-related diseases, whereas latency pattern type 0 is 
found in dormant EBV-infected B cells in healthy individuals (Table 3).  
 
Table 3. Patterns of latent EBV gene expression in different EBV-related 
malignancies 
Latency pattern EBV genes expressed EBV-related disease References 
    
Latency 0/True latency EBER-1, EBER-2, EBNA-1*, 
LMP-2A, BART* 
Dormant B cells in healthy carriers (31, 33, 34) 
Latency I/Latency 
Program 
EBER-1, EBER-2, EBNA-1, 
BART, BARF0 
Burkitt’s lymphoma, gastric 
carcinoma 
(32-35) 
 
Latency II/Default 
Program 
EBER-1, EBER-2, EBNA-1, 
LMP-1, LMP-2A, LMP-2B, BART 
Hodgkin lymphoma, nasopharyngeal 
carcinoma 
(31-36) 
 
Latency III/Growth 
Program 
EBER-1, EBER-2, EBNA-1, 
EBNA-2, EBNA-3 (A, B and C), 
LMP-1, LMP-2A, LMP-2B, 
EBNA-LP, BART, BARF0 
Post-transplant lymphoproliferative 
disease, infectious mononucleosis, 
AIDS-associated lymphomas 
(31-36) 
 
Abbreviations: AIDS, acquired immunodeficiency syndrome; BARF0, BamHI1 fragment A with a 3′ terminal open 
reading frame, BARTs, BamH1 fragment A rightward transcripts. EBER, Epstein–Barr virus encoded small RNAs; EBNA, 
Epstein–Barr nuclear antigen; EBV, Epstein-Barr virus; LMP, latent membrane protein; LP, leader protein  
* Gene may or may not be expressed (30, 34) 
 
 
 1.2.2 Biology of EBV infection  
Epstein-Barr virus virions enter the oropharynx via saliva and infect dormant B cells by 
binding the glycoprotein receptor gp350 to the host complement receptor 2, CD21 (also 
known as CR2). Also important to this process is a viral glycoprotein, gp42, which binds 
to a major histocompatibility complex (MHC) class II molecule via the 1
 
domain of the 
human leucocyte antigen (HLA) class II protein, HLA-DR (37, 38). Overall, these 
binding actions trigger endocytosis of the virus and subsequent entry into the host cell. 
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EBV virions then migrate into the host nucleus where they transform from a linear 
structure to a circular episome (27). At this point, two infection courses are possible: lytic 
and latent infection, each of which is mediated by the expression of different proteins 
(Table 4). 
 
Table 4. List of EBV lytic and latent proteins and their functions 
 
Abbreviations: BARTs, BamH1 A rightward transcripts; Bcl-2, B cell lymphoma-2; BCRF-1, BamHI fragment C rightward 
open reading frame-1; BHRF-1, BamHI fragment H rightward open reading frame-1; BRLF-1, BamHI fragment R leftward 
open reading frame-1; BZLF-1, BamHI fragment Z leftward open reading frame-1; EBER, Epstein–Barr virus encoded 
small RNAs; EBNA, Epstein–Barr nuclear antigen; IL, interleukin; LMP, latent membrane protein; LP, leader protein; OriP, 
origin of plasmid replication. 
 
 
Lytic infection is characterised by the production of free virions and high-level shedding 
of the virus into the oropharynx (38). Here, EBV-infected B cells express the immediate-
early proteins, BZLF-1 and BamHI fragment R leftward open reading frame-1 (BRLF-1), 
that mediate the switch from latency to the lytic cycle (39). These proteins trigger a 
cascade of events including the sequential expression of early and late proteins as well as 
EBV lytic genes Function References 
    
BZLF 1 Viral transactivator that mediates the switch from latency to the lytic cycle, 
triggers cascade of events that leads to the sequential expression of early 
and late viral proteins as well as down regulating some latent genes  
(39) 
BRLF 1 Viral transactivator that mediates the switch from latency to the lytic cycle, 
triggers cascade of events that lead to the sequential expression of early 
and late viral proteins as well as down regulating some latent genes 
(39) 
BCRF 1 Encodes a protein with homology to human IL-10; downregulation of host 
immune responses during EBV replication, activation factor for B cells 
(35, 39) 
BHRF 1 Encodes a Bcl-2 like protein that protects EBV-infected cells from apoptosis (35, 39) 
EBV latent genes Function References 
    
EBER 1 and 2 Possible role in translation regulation, viral latency stabilisation  (35, 39, 40) 
EBNA 1 Immortalisation, binds to OriP to initiate genome replication, segregation 
of viral episomes, genome maintenance 
(35, 36, 39) 
 2 Transcription co-activator, expression of viral and cellular genes (35, 36, 39) 
 3A Immortalisation, EBNA-2 antagonist, disrupts cell cycle, regulation of CD21 
receptor 
(35, 36, 39) 
 3B Function mostly unknown, possibly an EBNA-2 antagonist  (35, 36, 39) 
 3C Immortalisation, EBNA-2 antagonist, disables cell cycle check points, 
increases production of LMP1 
(35, 36, 39) 
 LP Interacts with EBNA-2 and transcription factors, redistributes EBNA-3A in 
nucleus, immortalisation 
(35, 36, 39) 
LMP 1 Viral oncogene, mimics CD40 ligand, increases Bcl-2 levels for cell survival, 
immortalisation 
(35, 36, 39) 
LMP 2A and 2B Viral oncogene, drives cell into latency, survival factor (35, 36, 39) 
BARTs  Function mostly unknown, inhibits viral reactivation, possible viral 
oncogene 
(35) 
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the downregulation of some latent genes, culminating in cell death and release of 
infectious virions (39). Also important in lytic infection are the proteins BamHI fragment 
C rightward open reading frame-1 (BCRF-1) and BamHI fragment H rightward open 
reading frame-1 (BHRF-1), both of which encode homologues of human genes (39). The 
BCRF-1 gene is expressed late in the lytic cycle and encodes a protein similar to human 
interleukin-10 (IL-10) (39). The BCRF-1 product is thought to downregulate the host 
immune response during EBV replication by inhibiting T cell helper 1 (Th1) cytokines 
(e.g. interferon-γ) (39, 41) allowing EBV to evade the host immune system (42). BHRF-
1, also expressed at high levels during the lytic cycle, encodes a Bcl-2 like protein, which 
protects EBV-infected cells from apoptosis, enabling the virus to survive (39).  
 
During latent infection, expression of EBNA-2, leader protein (LP) and the EBNA-3s (A, 
B and C) is downregulated to allow EBV to remain dormant in memory B cells (latency 
program 0/I) (43). Expression of LMPs and BamH1 fragment A rightward transcripts 
(BARTs) such as BHRF-1 continue to send signals to inhibit apoptosis and block 
interferon activity (latency program II) (32), allowing EBV virions to survive. Spread of 
EBV infection is augmented by transmission of virions through normal host cell division 
(i.e. via daughter B cells), which is achieved by EBNA-1 expression (latency program I) 
(32). During periods of low cellular immunity, EBV is able to switch from latent 
infection, re-enter into the lytic cycle and replicate at new sites within the host (43). This 
is known as reactivation and is a characteristic shared by all herpesviruses (44). For 
example, latently infected EBV cells in the lymphoid tissue and/or peripheral blood often 
undergo lytic replication in the oropharynx that results in virus production, with the virus 
then shed into the saliva (30). EBV persistence may also be achieved through integration 
into the host chromosome DNA (45), though this is not a regular feature of EBV 
infection (46). 
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 1.2.3 EBV genotypes 
Two distinct EBV genotypes (also known as genogroups, variants or clades) (47), A and 
B (also known as Type 1 and 2), have been described, based on sequence variations 
within the Epstein-Barr nuclear antigens (EBNA-1, 2, 3a, 3b, 3c, 4 and 6) (48, 49). Other 
EBV genotype distinguishing genes include the latent membrane protein-1 (LMP-1), 
BamHI fragment Z leftward open reading frame-1 (BZLF-1) and BamHI fragment R 
rightward open reading frame-2 (BRRF-2) (48, 50). Prototypic representation of 
genotype A is based on the B95-8 strain, while genotype B is based on strain AG876. 
These strains share 88% nucleotide sequence identities (51, 52), with genotypic 
differences largely based on in vitro transformation abilities (53) and geographical 
distribution (48, 54). Genotype A transforms and immortalises peripheral blood 
mononuclear cells (PBMCs) more efficiently in vitro than genotype B, which has poorer 
B cell transformation capabilities and significantly lower growth rates in cell culture (53, 
55). Geographically, genotype A is more common in Western countries and Southeast 
Asia (56, 57), while genotype B is mostly endemic to equatorial Africa and New Guinea 
(56, 58).  
 
 Human herpesvirus-6 1.3
Human herpesvirus-6 is a member of the β-herpesvirus subfamily and shares significant 
sequence homology with HHV-7. First isolated from the B cells of patients with human 
immunodeficiency virus (HIV) infection and lymphoproliferative disorders in 1986 (59), 
HHV-6 was initially designated human B-lymphotropic virus (HBLV), but was 
reclassified after it was found to infect other cells such as T cells, macrophages, 
monocytes, epithelial cells, endothelial cells, salivary glands and neural cells (60-63). 
Similar to EBV, HHV-6 infection can cause asymptomatic or mild disease in the 
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immunocompetent host. However, in those with compromised cellular immunity, HHV-6 
infection may cause severe pathology. Primary infection is common in infants and young 
children and causes the clinical syndrome, exanthem subitum (ES), a disease 
characterised by a febrile illness that may be accompanied by seizures. Most children are 
infected with HHV-6 by age three (64), with the peak age of infection occurring between 
9 and 21 months (65). Primary infection is rare in immunocompetent adults, but when it 
occurs, manifests as a mononucleosis-like syndrome (66). Around 90% of adults are 
HHV-6 seropositive (67), with seropositivity decreasing with advancing age (68-70), 
possibly as a result of an aging immune system (71). In immunocompromised 
individuals, HHV-6 infections can lead to severe diseases such as lymphoproliferative 
disorders and graft versus host disease. 
 
 1.3.1 The HHV-6 genome 
Human herpesvirus-6 is divided into two species: HHV-6A, represented by strain U1102; 
and HHV-6B, represented by strain Z29, that are 159 kb and 162 kb in length, 
respectively (72). The genome contains 119 unique ORFs that are organised into two 
major regions, a central UL region that is 143 kb in length, and terminal direct repeats 
(DR) capped at either end, of about 8-9 kb in length (73, 74) (see Figure 3). The UL 
region has seven major core genes that are conserved amongst the herpesvirus family and 
are responsible for replication, cleavage, and packaging of the viral genome into the 
mature virion (72). The right (DRR) and left (DRL) end DR consists of a hexamer repeat 
sequence (‘GGGTTA’) that is important for chromosomal integration (75-77).  
 
Within the HHV-6 genome are 17 genes conserved to β-herpesviruses (78) and several 
other genes that are specific to the Roseolovirus genus (e.g. U20-21, U23-24, U26, U85 
and U100) (79). Unique to HHV-6 and found in both species are the U83 and U94 genes. 
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U83 encodes for chemokines (78, 79) whereas U94 encodes a homologue of the human 
adeno-associated virus type 2 rep gene that binds to the transcription factor, human 
TATA-binding protein (72). TATA-binding protein is important for latency (78) and 
inhibiting the replication of other β-herpesviruses including CMV and HHV-7 (80). A 
selection of HHV-6 genes and their respective functions is shown in Table 5.  
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Figure 3. Diagram of the HHV-6 genome as represented by HHV-6A 
Two diagrams of HHV-6 genomes are shown: (i) Simple: showing the Unique Long (UL) and direct repeat (DR) regions, left to right (DRL and DRR); (ii) Detailed: 
showing a map of ORF genes. ORFs in the DR have the prefix ‘DR’, whereas those in the unique region are labeled U1-100 (from left to right). Image (i) modified 
from reference: (72); image (ii) modifed from references: (73, 74). 
 
 
(i) 
 
(ii) 
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Table 5. A selection of HHV-6 genes and their functions  
 
Gene Function References 
  
Immediate early proteins  
U86 CMV-homologue (79, 81) 
U89 Transcriptional transactivator (67, 79, 81) 
U95 Mouse CMV-homologue (79, 81) 
U16-19 HIV LTR transactivator (79) 
U3 Member of US22 gene family (CMV-related genes that are conserved amongst β-
herpesviruses) 
(79, 81) 
Early proteins: DNA synthesis/viral replication  
U27 Binds DNA polymerase, HIV LTR transactivator (67, 79, 81) 
U38 DNA polymerase (67, 79, 81) 
U41 Major DNA binding protein  (67, 79, 81) 
U43/74/77 Helicase/primase complex (HP), HSV primase (67, 79, 81) 
U73 Origin-binding protein (67, 79, 81) 
U94 Unique to HHV-6, AAV-2 rep gene homologue binds to human TATA-binding 
protein, involved in maintenance of latency, inhibits cell transformation and 
transactivation of HIV-1 long terminal repeats, inhibits replication of β-
herpesviruses 
(67, 79, 81) 
Early proteins: nucleic acid metabolism  
U28 Large ribonucleotide reductase subunit (67, 79, 81) 
U45 dUTPase enzyme (79, 81) 
U69 Phosphotransferase (79, 81) 
U81 Uracil-DNA glycosylase (67, 79, 81) 
Late proteins: glycoproteins & structural antigens  
U11 p100 major structural protein, a phosphoprotein that varies between HHV-6 species  (67, 79, 81) 
U39 Glycoprotein B (gB) (67, 79, 81) 
U48 Glycoprotein H (gH) (67, 79, 81) 
U72 Glycoprotein M (gM),  integral membrane protein (67, 79, 81) 
U82 Glycoprotein L (gL), gH accessory protein (67, 79, 81) 
U100 gp82-105, a glycoprotein that is distinct between HHV-6 species (79, 81) 
Miscellaneous  
U53 Protease, enzyme required for mature virion production (79, 81) 
U83 Viral chemokine (67, 79, 81) 
U12 Chemokine receptor, G-protein coupled receptor (67, 79, 81) 
U51 Chemokine receptor, G-protein coupled receptor (67, 79, 81) 
U67 Unknown function (79) 
U69 Protein kinase, confers anti-viral sensitivity, conserved phosphotransferase (79, 81) 
DR7 p53-binding protein, HIV LTR transactivator, US22 gene family, transformation (67, 79, 81) 
Abbreviations: AAV-2, adeno-associated virus type 2; CMV, cytomegalovirus; DNA, deoxyribonucleic acid; dUTPase, 
deoxyuridine triphosphate nucleotidohydrolase; HHV-6, human herpesvirus-6; HIV, human immunodeficiency virus; 
LTR, long terminal repeat. 
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 1.3.2 Biology of HHV-6 infection  
Human herpesvirus-6 virions enter host cells via saliva by binding a glycoprotein receptor 
complex to a host receptor. HHV-6A (82), and some HHV-6B strains such as Z29 and PL-
1 (83), use the glycoprotein receptor complex gH/gL/gQ1/gQ2 to bind to CD46, a broadly 
expressed glycoprotein found on all nucleated human cells (84). Other strains such as 
HHV-6B strain HST express the gH/gL/gO complex and cannot bind to CD46, and hence, 
their mode of entry into host cells is unknown (61, 83). These differences in binding ability 
are believed to contribute to the dissimilarities in disease associations and cellular tropism 
between the genotypes (72). Figure 4 shows entry of a HHV-6 virion into the host cell. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Diagram of a HHV-6 virion entering a host cell 
HHV-6 virions have two viral glycoprotein receptor complexes, gH/gL/gQ1/gQ2 and gH/gL/gO. Only the 
gH/gL/gQ1/gQ2 complex of HHV-6A attaches to the host CD46 glycoprotein receptor. Once these two 
receptors bind, the virion marches along the lipid raft and enters the host cell via endocytosis. The gH/gL/gO 
complex of HHV-6B (HST strain) binds to unknown receptors for viral entry. Image from reference: (61). 
 
Once in the cell, HHV-6 induces lytic or latent infection by expression of specific proteins 
(72). During lytic infection, HHV-6 proteins are also expressed as three classes: immediate 
early, early and late proteins (85). Immediate early proteins are expressed first to establish 
productive infection, regulate reactivation from latency and evade the host immune 
response (84). Expression of early proteins, which are immediate early gene-dependent, is 
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required for DNA metabolism and replication (67). The late proteins are usually involved 
in virion assembly and form components of the mature virus particle (67). In latent 
infection, only a small subset of genes is expressed, of which U94 is the most important. 
The U94 gene regulates viral gene expression and enables the establishment and/or 
maintenance of latent infection (85). During latency, HHV-6 virions persist in the salivary 
glands, brain tissue, monocytes and early bone marrow progenitor cells (86). Persistence 
can also ensue via chromosomal integration, which occurs in 0.2% to 3% of the world’s 
population (2, 87, 88). Chromosomal integration causes either clinical or subclinical 
disease (72) and results in persistently high viral loads (>10
6
 copies/mL) (89).  
 1.3.3 HHV-6 variants (species) 
Two HHV-6 species have been described, species A (HHV-6A) and species B (HHV-6B), 
based on differences in nucleotide sequence, disease associations, restriction fragment 
length polymorphism, and replication in specific cell lines (72, 79). HHV-6A and HHV-6B 
share approximately 90% sequence homology, and differ mostly between the U86 and 
U100 ORFs (79). The epidemiology and clinical importance of HHV-6A remains largely 
undefined, however many studies have found associations with neurological conditions or 
diseases such as encephalitis (90, 91), MS (72) and AIDS (92). In contrast, HHV-6B 
causes ES and mostly infects young children (93). HHV-6A and HHV-6B genomes also 
differ in length and cleavage patterns as demonstrated by restriction enzyme digestion (67, 
94), and replicate in different cell lines: HHV-6A in HSB-2 and J JHAN cells, and HHV-
6B in Molt-3 cells (67). The differences between the variants have become more apparent 
over the years, with the term “variant” recently revised to “species” by the ICTV in 2011 
(ICTV 2011 Master Species List, version 2) (3). Unlike EBV, the geographical variation of 
HHV-6 variants is unremarkable, and epidemiological (including in Australia) are limited. 
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HHV-6B predominates in children in the USA, and HHV-6A has been principally 
described in adult AIDS patients mostly from parts of Africa (95). 
 
 The human immune system 1.4
Under normal physiological circumstances, EBV and HHV-6 infections are controlled 
effectively by the host immune system. However, during compromised immunity, 
mechanisms for controlling EBV and HHV-6 become inadequate, allowing the viruses to 
proliferate and cause infection. In humans, the immune system has two lines of defence: 
innate and adaptive immunity (96). Innate immunity is non-specific, incurs no 
immunological memory and relies mostly on leucocytes, macrophages, natural killer cells 
(NK cells), cytokines and other pro-inflammatory molecules (97). In contrast, adaptive 
immunity is specific, anamnestic (has memory retention), and comprises mainly of B and 
T cells (lymphocytes) (98). Adaptive immunity is divided into cell-mediated and humoral 
immunity, with considerable cross-talk occurring between the two, and with the innate 
immune system (99). Figure 5 shows the overlap and the different cells involved in innate 
and adaptive immunity, both of which feature in the immune responses typically seen 
during EBV and HHV-6 infection.  
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Figure 5. Cells of the innate and adaptive immune system 
Innate immunity comprises macrophages, dendritic cells, mast cells, neutrophils, eosinophils, basophils and 
NK cells that are responsible for mediating a quick but short-lived inflammatory response. Adaptive 
immunity is mediated by B and T cells and is distinguished by slow initiation and the generation of memory. 
Natural killer T cells bridge the gap between the innate and adaptive immune system. Image from: 
http://www.sabiosciences.com/pathwaymagazine/minireview/innateadaptiveimmunity.php. 
 
 1.4.1 Innate immunity 
Innate immunity encompasses all mechanisms that are manifested at birth to prevent 
infection (100). These include mechanical (e.g. skin) and chemical barriers (e.g. saliva) as 
well as cellular and biological processes (e.g. inflammation, fever and biologically active 
substances) (101, 102). This response is the first line of defence, is antigen-independent 
and induces an immediate and maximal response. The main cells recruited here include 
macrophages and NK cells, and to a lesser extent, dendritic cells, mast cells, basophils, 
eosinophils and neutrophils (103). Macrophages produce specialised chemicals known as 
cytokines (e.g. interferons (IFNs) and interleukins (IL)), which act as messenger molecules 
to mediate an inflammatory response (103). NK cells destroy invading pathogens via 
cytolytic proteins (e.g. perforin and granzyme) which induce apoptosis (103). These 
immune cells recognise invading pathogens by pattern recognition receptors (e.g. Toll-like 
receptors) which when triggered produce an IFN response and activate NK cells (103, 
104). Innate immunity also activates the complement cascade to enhance the immune 
response (99). 
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 1.4.2 Adaptive immunity  
1.4.2.1 Cell-mediated immunity 
Cellular immunity is mediated by T cells, which include the subpopulations: T helper cells 
(Th or CD4
+
 T cells), cytotoxic T cells (CD8
+
 T cells), natural killer T cells (NKT cells), 
memory T cells and regulatory T cells. CD4
+
 T cells recognize proteins bound to MHC 
class II molecules, whereas CD8
+
 T cells recognise proteins bound to MHC class I 
molecules (105). CD4
+
 T cells control infection by assisting in B cell maturation (and 
ultimately antibody production) and inducing macrophage production of cytokines and 
chemokines. In contrast, CD8
+
 T cells destroy foreign cells through apoptosis. Cytokine 
producing CD4
+
 T cells include: Th1, Th2, Th17 and induced regulatory T cells (iTreg) 
(106). Th1 cytokines (e.g. IL-2, tumour necrosis factor-α (TNF-α) and IFN-γ) induce a 
pro-inflammatory response (41), while Th2 cytokines (e.g. IL-4, IL-5, IL-10, and IL-13) 
counteract Th1 imbalances by generating an anti-inflammatory response (41). Th17 
cytokines (e.g. IL-17A, IL-17F, IL-21, and IL-22) activate and recruit neutrophils to 
infection sites (106). iTreg T cells maintain immunological tolerance by inhibiting T cell 
proliferation and are important for Th17 T cell differentiation (107). Chemokines (and 
their receptors e.g. CCR5, CXCR3, CCR3 and CCR4) recruit leucocytes and other immune 
cells to infection sites (108). NKT cells (not to be confused with NK cells in innate 
immunity) include alpha beta T cells (αβ T cells) and gamma delta T cells (γδ T cells). 
NKT cells perform functions ascribed to both CD4
+
 and CD8
+
 T cells. Memory T cells 
enable a rapid and targeted immune response by expanding to large numbers of effector T 
cells (e.g. CD4
+
 and CD8
+
 T cells) upon re-exposure to a previously recognised antigen 
(109). Regulatory T cells are important for achieving self-tolerance and maintaining 
homeostasis. 
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1.4.2.2 Humoral immunity 
Humoral immunity is mediated by pathogen-specific serum antibody proteins known as 
immunoglobulins (Igs), in which production relies on both T and B cells. Although there 
are five classes of immunoglobulin: IgA, IgD, IgE, IgG, IgM; only IgM and IgG are 
generally measured in relation to viral infections (110). IgA has two subclasses (IgA1 and 
IgA2), is found mainly on body surfaces and is important in mucosal immunity (e.g. saliva, 
tears and mucous) (111). IgD is co-expressed with IgM on the surface of naive B cells and 
is found in abundance in the upper respiratory mucosa (112). When cross-linked with 
basophils, IgD may also induce cytokine and chemokine production to enhance 
antimicrobial immunity of mucosal membranes (112). IgE is found at low levels in blood 
or extracellular fluid and mediates allergic responses (111). IgG is the most abundant of all 
Igs and is divided into IgG1, IgG2, IgG3 and IgG4 in order of serum concentration. IgM, 
usually confined to blood, is found on B cell surfaces and is a potent activator of the 
complement system (111). 
 
Following primary exposure to an antigen (either by infection or vaccination), naive B 
cells (i.e. B cells derived directly from the bone marrow that have yet to encounter a 
specific antigen) differentiate into plasma cells (large, short-lived B cells) and memory B 
cells (long-lived B cells). This is T cell-dependent and requires antigen binding to MHC 
class II molecules (110). This response is slow and generates low-affinity antibodies. 
Secondary exposure (by either reactivation or re-infection) causes memory B cells to 
differentiate into plasma cells. This is T cell-independent, is fast and produces high affinity 
antibodies. In primary infection, IgM antibodies appear several days after the onset of 
symptoms, peak between days 7 and 10 and decline to undetectable levels within 1-2 
months (113). As such, IgM antibodies represent current or recent infection. IgG 
antibodies develop several days after IgM antibodies. Over the next few weeks, IgG 
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antibody levels exceed IgM antibody levels and persist at low quantities for life (113). A 
rise in IgG antibodies over time is suggestive of current or recent infection (113). During 
secondary (reactivation or re-infection) infection, IgG antibodies are produced in either the 
absence or presence of IgM antibodies (113). Figure 6 shows the typical IgM and IgG 
antibody response following viral infection. Antibody responses to different EBV antigens 
and HHV-6 are discussed in section 1.6.1. 
 
 
 
 
 
 
 
 
 
Figure 6. IgM and IgG antibody titres during primary and secondary infection 
The dotted line represents virus-specific IgG antibodies that can persist lifelong in low quantities following 
primary infection in the absence of reactivation or re-infection. Image from reference: (113). 
 
 EBV and HHV-6-related diseases  1.5
Epstein-Barr virus and HHV-6 have been directly or indirectly associated with a spectrum 
of human diseases ranging from reactive infection to life-threatening illnesses. Tables 6 
and 7 respectively list the diseases EBV and HHV-6 have been linked with. Diseases 
relevant to this thesis (denoted by an asterisk * in the table) are discussed in sections 1.5.1 
to 1.5.7. 
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Table 6. Human diseases that have been linked with EBV infection 
 
EBV-related disease  Cellular tropism 
Proportion of EBV-related 
cases (%)¥ 
References  
Reactive diseases    
 Infectious mononucleosis*† B cells or plasma cells >99%  (33, 114) 
 
Severe or fatal infectious 
mononucleosis 
B cells 
 
100%  
 
(115) 
 
 Chronic active EBV infection T, NK or B cells 100%  (114, 116, 117) 
 
Haemophagocytic syndrome* 
 
T or B cells 
 
100%  
 
(114) 
 
 
Oral hairy leukoplakia (HIV infection-
related) 
Epithelial cells 
 
>95%  
 
(26, 114) 
 
Non-Hodgkin and immunodeficiency related lymphomas 
 
AIDS-related non-Hodgkin disease 
 
T and NK cells 
 
40%  
 
(114)  
 
 
Post-transplant lymphoproliferative 
disease* 
B cells 
 
95% 
 
(35, 114) 
 
 
Burkitt’s lymphoma (HIV infection-
related) 
 
 
B cells 
 
 
 
Endemic >90%  
Non-endemic ~20%  
Sporadic 15-88%  
AIDS-related 30-90% 
(26, 34, 35) 
 
 
 
 
Lymphomatoid granulomatosis 
 
B cells 
 
90% 
 
(114) 
 
Carcinomas   
 
 Gastric carcinoma 
 
 
B cells 
 
 
Lymphoepithelioma-like ~90%  
Adenocarcinomas 5–25%  
 
(35)  
 
 
 
Nasopharyngeal carcinoma 
 
Epithelial or squamous cells 
 
>99%  
 
(33, 35) 
 
 
Smooth muscle tumour in 
AIDS/transplant  
Smooth muscle cells 
 
>95% 
 
(114) 
 
Hodgkin lymphomas   
 
 
Hodgkin disease Reed-Sternberg cells 
(originating from B cells) 
All subtypes 40-60% 
Mixed cellularity ~70%  
(33, 118) 
 
AIDS-related Hodgkin lymphoma Reed-Sternberg cells 
(originating from B cells) 
>95% (33, 118) 
Multiple sclerosis* 
 
Relapsing-remitting MS and   
unspecified MS subtypes 
 
B cells 
 
0-100% 
 
(119-125) 
Abbreviations: AIDS, acquired immunodeficiency syndrome; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; IM, 
infectious mononucleosis; NK, natural killer.  
¥ % of cases including serology and DNA positive. 
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Table 7. Human diseases that have been linked with HHV-6 infection  
Abbreviations: AIDS, acquired immunodeficiency syndrome; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; 
PBMC, peripheral blood mononuclear cells, PTLD, post-transplant lymphoproliferative disease. 
¥ % of cases including serology and DNA positive. 
 
 
HHV-6-related disease Species 
Proportion of HHV-6-
related cases (%)¥ 
 
 
 
 
 
 
References 
    
Reactive diseases    
 Exanthem subitum*† B 60-74% (126) 
 Chronic fatigue syndrome Unknown 70% (127) 
 Drug-induced hypersensitivity syndrome  B Low (128) 
 Reactivation in HIV/AIDS* A and B CSF 2.2-30% 
Blood 36-93.5% 
(129) 
(130) 
Heart diseases 
 
Myocarditis, cardiomyopathy, arterial dysfunction B 18-20.8% (128) 
Non-Hodgkin and immunodeficiency-related lymphomas 
 Hodgkin lymphoma B 12-98.2% (86) 
 Non-Hodgkin lymphoma B 25-100% (86) 
 PTLD (solid organ)* A, mostly B 22-91% (86, 128) 
 PTLD (stem cell or bone marrow) A, mostly B Stem cell 40-67% 
Bone Marrow 28-75% 
(128) 
(131) 
Hodgkin lymphomas 
 
Hodgkin disease A, mostly B 12-98.2% (86) 
Leukaemia 
 Acute lymphoblastic or myeloid leukaemia A and B 26.8% (132) 
Neurological diseases  
 Encephalitis B 31.8-40% (133-135) 
Multiple sclerosis* A and B 
 
 
3-100% (120, 136-141) 
 Clinically isolated syndrome (also known as a first 
CNS demyelinating event) 
Unknown Serum 30% 
 
(142) 
 Relapsing-remitting multiple sclerosis A and B, mostly A 
 
 
A and B 
PBMC 53.8-64.3% 
Plasma 57.1% 
 
CSF 0% 
PBMC 14.3% 
(143, 144) 
(143) 
 
(145) 
(145) 
 Secondary progressive multiple sclerosis A and B PBMC 37.6-57.1% (143, 144) 
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 1.5.1 Infectious mononucleosis 
Epstein-Barr virus infection is frequently asymptomatic in healthy individuals (146), and in 
young children, often causes acute but self-limiting disease. If primary infection is delayed 
until adolescence (e.g. between the ages 15 and 25), EBV infection manifests as infectious 
mononucleosis (IM; also known as glandular fever, ‘kissing disease’ or Pfeiffer’s 
Drüsenfieber) (146, 147). About 30% to 50% of late primary EBV infection is thought to 
result in IM (147), and in most individuals, infection subsides within 3 to 6 weeks and 
requires no medical treatment (32). Primary EBV infection is characterised by a triad of 
symptoms comprising fever, lymphadenopathy, and pharyngitis (30). Symptoms may vary 
in severity, with a minority of individuals suffering acute or life-threatening diseases from 
complications such as anaemia, thrombocytopaenia, myocarditis, hepatitis, encephalitis 
and meningitis (30). Very rarely, individuals with IM may experience severe and persistent 
symptoms lasting more than six months. This is known as chronic active EBV infection 
(CAEBV) (32) and carries a very poor prognosis; death often results from complications 
such as lymphoma, haemophagocytic syndrome or fulminant hepatitis (32).  
 
Diagnosis of IM is based on clinical symptoms and detection of heterophile antibodies, but 
this test (i.e. the ‘Monospot’ test) is often unreliable and prone to false negatives (148). 
Serological determination of virus-specific antibody profiles is more reliable and can 
determine infection status (see section 1.6.1). Nucleic acid testing (NAT) can also be 
performed for the detection of the virus and DNA load assessment. EBV DNA loads 
generally range between 10
3
 and 10
4
 copies/mL during IM (149), ~10
4
 copies/mL in 
CAEBV (150) and up to 10
7
 copies/mL in severe or fatal IM (150). 
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 1.5.2 Exanthem subitum 
In young children, primary HHV-6 infection causes undifferentiated and short-term febrile 
illnesses, but in ~17% of cases, develops into exanthem subitum (ES; also known as 
roseola infantum or sixth disease) (78). Although usually mild, ES is characterised by high 
fever and rash and may be accompanied by convulsions. Rarely, ES may be complicated 
by hepatitis, arthritis, encephalopathy and haemophagocytic syndrome (78). Nearly 100% 
of children are infected by age three (64), with delayed HHV-6 infection thought to cause 
more severe disease (151). In immunocompetent adults, HHV-6 infection is rare and 
occurs as a result of reactivation. In the immunocompromised (e.g. transplant recipients), 
HHV-6 reactivation may result in serious complications (e.g. graft rejection) requiring 
hospitalisation (78). Serological profiles are useful for discriminating between primary 
(IgM) and recent or recurrent HHV-6 infection (IgG), but NAT is the most reliable test for 
infection (152). Viral DNA load assessment using qPCR can also discriminate between 
infection types, with HHV-6 DNA loads reported at ~10
2 
copies/mL in acute ES, and ~10
1
 
copies/mL at convalescence (153). However, interpretation of HHV-6 DNA load results 
may be complicated by chromosomal integration, where high levels of viral DNA (>10
6
 
copies/mL in serum, whole blood, and CSF) may occur subclinically (154).  
 
 1.5.3 Haemophagocytic syndrome  
Epstein-Barr virus-associated haemophagocytic syndrome (EBVAHS, also known as 
haemophagocytic lymphohistiocytosis) is an aggressive and rare haematological disease 
characterised by increased cytokine levels (e.g. IL-12 and IFN-), hyperinflammation and 
overall immune system dysregulation (155). EBVAHS is often associated with severe and 
fatal IM, although it may develop independently (156). About two-thirds of cases are 
caused by EBV reactivation (indicated by EBNA-1 IgG positivity) and around 60% of 
cases are fatal (157). EBV DNA loads range between 10
3 
and 10
8
 copies/mL (157, 158). 
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 1.5.4 Lymphoproliferative disorders 
Lymphoproliferative disorders (LPD) encompass several diseases resulting from excessive 
lymphocyte production (4). There are a number of underlying causes, including EBV and 
HHV-6 infection. LPDs commonly occur post-transplantation (known as post-transplant 
lymphoproliferative disorders or PTLD) (49, 159), and may arise following solid organ 
(160, 161) or bone marrow transplantation (162, 163). Complications of PTLD include 
fever, rash, pneumonia, bone marrow suppression, encephalitis, hepatitis, delayed 
engraftment or more seriously, graft rejection (128, 164). The incidence of PTLD varies 
with the type of transplant, degree of immunosuppression and virus-specific sero-status of 
the recipient. Major risk factors include primary EBV or HHV-6 infection, with 
seronegativity prior to engraftment a major concern (165). While HHV-6A infection has 
been reported (166), the majority of HHV-6-related PTLDs are caused by HHV-6B 
reactivation and occur between 2 and 4 weeks post-transplantation (128, 165). EBV-related 
PTLDs are mostly caused by genotype A (49) and occur between 10 and 12 weeks post-
transplant, but cases as early as one week and as late as 9 years post-transplantation have 
also been documented (163). Viral load testing using qPCR is the most useful method for 
screening, diagnosing and monitoring treatment of EBV- and HHV-6 infected PTLD. EBV 
and HHV-6 DNA loads vary depending on specimen type (e.g. viral load is higher in 
EDTA whole blood compared to plasma) but generally range between 10
4
 and 10
6
 
copies/mL (167). 
 
 1.5.5 Opportunistic infections in HIV-infected persons  
HIV-infected individuals often develop EBV- or HHV-6-related opportunistic infections 
such as oral hairy leukoplakia (caused by EBV) and Hodgkin and non-Hodgkin lymphoma 
(associated with either EBV or HHV-6) (26). Many studies have suggested that HHV-6 
reactivation may play a role in accelerating HIV infection (92, 168, 169). In HIV-infected 
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individuals, viral load (either HIV RNA or viral-specific DNA) is useful for monitoring 
responses to therapy. EBV DNA loads ranging between 10
2
 and 10
6
 copies/mL have been 
described (170), while HHV-6 DNA loads ranged between 10
3
 and10
6
 copies/mL (171). 
 
 1.5.6 Hepatitis/liver disease  
Hepatitis is a rare complication of EBV or HHV-6 primary infection or reactivation (172, 
173). Hepatic disease is more common during late EBV infection (e.g. IM) than during 
primary infection (174). Severe liver injury is rare, but when it occurs, is a leading cause of 
death among patients with acute EBV infection (175). Most fulminant cases occur post-
transplantation, during chemotherapy, or during HIV or X-linked lymphoproliferative 
disease (175). In patients with chronic EBV infection, EBV is thought to contribute to the 
development of autoimmune hepatitis and hepatocellular carcinoma (175). In contrast, 
HHV-6-induced hepatitis occurs in ~6.7% of liver transplant recipients and results in 
elevated liver enzymes, lymphocytic infiltration, allograft dysfunction and acute rejection 
(164). In children, HHV-6-induced hepatitis may occur as a complication of ES (78), and 
in some cases, may lead to a rare form of hepatitis characterized by a severe, often fatal 
disease course known as syncytial giant-cell hepatitis (176).  
 
 1.5.7 Multiple sclerosis 
Both EBV and HHV-6 infection have been implicated in the development of the CNS 
demyelinating disease, MS. The evidence to date is not sufficient to include MS as a 
disease “known to be caused by EBV and HHV-6 infection”; therefore, EBV and HHV-6 
infection in relation to MS is discussed separately in section 1.8 (following a brief 
introduction to the disease in section 1.7). Laboratory methods that assist in the detection 
and measurement of EBV and HHV-6 DNA in individuals with MS (or those with first 
clinical evidence of disease) form a major part of the thesis. 
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 Diagnosis of EBV and HHV-6 infections 1.6
The presence and importance of viral infections pose three diagnostic challenges which can 
be resolved using detection, quantification and genotyping assays (177). These challenges 
are presented in Table 8 below.  
 
Table 8. Diagnostic challenges, testing goals and key benefits of detection, 
quantification and genotyping tests  
Diagnostic challenges Resolution Testing goals and key benefits 
 
Detection of virus  
(Is the virus present? If so, 
what is the causative agent? 
What is the infection status of 
the patient?) 
 
 
Any nucleic acid 
testing method; 
serology 
 
 Identification of pathogen allows disease diagnosis and 
elimination of other possible diagnoses  
 Identification of current, recent or past infection 
 Allows tailoring of therapy 
 Allows early administration of therapy and may prevent 
worsening/disease progression leading to improvement in 
symptoms and patient comfort 
 
Measurement of viral load  
(How much virus is there? Is 
the level increasing or 
decreasing compared to the 
initial sample measurement?) 
Quantitative 
polymerase chain 
reaction 
 Discriminates between lytic and latent infection 
 Monitor the effects of therapy (e.g. response to antivirals) 
 Screen for diseases (e.g. Burkitt’s lymphoma)  
 Risk assessment and disease prognosis (e.g. risk of fatality) 
 
 
Identification of genotype  
(Is there a particular genotype 
affecting the patient?) 
 
Genotyping assays 
 
 Risk assessment and identification of populations at risk 
 Allows tailoring of therapy  
 Determine drug resistance profiles and assist in vaccine 
development  
 Provide epidemiological data, allow for disease profiling and 
epidemic tracing 
 Forensic applications (e.g. pinpointing suspect ethnicity and/or 
geographical location  
 
 
In general, diagnosis of viral infections relies on three main tests: virus isolation (178), 
serology (including serological detection of viral antigens in vitro) (179) and NAT (180). 
Virus isolation using cell culture has long been considered the gold standard, however, not 
all viruses (e.g. EBV) can be grown in culture (181). Serology is useful for confirming 
infection status (e.g. current versus past infection), but is unreliable in those with 
malignancies (179) and immune derangements (84, 114). NAT using polymerase chain 
reaction (PCR) is considered the gold standard and may be applied to both healthy and 
immunocompromised individuals. Application of NAT is diverse, is amenable to all virus 
groups (e.g. DNA and RNA) and when coupled with real-time PCR and absolute 
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quantification (qPCR), can detect and measure the concentration of virus in a sample (i.e. 
viral load). Key benefits include the ability to identify and/or monitor acute versus 
persistent infection, and to discriminate between genotypes (180). Table 9 below lists the 
common laboratory tests for the detection and/or quantification of viruses.  
 
Table 9. Common laboratory tests for the detection or quantification of herpesviruses 
Test Advantages Disadvantages References 
 
Electron microscopy 
 
 Morphological and histological 
changes evident 
 
 Limited to special laboratories as special 
equipment and trained staff required 
 Labour intensive 
 Poor sensitivity 
 Requires high sample volume  
 
 
(182) 
Virus isolation/cell 
culture 
 Gold standard 
 Cytopathic cell changes evident 
(e.g. ballooning) 
 Cells can be used for other 
applications (e.g. PCR) 
 Not all viruses grow in culture (e.g. EBV) 
or grow very slowly (e.g. HHV-6) 
 Not all viruses produce cytopathic effects 
 Slow (up to 4 weeks) 
 Limited to special laboratories 
 Sensitivity compromised by use of 
antivirals 
 Difficult to standardise 
 Requires high sample volume  
 Expensive 
 
(146, 154, 
182, 183) 
 
Serology  Gold standard  
 Verify response to vaccination 
 Screening of immune status 
 
 Problematic in immunocompromised 
patients 
 Clinical symptoms may not coincide with 
antibody production 
 
 
 Immunofluorescence   Very sensitive 
 Titration allows for semi-
quantitation 
 Differentiates between acute, 
recent or past infection 
 Relatively inexpensive 
 
 Labour intensive 
 Inability to discriminate between 
genotypes 
 Requires serial samples to demonstrate 
rise or drop in titres 
(83, 146, 154, 
183, 184)  
 
 Complement fixation  Ability to screen for a panel of 
viruses simultaneously 
 Inexpensive 
 Less sensitive and less specific 
 Labour intensive and time consuming 
 Requires multiple samples  
 Not widely used as subject to cross-
reactivity  
 
(113, 146) 
 Neutralisation   Quantification possible 
 Performed on all viruses that 
can be grown in culture 
 
 Expensive 
 Labour intensive and time consuming 
 Trained staff required 
(113, 182) 
 Blot techniques 
 
 Highly specific and highly 
sensitive 
 Confirmatory test 
 Use of single sample 
 
 Prone to subjectivity 
 Expensive 
 Special equipment and trained staff 
required 
(146) 
 Antibody agglutination  Simple test 
 Commercial kits available for 
some viruses (e.g. “Monospot” 
test for EBV heterophile 
antibody diagnosis) 
 
 Less sensitive and less specific (e.g. 0 to 
50% of children do not produce 
heterophile antibodies to EBV) 
 Prone to subjectivity 
 
(146) 
 Antibody avidity   Use of a single sample 
 Useful when IgM is absent 
 
 
 Labour intensive (146) 
 Enzyme immunoassay 
or Enzyme-linked 
immunosorbent assay  
 Automated  
 Very sensitive 
 Use of a single sample 
 Inability to discriminate between 
genotypes 
 Subject to cross-reactivity 
 Requires a spectrophotometer for result 
 
 
 
(83) 
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Abbreviations: EBV, Epstein-Barr virus; HHV-6, human herpesvirus-6; PCR, polymerase chain reaction; qPCR, quantitative 
polymerase chain reaction 
 
 1.6.1 Serology  
Viral serology testing looks for the presence of virus-specific antibodies in serum (i.e. 
serum Igs) that are produced in response to viral antigens. For EBV and HHV-6 diagnoses, 
detection of virus-specific antibodies relies most commonly on immunofluorescence 
assays that target different viral antigens or Ig classes. For example, diagnosis of EBV 
infection includes the detection of antibodies to three antigens: viral capsid antigen (VCA), 
early antigen (EA; divided into diffuse and restricted, EA-D and EA-R, respectively) and 
Serology continued 
Test Advantages Disadvantages References 
  
Antigenaemia 
 
 Sensitive and specific 
 Ability to discriminate between 
genotypes 
 No cross-reactivity 
 Reflects active infection  
 No special equipment necessary 
 
 
 Labour intensive and time consuming 
 Semi-quantitative 
 Sensitivity unknown 
 
(83)  
 Fluorescent in situ 
hybridisation  
 Used for detecting tumour-
related diseases 
 Detection of chromosomal 
integration of virus 
 
 Limited to special laboratories as special 
equipment required 
 Prone to subjectivity 
 
(154, 185)  
 
Nucleic acid testing  New gold standard for diagnosis 
of certain virus-related diseases  
 Allows for surveillance of viral 
activity in immunocompromised 
patients 
 
 Expensive 
 Limited to special laboratories  
 Requires trained staff 
 
 Real-time PCR  Rapid and reproducible (<3 
hour turn-around) 
 Highly sensitive and specific 
 Large dynamic range 
 Suitable for semi, relative and 
absolute quantification 
 Ability to discriminate between 
genotypes and infection type 
 Less prone to contamination 
events 
 No need for agarose gel 
electrophoresis  
 Uses small sample volumes 
 Can be automated 
 Fluorescent signal is directly 
proportional to the number of 
amplicons generated 
 Correlated with serology results 
 
 Sophisticated equipment and software are 
needed to analyse data 
 Problematic if virus integrates into the 
chromosomes  
 Some fluorescent dyes are difficult to 
optimise for qPCR 
(83, 180, 186, 
187)  
 
 Conventional PCR  Sensitive and specific 
 Semi-quantitative (end-point) 
 Uses small sample volumes 
 Slower than real-time (4-8 hour turn 
around) 
 Open to contamination events 
 Limited to special laboratories 
 Trained staff required  
 Labour intensive 
 Expensive (but cheaper than real-time) 
 Poor precision 
 Small dynamic range 
 Non-automated 
 
(180, 186, 
187)  
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Epstein-Barr nuclear antigen-1 and -2 (EBNA-1 and EBNA-2, respectively). In contrast, 
HHV-6 diagnosis relies on the discrimination between HHV-6-specific IgM and IgG 
antibodies. 
 
During acute EBV infection, VCA IgM antibodies (in the absence of EBNA-1 IgG 
antibodies) develop to high titres quickly, but decline rapidly over a period of three 
months. Thus, the presence of VCA IgM antibodies represents primary or acute EBV 
infection (188). VCA IgM antibodies are followed by VCA IgG antibody production, with 
levels peaking 2 to 4 weeks after disease onset; levels then decline slightly and persist life-
long (42). Antibodies against EA-D increase in the first 3 to 4 weeks of infection and 
become undetectable after 3 to 4 months, though in some cases may remain detectable for 
years after primary infection (189). High levels of EA-D antibodies are therefore 
suggestive of acute, reactivated, or chronic active infection, and have been seen in patients 
with nasopharyngeal carcinoma (NPC) (189). Antibodies against EA-R also appear at the 
initial stages of infection, decline at similar intervals as EA-D, but may remain high for up 
to two years in those with silent infection (189). High levels of EA-R antibodies are found 
in atypical, chronic cases of IM, and in patients with Burkitt’s lymphoma (189).  
 
Lytic EBV infection is followed by antibody responses against the latent antigens: EBNA-
1 and EBNA-2 (39). EBNA-1 IgG antibodies are classic indicators of disease resolution 
(188). Detection of EBNA-2 antibodies are seldom used alone, and instead, are used as a 
ratio (EBNA-1 to EBNA-2 antibodies) for identifying EBV reactivation (146). 
Interpretation of EBV serological profiles is not always straightforward as a number of 
patterns may be generated (190). Thus, interpretation of serological results requires care, 
expertise, and most importantly, takes into consideration the patients’ symptoms, clinical 
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history and a medical examination. Figure 7 shows the typical antibody response following 
EBV infection.  
 
 
 
 
 
 
 
 
Figure 7. Antibody responses to EBV antigens during acute infection and 
convalescence  
Image from: http://img.medscape.com/pi/emed/ckb/pediatrics_general/1331341-1331368-963894-
1768116.jpg. 
 
Delineation between primary, recent and recurrent HHV-6 infection relies on the detection 
of HHV-6-specific IgM and IgG antibodies. Primary HHV-6 infection is diagnosed by a 
significant rise in antibody titre (at least four-fold), and/or the detection of HHV-6 IgM 
antibodies (84). HHV-6 IgM antibodies appear between 3 and 7 days after disease onset, 
peak in the second week, and remain detectable for up to 2 months (79, 191). HHV-6 IgM 
antibodies, however, may be generated in the absence of clinical symptoms in about 5% of 
adults (67). HHV-6 IgG antibodies generally appear within 7 to 10 days, peak in week 4, 
and persist lifelong (67). The presence of HHV-6 IgG antibodies indicates a previous 
infection, whereas a significant rise (four-fold increase) in IgG antibody titres is indicative 
of a recent HHV-6 infection.  
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 1.6.2 Nucleic acid testing 
1.6.2.1 Importance of viral load measurement 
In general, viral load measurement assists with determining the clinical status of a patient 
as the amount of virus often fluctuates with disease activity (158, 192). In healthy 
individuals, viral DNA is usually undetectable or present at low concentrations, reflecting 
an absence of either the virus or viral persistence (149, 193-196). During active infection, 
the viral burden intensifies, and is often correlated with worsening of symptoms. For 
example, in transplant recipients, high EBV or HHV-6 DNA loads are often predictive of 
PTLD (197-199), and in HIV-infected individuals, elevated HIV RNA loads are often 
associated with risk of disease progression and/or indicative of ineffective antiretroviral 
therapy (200). Viral loads may also indicate the type of infection. For example, during 
latent EBV infection, the viral genome is maintained at a constant copy number. During 
lytic infection, EBV DNA concentration is amplified (105). This is apparent in IM and 
EBVAHS, where EBV DNA loads are generally lower during convalescence and/or 
chronic infection, but increase in the acute phase when disease is severe, or prior to death 
(150, 153, 201, 202).  
 
Viral loads can reflect disease activity, and thus be used to monitor the clinical status of a 
patient. Nevertheless, several studies have shown that viral loads are not always predictive 
of disease activity and/or reflect clinical phenotype; therefore caution is required when 
interpreting results. For example, one study found high EBV DNA loads in a small number 
of transplant recipients, despite an absence of clinical symptoms (203). Some have found 
high HHV-6 DNA loads in asymptomatic, immunocompetent individuals, at levels that 
would otherwise have serious implications in immunosuppressed individuals (204, 205). 
Explanations for these anomalies include viral transience, sampling site and chromosomal 
integration. For example, EBV DNA is detected in blood at various stages of IM: EBV is 
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eliminated by week seven after disease onset but may reappear 6 months or more after 
primary infection (42). EBV DNA is eliminated from blood more rapidly than in cells from 
the oral mucosa (e.g. saliva), where the virus is known to persist for many months (42). 
HHV-6 DNA is known to integrate into host chromosomes to cause falsely high DNA 
loads (205, 206). In spite of these findings, the consensus is that, typically, increasing viral 
loads parallels worsening of clinical symptoms. Viral load measurement using qPCR has 
already proven useful in screening, diagnosing, and monitoring patients with a range of 
viral infections such as HIV, hepatitis B and C, and CMV (4, 146). 
 
1.6.2.2 Real-time qPCR  
Since the introduction of nucleic acid quantification by real-time PCR in 1993 (207, 208), 
technology has developed at a rapid pace, and so has clinical usage. This, however, has 
come at a cost. Flexibility in qPCR has also introduced variation amongst users, with 
system platforms, chemistries and methodologies differing between test sites (134). These 
variations have consequently made comparisons across laboratories difficult. The literature 
is encumbered with published works containing variable reporting formats (e.g. copies/mL, 
copies/µg, copies/10
6
 PBMCs, IU/mL), different terminology (e.g. house-keeping gene 
versus reference gene; and CT versus Cq), assortment of specimens (whole blood, 
fractionated blood (plasma, serum, PBMC), CSF, tissue biopsy), and inadequate disclosure 
of relevant information (e.g. failure to include primer sequences or thermal cycling 
conditions). These inconsistencies impede experiment reproducibility, complicate data 
comparisons and may influence overall reliability of the results. To overcome these 
challenges and ensure quality results, laboratories are encouraged to adhere to strict testing 
guidelines and to participate in external quality assurance programs (QAP). Testing 
guidelines include those set by the National Pathology Accreditation Advisory Council 
(NPAAC), which are enforced by the National Association of Testing Authorities, 
35 
 
Australia (NATA). QAP programs include Royal College of Pathologists Australia Quality 
Assurance Program (RCPA QAP) and Quality Control for Molecular Diagnostics 
(QCMD).  
 
1.6.2.3 Commercial versus in-house assays 
A number of commercial kit-based EBV quantification assays have been developed, 
including EBV R-gene
TM
 (Biomérieux), RealArt EBV LC PCR kit (Artus
®
) and the 
LightCycler
®
 EBV quantification kit (Roche Applied Science). These kits, however, are 
expensive, test a small number of samples simultaneously, require separate purchasing of 
reagents and have limited quantification ranges. For example, in 2006, the LightCycler
®
 
EBV quantification kit was quoted at AU$1,351.98 for 48 reactions (September 2013 
AU$1351), and RealArt EBV LC PCR kit was quoted at AU$4,609 for 96 reactions 
(October 2013 AU$3494). The EBV R-gene
TM
 is a 90-kit test that includes four dilution 
points ranging from 10
2 
to 10
5
 copies/mL; and RealArt EBV LC PCR kit has three 
components that are packaged and priced separately. Commercial kits are not available for 
all viruses. For example, at the time of project conception and planning, HHV-6 qPCR kits 
were non-existent. As such, some laboratories opt to use in-house or “home brew” assays. 
Evaluation studies of commercial and in-house assays for EBV quantification have shown 
a high correlation, indicating that both methods are suitable for clinical use (149, 209). 
While in-house assays require expertise to develop and extensive evaluation, they are more 
cost-effective than commercial assays, offer flexibility and are suited to large scale testing. 
More importantly, in-house assays can be designed to operate at the highest levels of 
sensitivity (e.g. 2.0 x 10
2
 copies/mL). 
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1.6.2.4 Detection chemistries 
There are two main detection chemistries for real-time qPCR: sequence-specific (e.g. 
probes) and non-sequence-specific (e.g. intercalating dyes) (187). Sequence-specific 
probes hybridise with complementary target sequences and therefore detect only the 
intended product. Probes are therefore highly specific, offer superior result resolution, but 
are often expensive. Examples include hydrolysis (e.g. TaqMan Probe), hybridisation (e.g. 
HybProbes) and single-labelled probes (e.g. Simple Probes). Non-sequence-specific 
chemistries include intercalating dyes (e.g. ethidium bromide, SYBR Green I Dye and LC 
green) (210) that bind to dsDNA to emit fluorescent signals at specific wavelengths 
(Figure 8). Generally, the fluorescence emitted from the dye is proportional to the amount 
of DNA. The technology is very simple, quick, and found to be as sensitive as probes 
(211). However, the method requires extensive optimisation as the dye binds to all dsDNA 
(including non-specific products) and at high concentrations, can be inhibitory to PCR 
(210).  
 
Figure 8. Process of SYBR Green I DNA 
intercalation  
During denaturation, SYBR Green dye molecules 
exist freely in solution. Once primers anneal to form 
dsDNA, SYBR Green slots between the strands and 
emit a light that can be measured at 522 nm. Image 
from: 
http://media.wiley.com/CurrentProtocols/ET/et1003/et
1003-fig-0008-1-full.jpg. 
 
 
 
 
1. Denaturation 
 
2. Annealing 
 
3. Extension 
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1.6.2.5 Nucleic acid extraction 
Nucleic acid (NA) extraction plays an important role in NAT as poor quality DNA can 
affect sensitivity and consequently, PCR detection. NA extraction can be automated or 
manually performed. Automated NA extraction platforms (e.g. MagNA Pure LightCycler 
(Roche Diagnostics), m1000 (Abbott Diagnostics) and EasyMag (Biomerieux)), offer fast, 
reproducible, and less ‘hands on’ operator time, turning around 8 to 48 samples per run, 
per 1 to 2 hours. Manual extractions rely on operator technique and expertise to ensure 
sufficient yield and quality NA but are time consuming and prone to contamination if 
performed incorrectly. While manual and automated methods were shown to be 
comparable in performance (212, 213), one study showed that manual extraction of whole 
blood yielded 57% more DNA than robotic methods (214). This is important where yield is 
crucial, particularly for quantification of NA at low-levels. 
 
1.6.2.6 Genotyping assays 
Genotypes arise from virus evolution brought about by sequence mutation and provide 
valuable epidemiological data. While some mutations do not generate phenotypic changes, 
mutation identification may be clinically important as genotypic differences can contribute 
to variation in disease pathogenesis, susceptibility, infectivity, virulence, and transmission, 
and can alter the response to therapy (54, 215-217). For example, some genotypes are 
endemic to certain parts of the world: EBV genotype A is found more frequently in 
westernised countries (e.g. USA, Europe, Australia) and Asia (56, 57), whereas genotype B 
is mostly endemic to equatorial Africa and New Guinea (56, 58). The occurrence of HHV-
6 species appear to differ more by disease than by location; HHV-6A is more commonly 
found in association with neurological disorders such as MS (144, 218) and encephalitis 
(90), and clinical conditions where there may be immune system impairment such as in 
transplant recipients (166, 219) and HIV-infected individuals (220) (genotypic differences 
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between HHV-6A and HHV-6B are discussed in section 1.3.3). Some studies suggest that 
there is also variation within genotypes, with specific strains found more frequently in 
certain diseases (e.g. EBV GD1 strain in NPC) (221). For genotypic analysis, phylogenetic 
analysis and sequencing remain the gold standard. Genotyping methods are listed in Table 
10. 
 
Table 10. Different types of genotyping assays  
 
Compiled from reference: (47). 
 
Method Advantages Disadvantages 
 
Sequencing and 
phylogenetic analysis 
 
 Gold standard 
 Highly informative 
 Allows classification of new genotypes and 
identification of recombinants 
 
 Time consuming but coupled with real-
time PCR is faster 
 Labour intensive 
 Requires expertise in use of specialised 
programs 
 Requires a reference sequence 
 
Restriction fragment 
length polymorphism 
 Restriction enzymes are inexpensive 
 Simple and quick method 
 Allows identification of known genotypes 
 Patterns produced are straightforward 
 Restriction enzyme sites must be known 
 Single nucleotide polymorphisms (SNPs) 
or incomplete digestion can make 
interpretation difficult 
 SNPs can result in misidentification of 
genotype 
 
Type-specific PCR  Simple procedure 
 Can give an indication of mixed infections 
with different genotypes 
 
 Sequences are required to design specific 
primers for each genotype 
 Mutations or SNPs may decrease PCR 
efficiency 
 Potential cross-reactivity of primers 
 Cannot identify mixed genotype infections 
 
Reverse phase 
hybridisation 
 Commercial assays available that 
improves quality control and 
reproducibility 
 Designed to suit most laboratories that do 
not have extensive genotyping experience 
 
 Expensive 
 Results do not always conform to 
manufacturer’s guidelines 
Heteroduplex mobility 
analysis 
 Consensus PCR primers can be used 
 Sequence knowledge not required  
 Simple and inexpensive technique 
 
 Interpretation can be difficult 
 Reference sequences required 
Restriction fragment 
mass polymorphism 
 Ability to genotype high quantities and 
quickly 
 Sensitive at detection of minor species 
 
 Equipment expensive 
 Expertise and sequence knowledge 
required to set up assay 
Microarray  Multiple specific primers can be used  
 Flexible design 
 Reproducible  
 Inexpensive dyes 
 
 Requires sequence knowledge 
 Instrumentation can be expensive 
 Single sample per chip 
Mass sequencing by 
synthesis 
 Provide full genomic sequencing 
 Very sensitive 
 Expensive instrumentation and start-up 
costs 
 Bioinformatic programs capable of 
evaluating the large amount of data 
generated are expensive and not readily 
available yet 
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 Multiple sclerosis  1.7
Multiple sclerosis is a chronic neurological disorder caused by demyelination of axons 
within the CNS (i.e. brain and spinal cord). Common presenting symptoms include loss of 
muscle control, vision, balance, and/or sensation. The disease affects over two million 
people worldwide (222) including ~21,000 Australians (223), and is the commonest cause 
of non-traumatic permanent disability amongst young adults (224). MS presents a huge 
health burden, costing around AU$35,000 to 47,000 per annum per patient in direct and 
indirect expenses (225, 226). The average age of disease onset is 30 years (late thirties in 
Australian studies) (227), but may occur from infancy up until the seventh decade of life 
(228, 229). The disease course is unpredictable and varies from person to person: more 
than two-thirds of patients remain ambulatory 20 years after diagnosis (230), while a small 
proportion advance to severe and irreversible disability (231), sometimes within weeks. 
The disease is seldom fatal, with most patients surviving approximately six years less 
relative to the general population (232). The cause of MS is unknown and there is no cure. 
A summary of MS disease characteristics is shown in Table 11 below. 
 
Table 11. A summary of multiple sclerosis disease characteristics 
Abbreviations: EAE, experimental autoimmune/allergic encephalomyelitis; HLA, human leucocyte antigen; IM, infectious 
mononucleosis; MHV, mouse hepatitis virus; MS, multiple sclerosis; TMEV, Theiler's murine encephalomyelitis virus; UVR, ultraviolet 
light radiation. 
MS variables Outcomes References 
 
Subtypes  
 
Relapsing-remitting, secondary progressive, primary progressive, primary-
relapsing, benign. 
 
(233-235) 
Gender Female:male = ~3:1 (variable by location; seems to be increasing over time). (236-240) 
Distribution Worldwide but greater incidence and prevalence with further distance from 
the Equator. Common in Northern Europe, North America and Australasia. 
Affects one in a thousand people in western countries. 
(241-244) 
At-risk populations Caucasians, particularly of European descent. Disease uncommon among 
Samis, Turkmen, Uzbeks, Kazakhs, Kyrgyzis, native Siberians, North and 
South Amerindians, Chinese, Japanese, and New Zealand Maoris.  
(245, 246) 
Age (% of those with MS) Mean age is 30 years (range 20-40 years). Early onset MS: <16 years (0.4% 
to 10.5%); late onset MS: >50 years (4.6%). 
(247, 248) 
Animal and viral models Animal: Autoimmune (EAE) and toxin-induced (lysolecithin and cuprizone); 
viral: TMEV and MHV  
(249-251) 
Environmental influences Latitudinal gradient, history of IM infection, low UVR (sunlight and vitamin D), 
cigarette smoking, trauma and stress, exposure to organic solvents, 
vaccinations and diet. 
(252-262) 
Genetic or biological 
influences 
“MS genes” (particularly HLA class II alleles), degree of relatedness to person 
with MS, ethnicity, sex, pregnancy. 
(263-266) 
Treatment There is no cure. Symptoms are managed by disease-modifying drugs such 
as interferon-β, glatiramer acetate, mitoxantrone, natalizumab. 
(235) 
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 1.7.1 MS diagnosis 
Diagnosis of MS can be difficult as symptoms may be non-specific and mimicked by other 
neurological diseases. Over the last thirty years, successive “diagnostic criteria” have made 
use of advances in technology to better define and improve the accuracy of MS diagnosis. 
For example, the Poser Criteria (1983) (267) were succeeded by the McDonald Criteria 
(2001), which were revised in 2005 (268) and 2010 (269). Considered the ‘gold standard’, 
the McDonald Criteria (2010) relies on the demonstration of lesions disseminated in space 
and time, the exclusion of other diseases (269), and may require supporting data such as 
radiological findings (e.g. MRI), CSF analysis (e.g. oligoclonal band (OCB) detection) and 
evoked potentials (e.g. visual evoked potentials) (268, 270). To fulfil the McDonald 
Criteria, an individual must show objective clinical evidence of two lesions or objective 
clinical evidence of one lesion with reasonable historical evidence of a prior attack (269). 
Individuals are identified as “have MS”, “possible MS” or “not MS” (271).  
 
 1.7.2 MS subtypes  
Multiple sclerosis is categorised into four main subtypes: relapsing-remitting MS (RRMS), 
secondary progressive MS (SPMS), primary progressive MS (PPMS) and progressive-
relapsing MS (PRMS). The most common form of the disease is RRMS, which affects 
~85% of persons with MS. The disease course is highly variable, but is generally 
characterised by exacerbations of symptoms that last for days or weeks (233, 234), but 
with good recovery between episodes. Frequency of these relapses is unpredictable and, 
over time, recovery from each episode may become incomplete with accumulating 
disability. This progression is known as SPMS, and eventually occurs in 70% to 80% of 
MS patients (233). PPMS comprise between 10% and 15% of MS patients at diagnosis and 
is characterised by a gradually progressive increase in disability (233). Approximately 1% 
of persons with MS are diagnosed with PRMS, in which only partial or no recovery after 
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exacerbation occurs and disability accumulates in a stepwise manner (233). Figure 9 shows 
the MS subtypes by time versus disability. 
 
 
 
 
 
 
Figure 9. MS subtypes according to time and disability 
Image from: http://www.redefiningmyself.com/p/ms-articles.html. 
 
Within the RRMS course exists the subset of benign MS, which describes patients that 
show little or no disease progression over time, and minimal disability from disease onset 
(272, 273). Benign MS is uncommon and difficult to diagnose (273); lesions are often 
discovered retrospectively by chance imaging or at postmortem (274). The true frequency 
is unknown but it is thought to represent about 6% to 64% of all MS cases (272).  
 
Between 85% and 90% of RRMS and PRMS patients present with a first attack, known as 
a first demyelinating event (FDE) or a clinically isolated syndrome (275, 276). A FDE can 
occur anywhere in the CNS and produces a range of symptoms affecting vision, 
movement, senses and/or cognition, depending on the demyelination site (277-280). The 
attack lasts for at least 24 hours with demyelination and/or inflammation occurring in one 
or more CNS sites (281). A FDE is often a good prognostic indicator of the eventual 
disease course: between 30% and 72% of FDE patients progress to “have MS” within 12 
months after presentation (275, 278).  
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 1.7.3 Pathology of MS 
In the human brain, neuroglial cells (or glial cells), which are divided into macroglia and 
microglia, support neurons by insulating them and regulating the extracellular environment 
(282). Macroglia include astrocytes, oligodendrocytes and Schwann cells. Astrocytes 
maintain homeostasis by creating a tight physical barrier known as the blood-brain barrier. 
Oligodendrocytes and Schwann cells produce myelin, a fatty layer that surrounds and 
insulates axons, and is essential for effective neuronal conductivity and signal transmission 
(283). Oligodendrocytes are found within the CNS, whereas Schwann cells are located in 
the peripheral nervous system (i.e. outside of CNS). Microcroglia are macrophagocytic 
cells that are responsible for immune function in the CNS (284). 
 
Multiple sclerosis is characterised by sclerotic plaques or lesions in the brain and/or spinal 
cord representing macroscopic areas (viewable using a magnetic resonance image (MRI) 
scan) of damaged myelin sheaths (285). In a healthy neuron, myelination of the axon 
increases the conduction speed of the electrical impulse (286, 287). Loss of myelin is 
termed demyelination, and results in slowed electrical impulse transmission. Figure 10A 
shows the basic structure of a neuron; Figure 10B shows a healthy versus a damaged 
neuron. Demyelination typically involves the inner part of the brain (consisting of 
neuroglial cells and myelinated axons) known as the ‘white matter’ (288), but lesions in 
the cerebral cortex or the outer brain compartments (comprising of capillary blood vessels 
and neuronal cell bodies) known as the ‘grey matter’ have also been reported (289). 
Generally, MS symptoms and signs are reflected at the location of CNS damage. Table 12 
shows the lesion site and the associated symptom(s). 
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Figure 10. A. Basic structure of a neuron B. A myelinated versus a demyelinated axon  
Image A modified from: http://neuro.psyc.memphis.edu/1200/neuroscience/media/m03t008a1f1.gif; image B 
modified from: http://activebiotech.com/$2/ab-2001-eng.pdf (page 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuron 
 
B. A. 
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Table 12. Lesion site and associated MS symptoms and signs 
 
Images: Panel 1, cerebrum (longitudinal section); Panel 2, optic nerve (transverse section); Panel 3, cerebellum; Panel 
4, brainstem (arrow; mid-section); Panel 5, cervical spinal cord; Panel 6, full body scan. Red arrow shows region of 
demyelination. Images 1-5 from: (290). Image 6 from: http://www.aimmedicalimaging.com/.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRI panel Lesion site MS symptoms and signs References 
    
 Cerebrum Cognitive impairment (e.g. deficits in attention, 
reasoning and executive function), affective disorders 
(e.g. depression), epilepsy, dementia, mood swings, 
anxiety 
(270, 290)  
 Optic nerve Eye pain, vision loss, decreased visual acuity, blind 
spots, loss of colour vision, lack of eye coordination, 
abnormal pupil responses, flashes of light, double vision 
(270, 290-292)  
 Cerebellum Tremor, poor balance, clumsiness, limb incoordination, 
gait disturbances 
(270, 290-293)  
 Brain stem Vertigo, double vision, impaired speech, swallowing 
difficulties, loss of coordination, tinnitus, hearing loss, 
facial numbness, electric shock-like pain in face  
(270, 290, 293) 
 Spinal cord Muscle weakness, stiffness and painful spasms, bladder 
dysfunction, constipation, sexual dysfunction, numbness, 
burning/stabbing sensations, electrical sensations 
(270, 290-293)  
 Other  Pain, fatigue, temperature sensitivity, exercise 
intolerance, headaches, itching, pathological laughing 
and crying 
(252, 270, 290, 
293-297)  
 
1
2
3
4. 
5. 
6
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 1.7.4 Pathogenesis of MS 
The exact pathogenesis of MS remains uncertain, but the disease process is traditionally 
thought to be an example of an autoimmune disease mediated by both the innate and 
adaptive immune systems (298, 299). Histological examination of demyelinating lesions 
shows T cells (e.g. CD4
+
/CD8
+
 T cells, αβ and γδ T cells) (300), macrophages, monocytes, 
the occasional B cell and plasma cells (288). However, it unclear as to which immune 
cell(s) initiates the original damage; some cells are thought to be present as a reactive 
response to demyelination.  
 
For decades, CD4
+
 T cells were believed to mediate the inflammatory response. This 
perception was largely due to similarities with the animal model representing MS as an 
autoimmune disease (see section 1.7.5), where CD4
+
 T cells predominate (249, 250). 
However, studies of human MS found that CD8
+
 T cells outnumber CD4
+
 T cells (301-
304), suggesting that CD8
+
 T cells drive the inflammatory process. Supporting this are a 
number of studies which have shown an enrichment and persistence of CD8
+
 T cells in the 
brain (305) and CSF of MS patients (304, 306). In the viral animal models of MS (see 
section 1.7.5), the number of CD8
+
 T cells has been shown to correlate with the axonal 
injury and motor disability (307). In relation to EBV, a number of studies have shown a 
strong EBV-specific CD4
+
 T cell (308, 309) and CD8
+
 T cell response in those with MS 
(303, 310). In regards to HHV-6, the role of CD4
+
 T cells and CD8
+
 T cells in association 
with MS is unclear.  
 
The antigen or ‘autoantigen’ eliciting the T cell autoimmune response has yet to be 
elucidated, but a number of targets have been identified including myelin and non-myelin 
antigens. Myelin derivatives comprise proteolipid proteins (311), myelin basic proteins 
(311), myelin oligodendrocyte glycoproteins (312) and myelin-associated glycoproteins 
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(311, 313, 314). Non-myelin antigens include αβ-crystallin (315) (see ‘mistaken identity’ 
hypothesis in section 1.8.3), a small heat-shock protein found in small quantities in only a 
select few tissues (e.g. cardiac and skeletal muscle) (316), and contactin-2, a neuronal 
protein found in brain grey matter (317). 
 
Support for a role for B cells in the pathogenesis of MS comes from several findings. For 
example, electrophoretic separation of CSF antibodies reveals OCBs, which provide 
powerful evidence for the diagnosis of MS (318). OCBs persist throughout the course of 
disease and are found in the CSF of more than 95% of MS patients (319). Furthermore, 
increased antibody titres to specific viruses such as EBV (320, 321), HHV-6 (322) and 
CMV (323) have also been found in the blood of MS patients, particularly during the early 
stages of disease (142, 324, 325). These findings suggest that the viruses may be involved 
in triggering MS, with a number of studies linking the risk of MS with increasing EBV-and 
HHV-6-specific antibody titres (321, 326, 327). Also, antibodies appear to function in 
combination with the complement system to enhance immune function (328). Both 
complement and IgG antibodies (but not complement alone), have been detected within the 
brains of MS patients (329). Adding to this evidence of B cell involvement in MS, 
therapeutic studies of the drug, Rituximab, a monoclonal antibody that acts specifically 
against the B cell surface protein, CD20, has proven successful in the treatment of MS 
(330, 331) and other autoimmune diseases (e.g. Sjögren's syndrome) (332). Rituximab 
depletes CD20-expressing B cells, leading to fewer numbers of MS lesions and relapses 
(330, 333). Despite these findings, the role of B cells and antibodies in MS is unclear for 
two reasons. First, the number of B cells and plasma cells within MS lesions is variable 
and thus, cannot account for the entire inflammatory process. Second, in a rat model, 
administration of rabbit anti-rat IgM antiserum was shown to suppress B cell functionality 
and failed to induce clinical or histological evidence of MS (328, 334).  
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 1.7.5 Animal models of MS 
Three animal models, representing three possible causal factors, are used in MS research: 
1.) An autoimmune model (experimental allergic or autoimmune encephalomyelitis 
(EAE)) (249, 250); 2.) A toxin-induced model (249); and 3.) A viral model (Theiler’s 
murine encephalomyelitis virus (TMEV) and Murine hepatitis virus (MHV)) (250). The 
EAE model supports the concept that MS is an autoimmune disease (249, 251). Here, 
injection of known myelin proteins (e.g. myelin oligodendrocyte glycoprotein, myelin 
basic protein or proteolipid protein) produces features similar to human MS, although 
depending on the antigen and the genetic background of the mice used, the disability is 
generally of short duration and recovery between episodes is complete (335, 336). The 
second model focuses on the paradigm that MS is toxin-induced, with lysolecithin, an 
activator of phospholipase A2, and the copper chelator, cuprizone, used to produce the 
animal model. Here, introduction of the toxin(s) causes demyelination, but upon removal, 
remyelination occurs usually within weeks (249). The viral model is based on the notion 
that viral infection early in life in association with a specific genetic background, may 
result in an immune-mediated attack against CNS tissues. However, this model does not 
produce relapses (as in RRMS), and a MS-specific virus has yet to be identified (249, 250).  
 
 1.7.6 Risk factors for MS 
Multiple sclerosis is a complex disease caused by the interplay between genetic and 
environmental factors, with the relative importance of each factor varying between 
individuals. Risk factors may work alone (e.g. genetics only), or interact with one another 
for an additive effect to enhance the risk (e.g. genetics plus cigarette smoking). Interactions 
may involve gene-environment or environment-environment interactions. Figure 11 shows 
how these factors work together to increase the risk of MS. 
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Figure 11. The overlap between genetic and environmental risk factors for MS  
Image from reference: (265). 
 
1.7.6.1 Genetic and biological risk factors  
Genetic and biological risk factors for MS include: 
 Degree of relatedness. First, second and third degree relatives of people with MS are 
more likely to develop the disease than the general population (265, 337).  
 Susceptibility genes. Genome-wide association studies have identified >50 distinct MS 
susceptibility genes (265, 266). Those carrying the HLA class II alleles have the highest 
MS risk (263-265, 338), and the greater the number of susceptibility genes an individual 
has, the greater the MS risk (339). 
 Race and/or ethnicity. MS predominately affects Caucasians and is virtually non-
existent amongst New Zealand Maoris, western Pacific Islanders, Chinese, Japanese and 
African blacks (246, 340). In the USA, MS is twice as common in American whites 
compared to African-Americans (although this trend is changing) (341), and is 
uncommon among North American Indians (246) and Latin Americans (342). In 
Australia, MS occurs more frequently in Caucasians and is rare in Australian 
Aborigines (246).  
 Sex. More females than males are affected with MS (237). In Australia, females 
comprise approximately 73% of MS cases (292), with the average F:M ratio at 3:1 
(343). This difference in sex ratio may be attributed to both biological (e.g. pregnancy 
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and parity) and environmental (e.g. smoking and latitude) influences (236, 240). 
 
1.7.6.2 Environmental risk factors 
Since only a small fraction of the MS risk may be explained by genetics and/or biology 
(i.e. there is an incomplete genetic or biological penetrance), there is reason to believe that 
other factors, such as the environment, may contribute to the development of MS. Four 
environmental risk factors consistently linked with MS include:  
 Geographical latitude. Generally, the greater the distance from the Equator (in both 
northern and southern directions), the greater the prevalence (260), incidence (261, 344) 
and mortality of MS (345, 346). In Australia, the highest prevalence of MS (based on 
1981 data) is in Tasmania at 68 cases per 100,000, followed by South Australia at 30 
cases per 100,000, 34 cases per 100,000 for New South Wales; 24 cases per 100,000 for 
Western Australia and 19 cases per 100,000 for Queensland (340). Although the 
prevalence has increased in some states (e.g. 100 cases per 100,000 in Tasmania) (292), 
this trend has remained constant since the 1960s (347). The latitudinal effect has also 
been demonstrated in New Zealand (348), Europe (349-352), North America (243) and 
Central and South America (241).  
 Ultraviolet radiation (UVR) and vitamin D status. Increased sun exposure, either 
antenatally (353), in childhood (262, 354) or in adulthood (355, 356) is associated with 
decreased risk of MS. High UVR exposure and vitamin D is thought to lower the MS 
risk by suppressing the Th1 and Th17 pathways and inducing iTreg cells (357-359). 
 Cigarette smoking. The risk of developing MS is higher in those who have smoked 
cigarettes compared with never-smokers (360). In persons with MS, cigarette smoking 
may lead to an aggravation of symptoms (361), acceleration or transition of disease (e.g. 
clinically isolated syndrome to clinical definite MS (362) or RRMS to SPMS (363)), 
and a worsened disease prognosis (364). One theory is that MS ensues from an 
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overactive system attempting to repair damaged endothelial cells caused by smoking 
(365). 
 History of viral infection. The risk of MS in those with a history of IM (EBV 
infection) is increased by approximately two-fold (366, 367). This is regardless of sex, 
age, time since infection and severity of infection, with the risk of MS persisting for up 
to 30 years following IM (368). This risk appears to be EBV specific, with the 
probability of MS occurring following IM higher compared with other childhood 
infections such as rubella, measles, mumps and chicken pox (361, 369). The risk of MS 
following ES is unknown, but evidence of HHV-6 infection (i.e. HHV-6 IgM 
antibodies) has been found at higher proportions in persons with MS (clinically isolated 
syndrome and RRMS) compared with healthy controls (142, 370) (see sections 1.8.1.1 
and 1.8.2.1 for more detailed discussions). 
 
1.7.6.3 Interaction of risk factors 
Risk factors may also interact to increase the probability of MS development. For example: 
 Gene-environment. The presence of both HLA DRB1positivity and high EBNA-1 
antibody titres (371, 372) or history of IM have been associated with a super-additive 
increase in the risk of developing MS (373) (i.e. there is a marked increase in the risk of 
developing MS that is greater than the additive effects of the individual risk factors). 
The risk of MS following HHV-6 infection has been less studied, but IRF5 (374) and 
MHC2TA rs4774C (375, 376) have been designated putative risk genes for MS 
associated with HHV-6A infection. 
 Environment-environment. The risk of MS in persons infected with EBV may be 
enhanced by cigarette smoking (377, 378), however this has yet to be confirmed (379). 
The effects of smoking in association with HHV-6 infection on the risk of MS are 
unknown. Also, EBV infection combined with low vitamin D status (or low 25(OH)D 
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levels) has been hypothesised as the driving force behind the latitude gradient effect 
(360, 380). Low sun exposure has been theorised to decrease CD8
+
 T cells and thus, 
lead to inefficiencies in controlling EBV infection. Interactions between HHV-6 
infection and sunlight in relation to the risk of MS are unknown.  
 
 1.7.7 Viral infection as a cause of MS  
Several sources of evidence implicate viral infection as a cause of MS. Epidemiological 
studies of MS on the Faroe Islands between 1920 and 1977 suggests that MS may have 
originated from an infectious, transmissible source introduced by British troops, or by their 
luggage, stationed on the islands during World War II (381-383). There are also clear 
examples of virus-induced inflammatory demyelinating diseases in both humans (e.g. 
progressive multifocal leukoencephalopathy (PML) (384) and animals (e.g. TMEV, MHV 
and canine distemper virus (250); shown in Table 13). Furthermore, studies have shown 
that some viral infections cause abnormal immune responses, such as the production of 
OCBs as seen in persons with MS. OCBs are found almost exclusively in CNS disorders of 
infectious origins (i.e. there are no genetic disorders in which the brain and CSF produce 
OCBs) (383) such as neurosyphilis and subacute sclerosing panencephalitis (382).  
 
Table 13. Viruses reported as being associated with demyelinating diseases in animals 
and humans  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compiled from reference: (385). 
 
Virus Family Hosts 
Semliki forest virus  Togaviridae Mouse 
Ross river virus  Togaviridae Mouse 
Venezuelan equine encephalitis virus Togaviridae Mouse 
Mouse hepatitis virus  Coronaviridae Mouse, rat, non-human primates 
Measles  Paramyxovirus Rodents 
Canine distemper virus Paramyxovirus Dog 
JC virus  Papovaviridae  Humans 
Theiler’s virus  Picornaviridae  Mouse 
Maedi-visna virus  Retroviridae  Sheep 
Human T cell lymphotropic virus type I Retroviridae Humans 
Human immunodeficiency virus infection Retroviridae Humans 
Vesicular stomatitis virus  Rhabdoviridae  Mouse 
Chandipura virus  Rhabdoviridae Mouse 
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 Role of EBV and HHV-6 in MS  1.8
Two herpesviruses, EBV and HHV-6, have consistently been implicated in the 
pathogenesis of MS. Key laboratory evidence supporting EBV involvement in MS is 
discussed in section 1.8.1 (plus the collaborative review paper, Publication 1; Lucas et al, 
2011) and HHV-6 in section 1.8.2. 
 
Evidence to support a role of EBV and/or HHV-6 in the pathogenesis of MS includes that:  
1. Both viruses are capable of inducing CNS demyelination in humans. For example, 
EBV-associated LPD has been shown to trigger demyelinating polyneuropathy 
(386), while HHV-6 infection (in conjunction with JC polyoma virus infection) has 
been associated with PML development (387).  
2. Each of the viruses shares small sections of their genomes that are genetically and 
structurally similar to specific proteins in the human body, thus rendering the host 
susceptible to autoimmune attacks. For example, a small number of EBNA-1-
specific CD4
+
 T cells (308) and the HHV-6 gene, U24 (388, 389), have the 
potential to cross-react with myelin basic protein, a candidate autoantigen 
hypothesised to cause demyelination.  
3. Evidence of infection with either or both viruses is common in the MS population. 
For example, observational studies have shown that EBV and HHV-6 seropositivity 
is higher in MS patients compared with healthy, matched controls (218, 360, 390-
393).  
4. An immune response to both viruses has been found in the early stages of MS 
(142). For example, a greater immune response (i.e. high levels of CD8
+
 T cell 
activation) against EBV has been found in FDE patients compared with any MS 
subtype (303). Studies have shown EBV and/or HHV-6 infection to be more active 
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in the initial stages of MS, with viral DNA frequently detected in the early stages of 
disease (139, 394).  
5. Both viruses persist lifelong following primary infection and can reactivate during 
periods of immunosuppression (166, 395), sudden illness (396, 397), trauma (398) 
and pregnancy (399, 400). Most other viruses are eliminated after acute infection 
(e.g. measles). This is important as MS is a permanent disease characterised by 
periods of ailment followed by remission. 
6. EBV infection often precedes the primary onset of MS by years. This contrasts with 
other viral infections that precede MS relapses by weeks (e.g. influenza) (401). 
7. EBV is the main virus known to transform B cells. B cells are hypothesised to play 
a role in the pathogenesis of MS. B cells also produce virus-specific antibodies (i.e. 
OCBs) that are consistently found in MS patients and are considered strong, robust 
markers of MS risk (320).  
8. HHV-6 has been linked with other neurological conditions (e.g. encephalitis) (127, 
402) and is capable of infecting different CNS cells (e.g. astrocytes) (127, 403).   
9. EBV and HHV-6 appear to have a synergistic effect; co-expression of these viruses 
has been associated with an increase in clinical disease activity (120). 
 
 1.8.1 Laboratory evidence for a role of EBV in MS  
1.8.1.1 Serological evidence 
Observational studies have found that between 98.6% and 100% of MS cases are EBV 
seropositive compared with 35.7% to 90.1% of healthy controls (matched by age, sex, race, 
ethnicity, area, socioeconomic status or dates of blood collection) (390, 391, 393). This 
finding appears to be mostly specific for EBV, with significant case-control differences not 
found for other viral infections (e.g. HSV-1, CMV, VZV or parvovirus B19) (393, 404). 
The risk of MS is much lower among those previously not infected with EBV, but 
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increases sharply in the same individuals following EBV infection (390). In a paediatric 
study of children with acute demyelination, those with serological evidence of past EBV 
infection were twice as likely to be diagnosed with MS compared with those that were 
EBV seronegative (hazard ratio = 2.55, 95% CI 1.26 to 5.18) (405). This risk also 
intensified with increasing EBV-specific antibody titres (326, 406-408). For example, 
several studies have shown that in serum collected years prior to disease onset (one year up 
to 20 years), a four-fold or greater increase in EBNA (including EBNA-complex, EBNA-1 
and EBNA-2) IgG antibody titre was associated with a two-fold greater risk of developing 
MS (320, 326, 406, 408), with elevated VCA-specific serum antibody titres another strong 
contributor (407). 
 
In a number of prospective studies, EBV antibodies were found at significantly high titres 
five or more years preceding the onset of MS symptoms (326, 407-409). This suggests that 
EBV infection prior to the onset of MS may be important in disease development. The risk 
of MS also appears to be age-dependent (risk increases between late teens and the mid to 
late twenties) (408), with serum antibody titres to EBNA-1 IgG shown to be two- to three-
folds higher in persons 25 years or older with an eventual MS diagnosis, compared with 
matched controls (P < 0.001) (408). This data is consistent with findings that late rather 
than early EBV infection in life (i.e. IM versus primary infection) is associated with a 
greater risk of MS. In a meta-analysis of MS risk following IM, the combined relative risk 
from 18 studies was 2.17 (95% CI 1.97 to 2.39, P < 0.00001) (366). This risk also appears 
to be modified by the age at which IM occurs. For example, one study showed that 
individuals with a self-reported history of IM before the age of 17 years had nearly an 
eight-fold higher risk of MS compared to seronegative individuals with no recall of prior 
IM (OR = 7.9, 95% CI 1.7 to 37.9, P = 0.01) (410). Again, this appears mostly specific for 
EBV, with the recall of other viral infections (e.g. measles, mumps, rubella and 
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chickenpox) in the first few years after puberty not correlated with an increased risk of MS 
(369, 410). Taken together, the data supports the hypothesis that EBV infection, 
particularly the age at which infection occurs, could be important in the pathogenesis of 
MS. Figure 12 shows the typical patterns of the incidence of MS by early, late and no EBV 
infection. 
 
 
 
 
 
 
 
Figure 12. Hypothetical patterns of MS incidence according to the age at which EBV 
infection occurs  
The above curves are a schematic representation only. The curve labelled “Early EBV infection without IM” 
is based on the typical age-specific MS incidence in most populations; incidence begins to increase in 
adolescence, peaks around age 25 to 30 years, and declines to nearly zero by age 60. The age-specific 
incidence for the group “No EBV infection” has been drawn at one-tenth the incidence among EBV-positive 
individuals (based on a previous review) (411). Those with “Late EBV infection and IM” have been 
estimated to be 2.3 times higher than that of EBV-positive individuals without history of IM (367). Image 
from reference: (367). 
 
1.8.1.2 NAT evidence 
Epstein-Barr virus DNA has been detected in MS patients from various specimen types 
including blood (125, 412, 413), saliva (120), CSF (121) and brain tissue (392), but the 
evidence in relation to MS risk is so far inconclusive. For example, a number of studies 
have found EBV DNA in only a small proportion of persons with MS (121, 414-416), or 
have failed to detect EBV DNA altogether (122, 417, 418). One study however, found a 
statistically significant difference in the prevalence of EBV DNA positivity (and HHV-7 
DNA) between MS patients and healthy controls (31.3% v 3.9% and 33.3% v 9.8%; 
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P < 0.001 and P = 0.03, respectively) (419), but the sample size was small (n = 51) and the 
data derived from a small North African country with a medium MS prevalence (420). In 
another study, the presence of EBV DNA was associated with a more than two-fold 
increase in MS risk, but the difference was not statistically significant (RR = 2.5, 95%, CI 
0.78 to 7.8, P = 0.12) (125). EBV DNA has often been detected in the early stages of 
disease, with studies finding up to 72.7% of serum EBV DNA in MS persons experiencing 
exacerbations (compared with 0% with clinically stable disease (n = 19)) (393), and 42.8% 
of RRMS patients with acute episodic attacks (i.e. on day 1 of symptoms) (119). Slight 
increases in DNA load have also been found before or during clinical relapses, but again, 
the results were from a small number of subjects (n = 10) (413). Co-infection with HHV-
6B has also been found to enhance MS activity, with one study finding the presence of 
EBV and HHV-6B DNA in plasma associated with higher MS disability scores, lesion 
number and attack rate (120). However, it is important to note that NAT methods are 
highly variable and PCR results may be influenced by other factors (e.g. biological and 
technical variability such as PCR target, DNA extraction, detection chemistry, specimen 
type) (195, 421-424), and thus, may not mirror the actual EBV DNA activity in persons 
with MS. 
 
1.8.1.3 Genotypic evidence 
Few studies have shown specific EBV genotypes in association with MS. For example, in a 
small Danish study of eight MS patients, all were identified as being infected with EBV 
genotype A. Interestingly, all subjects harboured the same mutation consisting of three 39 
bp repeats within the EBNA-6 region (425). In a more recent study, extensive sequence 
polymorphisms within the EBNA-1 and BRRF-2 genes occurring at marginally different 
frequencies were found between MS patients and controls, however this was not 
statistically significant (50). Again, all persons with MS were infected with EBV genotype 
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A, but a definitive link between the EBV strains and MS could not be established. Other 
studies have not been able to verify the existence of a specific EBV genotype and/or strain 
affecting those with MS (426, 427). 
 
 1.8.2 Laboratory evidence for a role of HHV-6 in MS 
1.8.2.1 Serological evidence 
The seroprevalence of HHV-6 is generally higher in MS patients compared with healthy 
controls. Previous studies have demonstrated a higher HHV-6 IgG antibody positivity in 
MS patients (up to 100%) versus those with other neurological diseases and healthy age- 
and sex-matched controls (between 69% and 75%) (138, 141, 218, 324). Antibodies to 
HHV-6A have been detected more frequently than HHV-6B, with HHV-6A often found at 
a higher positivity in patients with clinically definite and clinically possible MS versus 
those with other neurological diseases (14.8% and 21.1% versus 3.8%, respectively) (218). 
HHV-6-specific serum antibodies appear to develop in the early stages of MS, with one 
study finding a higher seroprevalence and antibody titres to HHV-6 IgG and IgM in 
clinically isolated syndrome and RRMS patients compared with healthy controls (325). 
IgM antibodies to HHV-6 have also been found more frequently in RRMS patients (142), 
with high titres associated with an increased risk of relapse (428). 
 
The serological evidence of a role of HHV-6 in MS is mixed. In one particular study, 
HHV-6 IgG intrathecal antibodies were detected in only 20% of MS patients (429), of 
which a subset of patients also showed immune reactivity against at least one other, 
unrelated virus (e.g. HSV-1, measles virus, CMV, rubella virus, VZV). This suggests that 
the immune response to HHV-6 may be non-specific and that MS is not triggered directly 
by HHV-6 infection, but rather a coincidental immune response mounted against the virus 
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(429). In support of this, other studies have not been able to find any differences in HHV-
6-specific antibody positivity or titres between MS patients and controls (430, 431). 
 
1.8.2.2 NAT evidence 
Human herpesvirus-6 DNA has been detected more frequently in MS patients compared 
with healthy blood donors (138) and in those with other neurological diseases (415). HHV-
6 DNA positivity appears to be higher in MS patients with active disease versus remission 
(432-435), with HHV-6 DNA positivity and load increased during relapses (143). The 
HHV-6 DNA load also appears to fluctuate with disease severity, with studies finding 
significant increases in HHV-6 DNA load in acute MS disease versus remission (e.g. 7.7 x 
10
2
 versus 4.9 x 10
2
 copies/mL of serum) (138, 436). However, it has been suggested that 
HHV-6 DNA load may not be a good indicator of viral activity in MS compared to other 
diseases (e.g. PTLD), as a number of studies have not found significant differences in the 
median HHV-6 DNA load between MS patients and controls (140, 144, 415, 433).  
 
While the evidence presented thus far suggests a degree of HHV-6 involvement in MS, a 
number of observational studies have not been able to find significant differences in HHV-
6 DNA positivity between those with MS (5.8% to 34.3%) and controls (1.96% to 39%) 
(120, 419, 437, 438), and some have failed to detect HHV-6 infection in persons with MS 
(439, 440). 
 
1.8.2.3 Genotypic evidence 
Evidence of HHV-6A and/or HHV-6B infection has been found in patients with MS. In 
early studies, HHV-6B infections predominated in MS patients (136, 441, 442), however, 
this has shifted towards HHV-6A after it was discovered that this species was more 
neurotropic and had a tendency to persist in CNS tissues (443). Since then, the vast 
59 
 
majority of studies have found a higher prevalence of HHV-6A than HHV-6B in serum, 
PBMC and urine from persons with MS compared with healthy controls and those with 
other neurological diseases (137, 218, 444-447). HHV-6A infection also appears to modify 
disease activity, with one study showing active HHV-6A infection was correlated with 
disease exacerbation in a small subset of RRMS patients (432). Despite the evidence, a 
definitive link between MS and a particular species of HHV-6 has yet to be confirmed. 
 
 1.8.3 Potential mechanisms whereby EBV and HHV-6 could cause MS 
Mechanisms by which EBV and HHV-6 could modulate the immune system to cause MS 
include: 
1. The cross-reactivity (molecular mimicry) hypothesis. T and B cells that have been 
exposed to EBV antigens cross-react with CNS antigens (i.e. self-antigens) to mount 
an immune response (5, 448). In support of this, between 3% and 4% of EBNA-1-
specific T cells in MS patients (and healthy individuals) cross-react with peptides 
derived from myelin proteins (308). In the same way, the HHV-6 protein, U24, shares 
sequence similarities with the myelin basic protein (388, 389). 
2. The bystander damage hypothesis. Damage to the CNS occurs from a direct attack 
against EBV or HHV-6. That is, cytotoxic molecules diffuse from virus-infected sites 
to CNS tissues to cause ‘spectator’ damage (392). 
3. The mistaken self or αB-crystallin hypothesis. αB-crystallin, a small heat shock 
protein expressed following EBV infection, activates T or B cells to mount an attack 
on αB-crystallin derived from oligodendrocytes (cross-reactivity hypothesis), which in 
turn causes damage to CNS tissues (319, 449). 
4. The EBV-infected auto-reactive B cell hypothesis. In genetically susceptible 
individuals, EBV infection causes the activation of CD4
+ 
T cells which then cross-
react with CNS antigens to cause tissue damage (448, 450, 451).  
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5. The viral infection variant of the hygiene hypothesis. Viral infection without the 
protective benefit of an earlier infection with another virus (e.g. HSV) increases the 
risk of MS (310).  
6. The cytopathic action hypothesis. Exposure to viral proteins may produce immune 
responses that cause direct cellular changes to the CNS tissue. For example, HHV-6A 
virions are capable of inducing apoptosis of neuroglial cells (452) by releasing 
cytokines (e.g. IL-17A and IL-1β) (453) or by modulating glutamate levels, which at 
high concentrations may cause neuroaxonal cell death (403). 
7. The epitope spreading hypothesis. As demonstrated in the TMV rodent model (454), 
the immune system begins to respond to other antigens after being exposed to an 
initial antigen (455).  
 
 Publication 1 summary (Lucas et al, 2011)  1.9
This publication accompanies the literature review and appraises the evidence published 
over the last forty years connecting EBV infection to MS risk and development. 
Supporting data include latitudinal gradient similarities between MS and EBV, history of 
IM, serology and DNA work, host T cell responses, and a brief discussion on the 
mechanisms by which EBV could initiate or perpetuate the disease process. The quality 
and quantity of evidence in relation to measures of EBV infection and the risk of MS were 
also assessed, with the level of evidence for MS association greatest for history of IM and 
the presence of EBV serum antibodies. Note: an online supplement accompanying the 
manuscript describing the background to the virus and its interactions with the human host 
is available at http://jnnp.bmj.com/content/82/10/1142/suppl/DC1. 
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 Thesis aims 1.10
A review of the literature on EBV and HHV-6 in association with MS has highlighted the 
following gaps: 
 There is an apparent lack of consensus and standardisation on how to perform and 
interpret real-time qPCR experiments, mostly brought about by variations in qPCR 
design   
 Some studies of EBV and HHV-6-specific antibody responses have shown that virus-
specific serology is useful in predicting disease outcome in FDE patients. More recent 
literature has focused on the detection and quantification of EBV and HHV-6 DNA in 
those with clinically definite disease such as RRMS and PPMS, rather than at FDE, a 
precursor for MS. The importance of viral DNA in FDE patients is largely unknown, 
and the data generated thus far are inconclusive  
 Little is known about the EBV and HHV-6 genotypes and strains affecting MS 
patients. Instead, the majority of work over the past decade has focused on sequence 
mutations at specific gene loci. Again, most work has centred on those with clinically 
definite disease (e.g. RRMS and PPMS). To date, there has been no EBV and HHV-6 
genotyping data published on individuals with FDE. Added to this are the inadequate 
and out-dated genotype and strain data for EBV and HHV-6 in virus-related illnesses, 
particularly in Australia. 
 
Thus, the aims of this thesis were to:  
1. Develop a sensitive real-time qPCR assay using SYBR Green I for detection and 
quantification of EBV and HHV-6 DNA. This objective was divided into two 
separate aims: 
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i. To develop a qPCR assay for the detection and quantification of EBV 
DNA (Chapter 4) 
ii. To develop a qPCR assay for the detection and quantification of HHV-6 
DNA (Chapter 5) 
Note: These aims involved the development of a human β-globin qPCR, a reference gene 
that was used specifically to normalise data for the Ausimmune Study for expression of 
viral load as copies/µg. 
 
2. Application of the above qPCR methods to clinical and research populations with 
individual aims consisting of: 
i. Detection and measurement of EBV and HHV-6 DNA in hospitalised 
patients with an EBV or HHV-6-related illness or an immune derangement 
ii. Detection and measurement of EBV and HHV-6 DNA and virus-specific 
antibody titres in case and control participants from The Ausimmune 
Study (newly diagnosed FDE cases versus non-FDE controls). This aim 
accompanied the viral infection sub-study of The Ausimmune Study  
 
3. To identify the EBV and HHV-6 genotypes and strains circulating in the above 
populations (Chapter 6).  
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2.1 Materials and methods 
 2.1.1 Study populations and ethics 
Data in this thesis were derived from biological samples from two population-based 
research studies examining environmental risk factors for MS: The Ausimmune Study; and 
The Southern Tasmanian Multiple Sclerosis Longitudinal Study (MSL). The Ausimmune 
Study was approved by nine regional Human Research Ethics Committees. The MSL 
Study was approved by the Southern Tasmania Human Research Ethics Committee. All 
participants provided written informed consent. Additional samples comprising specimens 
from hospitalised patients suspected of having a virus-related disease were also tested. 
These samples were tested following approval by the Sydney West Area Health Service 
Human Research Ethics Committee. 
 
2.1.1.1 The Ausimmune Study 
The Australian Multicentre Study of Environment and Immune Function, otherwise known 
as the Ausimmune Study, is a National Multiple Sclerosis Society of the United States of 
America (USA) funded study formed to understand the influences of environmental factors 
on the onset of CNS demyelination. Primary aims of this study included examination of: 
1.) how immune disorders vary by latitude across Australia; and 2.) how environmental 
factors influence immune diseases (e.g. past and recent sun exposure (and vitamin D), viral 
infections, chemical exposures and diet, and genetic factors). 
 
This thesis focuses on infectious agents (namely the herpesviruses, EBV and HHV-6) as 
environmental risk factors for the onset of CNS demyelination, particularly a first 
demyelinating event (FDE), which is a common precursor to MS. This viral sub-study was 
established in 2005 and funded by National Health and Medical Research Council 
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(NHMRC) of Australia, Project Grant 316901 (both supervisors are investigators in this 
grant). 
 
The Ausimmune Study is a multi-centre case-control study in four Australian regions: 
Brisbane, Newcastle, Geelong and the Western Districts of Victoria, and Tasmania (Table 
14; Figure 13). These regions were chosen to cover a wide latitudinal span and to allow 
large enough populations to generate sufficient case numbers. The Ausimmune Study 
recruited 840 participants aged between 18 and 61 years that were divided into cases (n = 
282) and controls (n = 558). Case participants included those with a first clinical diagnosis 
of CNS demyelination (FCD) such as individuals presenting with an FDE (n = 216), a first 
diagnosis of PPMS (n = 18), and those with a history suggestive of a previous, 
undiagnosed demyelinating event (thus now presenting with MS (n = 48). Control 
participants included individuals randomly selected from the Australian electoral roll and 
case-matched by sex, study region (postcode) and age (± 2 years). For this thesis (i.e. the 
viral infection sub-study), a subset of these participants (n = 431) and their samples were 
randomly selected from the full study group, culminating in 213 cases and 218 controls. 
The design and conduct of the Ausimmune Study is described in detail elsewhere (1).  
 
Table 14. The viral infection sub-study of the Ausimmune Study 
Recruitment took place over 3 years (1 November, 2003 to 31 December, 2006). 
 
*ABS 2001 Census 
 
Latitude Australian region Total population* Case Control 
     
27º Queensland; Brisbane 1,602,251 73 78 
33º New South Wales; Newcastle 485,977 28 28 
38º Victoria; western districts and Geelong  475,257 45 45 
43º Tasmania; Hobart 456,652 67 67 
  n = 431 213 218 
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Figure 13. The four Ausimmune Study regions 
Participants were resident in one of the study areas; cases and controls were matched on sex, study region 
and age. 
 
2.1.1.2 Southern Tasmanian Multiple Sclerosis Longitudinal Study 
The Southern Tasmanian Multiple Sclerosis Longitudinal Study (MSL) was formed in 
2002. This three-year prospective cohort study evaluated the role of lifestyle and 
environmental factors, particularly personal sun exposure, vitamin D status (measured as 
serum 25-hydroxyvitamin D (25(OH)D concentration), diet and viral infection on the 
clinical course (progression) of MS. Due to time and cost constraints, samples from  only a 
selection of MSL Study subjects were available for testing. 
 
2.1.1.3 Clinical samples 
Hospitalised individuals from Westmead Hospital (Westmead, NSW, Australia), 
Westmead Children’s Hospital (Westmead, NSW, Australia), Concord Hospital (Concord, 
NSW, Australia) and Royal Perth Hospital (Perth, WA, Australia) were tested. Individuals 
were suspected of having an EBV or HHV-6-related disease such as PTLD, IM or 
EBVAHS, or an immune dysfunction such as HIV infection. 
 
27° Brisbane, QLD 
33° Newcastle, NSW 
38° Western districts and Geelong, VIC 
43° Hobart, TAS 
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 2.1.2 Specimen collection and storage  
Nucleic acid testing was performed on ethylenediamine tetraacetic acid (EDTA) whole 
blood, peripheral blood mononuclear cells (PBMCs), plasma, cerebrospinal fluid (CSF) 
and liver tissue (see Table 15). The Ausimmune Study samples were collected in two 9 mL 
tubes for serum and one 9 mL EDTA tube for whole blood. Serum tubes were spun for 10 
min at 2,500 rpm; both serum and EDTA whole blood were aliquoted into 1 mL volumes 
and frozen short-term at -20°C until required. For the MSL Study, PBMC were collected 
processed and aliquoted at a centralised location. Bloods were left to stand for a minimum 
of 30 min prior to buffy coat separation and aliquoting into a secondary tube. All EDTA 
bloods were refrigerated at 4ºC within 4 hours of venepuncture and processed within 48 
hours.  
 
Table 15. Population groups and specimens tested in this thesis 
Population groups Specimens Number tested 
  
 
The Ausimmune Study 
 
 
 Refer to individual 
chapters for number of 
participants and samples 
tested  
   Cases 
 
EDTA whole blood, serum 
 
   Controls  
 
EDTA whole blood, serum 
 
MSL 
 
PBMC, serum 
 
Clinical samples 
 
EDTA whole blood, plasma, PBMC, CSF, tissue biopsy 
 
Abbreviations: CSF, cerebrospinal fluid; EDTA, ethylenediamine tetraacetic acid; PBMC, peripheral blood 
mononuclear cell. 
 
 2.1.3 Equipment and work areas   
Specimens from all three study groups were transported to Westmead Hospital in 
accordance to local laboratory requirements. Biological samples were handled in pre-
sterilised Class II Biological Safety Cabinets according to in-house protocols. Where 
possible, equipment was sterilised by autoclaving for a minimum 20 min at 121°C (103 
kPa). Work spaces were disinfected with 1% sodium hypochlorite (IDL Chemicals Pty. 
Ltd., Smithfield, NSW, Australia), wiped with purified water (Baxter Pty. Ltd, Old 
Toongabbie, NSW, Australia) and absolute ethanol (EtOH; Ajax Finechem, Minto, NSW, 
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Australia). Cabinets were decontaminated by ultraviolet light exposure for 20 min prior to 
and following use. To prevent carry-over contamination, DNA extraction, master mix 
preparation, nucleic acid amplification and post-PCR analysis were performed in a 
unidirectional workflow in separate Physical Containment Level 2 (PC2) laboratories. All 
cloning work was carried out in approved PC2 laboratories in accordance with the rules set 
by the Office of the Gene Technology Regulator. 
 
 2.1.4 Reagents, consumables and media preparation 
Commercially available reagents and consumables used in this thesis, including the 
manufacturers and suppliers, are listed in Table 34, Appendix 8A. Solutions, media recipes 
and storage conditions are listed in Table 35, Appendix 8B. Solutions were made using 
Milli-Q Ultrapure Water System (<0.001 EU/mL, 1-5 ppb TOC, 18.2 MΩ∙cm at 25°C) 
(Sigma-Aldrich Pty. Ltd., Castle Hill, NSW, Australia) and where possible, heat-stable 
solutions were sterilised by autoclaving for a minimum of 15 min at 121°C (103 kPa). 
Otherwise, filter sterilisation with 0.2 µm filters (Sartorius Stedim Australia Pty. Ltd., East 
Oakleigh, VIC, Australia) was used.  
 
2.2 qPCR protocol 
 2.2.1 Nucleic acid extraction 
2.2.1.1 GenElute™ Mammalian Genomic DNA Miniprep Kit® 
Viral nucleic acid was extracted and purified from EDTA whole blood, plasma and CSF 
using The GenElute™ Mammalian Genomic DNA Miniprep Kit® Whole Blood 
Preparation protocol. Samples were equilibrated at room temperature for 30 min, vortexed 
and pulsed centrifuged before transferring 200 µL into 1.5 mL Eppendorf Safe-Lock Tubes 
(Eppendorf South Pacific, North Ryde, NSW, Australia). Another 200 µL was archived at -
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80°C for long-term storage. Twenty microliters proteinase K and 200 µL Lysis C were 
added and the tube vortexed thoroughly before incubation at 55°C for at least 10 min. 
Following a quick pulse, 200 µL absolute EtOH was added and the tube was vortexed for 
another 5 to 10 sec. A new 2 mL collection tube (pre-assembled with the GenElute 
MiniPrep Binding Column), approximately 500 µL Column Preparation Solution was 
added into the column and centrifuged at 13,000 rpm for 1 min. The flow-through contents 
were discarded and the binding column transferred into a new 2 mL collection tube. 
Another 500 µL Wash Solution Concentrate was pipetted into the binding column and 
centrifuged at 8,000 rpm for 2 min. The flow-through liquid and collection tube were 
discarded and the binding column placed into a new 2 mL collection tube. This was 
repeated but concluded with a 13,000 rpm spin for 3 min. If residual wash solution was 
seen, tubes were centrifuged for another minute. Binding columns were then placed into a 
new 2 mL collection tube and 200 µL Elution Solution was added. To increase elution 
efficiency, tubes were placed in a 70°C heating block for 5 min. Following this, column 
preparations were spun at 8,000 rpm for 1 min and the column discarded. The flow-
through contents containing the nucleic acid were aliquoted into single-use (12 µL) 
volumes and stored at -80°C. 
 
Tissue samples were purified using the Mammalian Tissue Preparation protocol. This 
method was similar to the Whole Blood Preparation, except that Lysis T solution was used 
in place of Lysis C, and a 1 to 2 hour pre-incubation step precluded the absolute EtOH step 
to ensure complete tissue digestion.  
 
2.2.1.2 QIAamp DNA mini kit 
Viral DNA from PBMC was extracted using the QIAamp DNA blood mini kit (Qiagen) 
according to the Blood or Body Fluids Spin Protocol. This involved pipetting 200 µL 
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sample into a 1.5 mL Eppendorf tube followed by the addition of 20 µL Proteinase K and 
200 µL Buffer AL. Following this, tubes were vortexed for 10 sec and incubated at 56°C 
for 10 min. Tubes were pulsed to remove condensation and 200 µL absolute EtOH added 
to precipitate the nucleic acid. Next, tubes were vortexed and pulsed to ensure complete 
mixture. The contents were then transferred into the QIAamp Mini spin column 
(preassembled in a 2 mL collection tube) and spun at 8,000 rpm for 1 min. After discarding 
the flow-through contents, the spin column was transferred into a new 2 mL collection tube 
and 500 µL Buffer AW1 was added. The tube was centrifuged again at 8,000 rpm for 1 
min, and the flow-through discarded. This was repeated but 500 μL Buffer AW2 was 
added in place of Buffer AW1. The tubes were spun at 13,000 rpm for a further 3 min. 
Spin columns were then placed into new 2 mL collection tubes where 200 μL Buffer AE 
was added to each tube. This was followed by a 1 min incubation at room temperature 
before concluding with a final spin at 8,000 rpm for further 1 min. Columns were 
discarded and the flow-through contents containing the viral nucleic acid retained. DNA 
extracts were aliquoted into single-use (12 µL) volumes and stored at -80°C. 
 
 2.2.2 Reference strains and cell lines 
Reference strains and cell lines used in this thesis were provided by the Serology 
Department, CIDMLS, ICPMR, Westmead Hospital. These are listed in Table 16 below. 
Nucleotide sequences for these strains were obtained from GenBank (2). 
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Table 16. Reference strains and cell lines 
Organism Strain or 
cell line 
GenBank accession or 
(ATCC number) 
Size (bp) Use in this thesis References 
      
EBV 
 
B95-8 
 
AJ507799 
 
171,823 
 
qPCR, sequencing 
 
(3) 
 Raji
¥ 
 
(CCL-86TM) 
 
N/A 
 
Development 
 
(4-6) 
 GD1 
 
AY961628 
 
171,657 
 
Sequencing 
 
(7) 
 M-ABA 
 
M11659 
 
933 
 
Sequencing 
 
(8) 
 AG876 
 
DQ279927 
 
172,764 
 
Sequencing 
 
(9) 
      
HHV-6 
 
U1102 
 
X83413 
 
159,321 
 
qPCR, sequencing 
 
(10) 
 Z29 
 
AF157706 
 
162,114 
 
Sequencing 
 
(11) 
 
 
HST 
 
AB021506 
 
161,573 
 
Sequencing 
 
(12) 
      β-globin 
 
TAL57€ 
 
EU760960 
 
730 
 
qPCR 
 
(13) 
 
 MRC-5 
 
(CCL-171TM) 
 
N/A 
 
development, sequencing 
 
(14) 
 
      
HHV-7 JI U43400 144,861 Sequencing (15) 
HHV-7 RK AF037218 153,080 Sequencing (16) 
¥ Raji DNA sequence is similar to B95-8, but contains segment deletions at positions 86839 – 89829 and 163520 – 
166177 according to GenBank. 
€ TAL57 is a β-globin gene (not a strain or cell line) 
 
B95-8 and Raji cell lines were used as positive EBV controls for genotype A (17). The 
B95-8 strain originated from transformed marmoset monkey leucocytes, and contains 2 to 
200 EBV genome copies per cell (18). The Raji strain was first isolated from a Burkitt’s 
lymphoma patient and is a human B lymphoblastoid cell line containing both the integrated 
and circular EBV DNA forms. The Raji strain cell line contains 50 to 60 EBV genomes per 
cell (19, 20), and was used in the construction of the EBV plasmid. Both B95-8 and Raji 
cell lines were routinely harvested for serology use at CIDMLS, ICPMR, Westmead 
Hospital. The maintenance of these cells lines is described in section 2.4.1.1. A frozen 
aliquot of the AG876 strain was kindly donated by Queensland Institute of Medical 
Research, Brisbane, Australia, and used as the EBV genotype B positive control. This 
strain was first isolated from a Ghanaian case of Burkitt's lymphoma (9, 21). The U1102 
strain was used as the HHV-6 positive control. This strain was first isolated in Uganda 
from a HIV-infected individual and is classified as HHV-6A (22). Strains GS (HHV-6A) 
and Z29 (HHV-6B) obtained from the 2008 and 2009 QCMD QAP program were used for 
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PCR development and reference control strains for sequencing. β-globin was extracted 
from the MRC-5 cell line derived from human lung tissue (23) and used as the reference 
gene for normalising qPCR results, checking DNA integrity and monitoring for PCR 
inhibition.  
 
 2.2.3 Plasmid preparation 
2.2.3.1 Plasmid construction 
The Raji, U1102 and TAL57 cell lines were used to construct plasmids for EBV, HHV-6 
and β-globin qPCR, respectively. The two EBV DNA targets, EBNA-1 and BHRF-1 were 
linked by randomised primers, EA-F and EB-F. Complementary in ambient conditions, 
BHRF-1 and EBNA-1 PCR amplicons were combined in a 1.5 mL Eppendorf tube and left 
to anneal for 1 hour at room temperature. The annealed product was then amplified by 
PCR and the amplicon verified by DNA sequencing. Construction of the HHV-6 plasmid 
involved U67 gene amplification using the U6-7F and U6-6R primer pairs. The β-globin 
TAL57 gene was amplified using the primers PC03-F and PC04-R. Amplicons containing 
this DNA region of interest were ligated into the plasmid vector pGEM as described in 
section 2.2.3.  
 
2.2.3.2 Plasmid cloning  
All cloning work was carried out in approved PC2 laboratories in accordance with the rules 
set by the Office of the Gene Technology Regulator. Plasmid target regions were cloned 
using pGEM
®
-T Easy Vector System II (Promega Corporation, Annandale, NSW, 
Australia; Figure 27, Appendix 8C). Newly synthesised plasmids are shown in Figure 28, 
Appendix 8C. Solutions not provided in the kit such as LB plates with ampicillin, IPTG 
(Invitrogen), X-Gal (Invitrogen), S.O.C medium (Invitrogen), and LB Broth were prepared 
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at Westmead Millennium Institute, Westmead, NSW, Australia. All recipes are listed in 
Table 35, Appendix 8B.  
 
To prepare for ligation, one vial of pGEM
®
-T Easy Vector was centrifuged briefly and kept 
on ice. After vigorous vortexing, 5 µL 2X rapid ligation buffer was pipetted into a 1.5 mL 
Eppendorf tube. This was followed by the addition of 1 µL pGEM
®
-T Easy Vector, 3 µL 
PCR product and 1 µL T4 DNA ligase (3 Weiss units/µL). Ligated products were mixed by 
pipetting and incubated at 4ºC overnight.  
 
In preparation for transformation, two fresh LB plates containing 100 µg/µL ampicillin 
were equilibrated at room temperature. One vial of JM109 High Efficiency Competent 
Cells (Promega Corporation) was thawed on ice for 5 min. Once defrosted, contents were 
mixed gently by flicking and 100 µL pipetted into a 1.5 mL tube. Five microlitres of the 
ligated product was transferred to the 1.5 mL tube and mixed gently again by flicking. For 
transformation, the mixture was placed on ice for 20 min, heat shocked for 45 sec in a 42ºC 
water bath and returned to ice immediately for 3 min. After the addition of 750 to 950 µL 
S.O.C medium, products were incubated at 37ºC in a shaker for 1.5 hours. Following 
transformation, the tube was centrifuged at 3000 rpm for 5 min and the supernatant 
discarded leaving behind ~50 µL. The pellet was resuspended by pipetting and spread 
equally onto each LB/ampicillin plate containing 50 µL X-Gal and 20 µL IPTG. Plates 
were incubated at 37ºC overnight and placed at 4ºC for storage the following day. 
 
For screening, cloned targets were identified by a colour change. Using a sterile pipette tip 
(Neptune™ by Pathtech Pty. Ltd, Preston, VIC, Australia), white colonies containing the 
insert were plated onto a new LB plate with 100 µg/µL ampicillin and incubated at 37ºC 
for 24 hours. For confirmation, two colonies were added into a 1.5mL Eppendorf tube, 
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diluted with 20 µL PCR-grade H2O and denatured at 95ºC for 10 min. Products were 
amplified by PCR and checked by DNA sequencing. An additional three to five colonies 
were selected using a sterile pipette tip and added to 200 mL LB broth containing 200 µL 
ampicillin. Broth solution was then poured into 50 mL Falcon tubes (Becton Dickinson, 
North Ryde, NSW, Australia), mixed vigorously and further sub-divided into 25 mL 
aliquots for overnight growth at 37ºC in a shaker.  
 
2.2.3.3 Plasmid extraction  
Plasmid DNA was extracted using the PureYield
TM
 Plasmid MidiPrep System (Promega 
Corporation) according to the package insert for DNA Purification by Centrifugation. 
Extraction columns were centrifuged using the Sigma 4K15 and 11150/13350 swing-out 
rotor (Sigma-Aldrich). Elution was increased to 2 mL for larger working stock volumes. 
 
2.2.3.4 Plasmid purity  
Plasmid DNA concentration was determined by optical density (OD) at wavelength 260 
nm (A260) using the Beckman DU
®
 530 Life Science UV/Vis spectrophotometer, version 
1.04 (ThermoFisher Scientific Pty. Ltd., Scoresby, VIC, Australia) (1 A260 = 50 µg/mL of 
DNA). Molecular grade H2O was used to blank the instrument and dilute samples. Fifty 
microlitres of extracted plasmid DNA was added into a clean quartz cuvette and measured 
ten times (for an average). Following each measurement, the cuvette was rinsed with 
molecular grade water and Trace Klean
TM
 Concentrated Solution (ThermoFisher 
Scientific). To determine purity, the A260/A280 ratio was calculated. Ratios between 1.8 and 
2.0 were indicative of pure DNA; OD readings outside of this range were deemed to 
contain high background and protein contamination and required re-extraction.  
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2.2.3.5 Plasmid concentration 
Plasmid copy number was determined using the following formula (24);  
Copy number = 
 
Concentration of DNA (g/µL)   x   Avogadro’s number (6.0221415 x 1023 mol-1) 
MW (total construct size in bp)   x   330 (Daltons/bp) x 2 (dsDNA) 
 
To calculate total MW, the plasmid pGEM
®
-T Easy Vector (3015 bp) and the insert were 
added to give a total construct size (bp). Insert sizes for EBV, HHV-6 and β-globin 
plasmids were 554 bp, 223 bp and 299 bp, respectively.   
 
 2.2.4 Master mix preparation 
Master mix reactions were prepared in a PCR-certified colourless 200 µL flat capped tube 
(ABgene
®
 Nucleic Acid Amplification, Integrated Sciences Pty. Ltd., Chatswood, NSW, 
Australia) seated in a 96-well PCR rack (Greiner Bio-One, Interpath Services Pty. Ltd., 
Caringbah, NSW, Australia) placed on ice. The master mix comprised one vial of the 
LightCycler
®
 FastStart DNA Master SYBR Green 1 dye at 10X concentration pre-
combined with the LightCycler
®
 FastStart enzyme (FastStart Taq DNA polymerase). This 
reaction contained the buffer, dNTP mix and SYBR Green I dye. Added to this reaction 
were 0.5 µL 10 µM sense and antisense primers (Invitrogen), 0.8 µL 25 mM MgCl2 and 
PCR-grade H2O totalling 20 µL. Five microlitres of extracted DNA was mixed gently by 
pipetting and added to make a final PCR reaction volume of 25 µL.  
 
 2.2.5 Standard curve construction 
Four separate standard curves were constructed for qPCR: two for EBV (BHRF-1 and 
EBNA-1) and one each for HHV-6 and β-globin. A fresh plasmid aliquot was used for 
each assay consisting of triplicates of each dilution. Plasmids were diluted using PCR-
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grade H2O and either discarded immediately after use or frozen for same-day use. To 
improve accuracy, the eLine single channel electronic pipette (Biohit Oyj, Biolab, 
Australia) was used to add DNA into the PCR mixture. This pipette was calibrated twice 
yearly to ensure optimum performance. Plasmids were serially diluted to contain 10
1
 to 10
6
 
copies/5 µL.  
 
 2.2.6 Line of best fit 
Viral DNA loads were extrapolated from the plasmid-generated standard curve. A line of 
best fit was used to linearise data. Linearity was shown by the regression value (R
2
-value) 
and the square root of the regression value (R-value). To ensure reliable and accurate 
quantification, PCR runs were accepted if R-values were ≥0.99; runs that generated R-
values <0.99 were rejected and the run repeated. 
 
 2.2.7 PCR controls 
PCR-grade water controls were used to check for contamination in all experiments. A 
‘specimen no DNA control’ (sndc) was included after every five samples to monitor for 
contamination introduced at extraction. A ‘no template control’ (NTC) was used for 
screening carry-over contamination introduced during PCR set-up. Positive controls 
including reference strains were used to ensure successful target amplification. Thus, each 
PCR run contained one NTC, a number of sndc, test samples and a set of serially diluted 
plasmids. β-globin amplification was also done to screen for PCR inhibition; samples 
negative for β-globin were re-extracted and the PCR repeated. 
 
 2.2.8 Real-time instrumentation and thermal cycling conditions 
Samples were amplified by real-time PCR on the 36-well rotor on the Rotor-Gene
TM
 6000 
analyser (model 5-plex). This real-time PCR instrument is an open chemistry platform 
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containing five channels for fluorophore detection and is capable of high-resolution melt 
analysis and measuring DNA concentration. All qPCR data were generated using this 
instrument and optimised thermal cycling conditions for each PCR target. Where 
applicable, denaturation and annealing temperatures were altered depending on 
oligonucleotide and PCR product size. Optimised denaturation and annealing temperatures 
and times for each qPCR assay are shown in Table 17. Data were acquired using the green 
channel (source: 470 nm, detector 510 nm) immediately following the extension step at 
stage 2. A melting curve analysis between 60°C to 99°C concluded each PCR. 
 
Table 17. Thermal cycling conditions for EBV, HHV-6 and β-globin qPCR 
Abbreviations: BHRF-1, BamHI fragment H rightward open reading frame-1; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-
Barr virus; HHV-6, human herpesvirus-6; min, minute; PCR, polymerase chain reaction. 
 
 2.2.9 Product identification 
Target sequences were identified using the parameters listed in Table 18. Single melting 
curves for EBV, HHV-6 and β-globin are shown in Figure 14. 
 
 
 
 
 
 
 
 
PCR Steps EBV EBNA-1 EBV BHRF-1 HHV-6 U67 
β-globin 
TAL57 
All Plasmid 
Constructs 
Number of 
cycles, time 
Initial 
denaturation 
95°C, 10 min 98°C, 13 min 97°C, 12 min 95°C, 10 min 95°C, 10 min 1 cycle 
Denaturation 95°C 95°C 95°C 95°C 
 
95°C 
 
Stage 1: 3 cycles, 
40 sec/stage 
 
Stage 2: 40 cycles, 
30 sec/stage 
Annealing 58°C 60°C 61°C 61°C 55°C 
 
Extension 
72ºC 72ºC 72ºC 72ºC 72ºC 
 
Final extension 
72ºC 72ºC 72ºC 72ºC 72ºC 1 cycle 
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Table 18. Product characteristics for identification of target organisms 
 
 
 
 
Abbreviations: BHRF-1, BamHI fragment H rightward open reading frame-1; bp, base pairs; Cq, 
quantification cycle; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; HHV-6, human 
herpesvirus 6. 
*EBV and HHV-6 dynamic range spans five logarithms whereas β-globin spans eight logarithms. 
Negative samples had Cqs >40. 
 
 
Organism Target Cq (average sample range)* Melting Peak Size (bp) 
EBV EBNA-1 1-40 (18.97-33.19) 86–87°C 213 
 BHRF-1 1-40 (16.43-31.23) 86–87°C 208 
HHV-6 U67 1-40 (16.03-30.05) 81–83°C 108 
β-globin TAL57 1-40 (7.17-32.85) 87–87.5°C 247 
112 
 
 
  Figure 14. Melting curve analyses showing single peaks for each qPCR positive target  
 Melting curves derived from amplification of plasmid positive PCR samples in triplicate for: (i) β-globin; (ii) EBNA-1; (iii) BHRF-1 and (iv) HHV-6.  
 Note: X-axes display degrees in Celcius and Y-axes display derivative of fluorescence with respect to temperature (dF/dT). 
(i) 
 
(ii) 
 (iii) 
 
(iv) 
 
β-globin EBNA-1 
BHRF-1 
HHV-6 
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 2.2.10 DNA separation and visualisation 
PCR products and plasmids were separated by 1.5% agarose gel electrophoresis 
(Amresco
®
 Incorporated, Austral Scientific Pty. Ltd., Gymea, NSW, Australia) and 
visualised by 1:20 SYBR
®
 safe DNA gel stain (Invitrogen). The agarose gel was prepared 
by dissolving 0.02% agarose (w/v) in deionised water and heating in a conventional 
microwave oven. The dissolved gel mixture was set in a tray containing horizontal gel 
combs and left to solidify and cool. Once set, the combs were removed and the tray placed 
in an electrophoresis tank containing 0.25X TBE buffer (Amresco
®
 Incorporated). Ten 
microlitres of the PCR product was mixed with 2µL Blue/Orange Loading Dye (Promega 
Corporation) on a section of laboratory film (Parafilm
®
, LOMB scientific, Taren Point, 
NSW, Australia) and pipetted into the gel wells. To determine the length of the PCR 
fragments, 10 µL 100 bp DNA Ladder (1 µg/1 µL) (Invitrogen) was also loaded into wells 
of the same gel. A 200 V electric current was applied to the tank for 50 to 60 min, 
depending on the size of the gel tray, for electrophoretic separation. Gels were stained in 
1:20 SYBR
®
 Safe DNA gel stain for 30 min and visualised on a UV transilluminator 
(Pathtech Pty. Ltd, Preston, VIC, Australia). 
 
 2.2.11 Real-time qPCR analysis: Rotor-Gene™ 6000 software  
In preparation for DNA load measurement, the Rotor-Gene™ 6000 software version 1.7, 
Build 87 (see Table 36, Appendix 8D for a list of programs and software used in this 
thesis) required a number of manipulations. DNA concentration was estimated using the 
‘quantitation’ analysis function. ‘Dynamic Tube Normalisation’ normalised the 
background data for precise quantification. ‘Slope Correct’ averaged the background noise 
level and tightened replicate data. The ‘Ignore First’ function was set to discount the first 
five cycles. To distinguish genuine reactions from contamination and other non-PCR 
effects, ‘Outlier Removal’ was set to disregard any samples reporting an NTC threshold 
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fluorescence change of <3%. ‘Eliminate Cycles Before’ was set to five to remove the 
threshold line for low cycle numbers. To maintain continuity and consistency, the ‘Auto-
Find Threshold’ was used to maximise the R-value to approach 1.0 and to obtain the line 
of best fit for the standard curve.  
 
 2.2.12 Optimal standard curve statistics 
The R
2
-value and the R-value assessed the linearity of the standard curve. The slope of the 
reaction (M) was used to determine the exponential amplification and the reaction 
efficiency. Slope is calculated based on change in Cq divided by the change in log input 
(copy number). An amplification efficiency of 100% (1.00) was indicative of doubling of 
amplified product per PCR cycle. At 100% efficiency, the optimal M-value is 
approximately -3.322. The slope and the y-intercept varied for each PCR run and were 
calculated automatically by the Rotor-Gene
TM
 6000 software.  
 
 2.2.13 Viral DNA load calculation and interpretation 
Viral DNA loads were calculated according to the volumes used for DNA extraction, 
elution, and the number of replicates tested. Samples were extracted and eluted in equal 
quantities, enabling ratios to remain constant. Therefore, the amount of sample used for 
PCR (5 µL) was multiplied by a factor of 200 (elution volume) and divided by the number 
of replicates to obtain a final measurement expressed as DNA copies per millilitre 
(copies/mL) of sample.  
 
 DNA copies/mL = Unknown sample DNA load x 200 
 
                   Number of replicates tested 
 
Viral DNA loads were quantifiable in a dynamic range spanning up to six logarithms (2.0 x 
10
2
 to 2.0 x 10
6
 copies/mL of sample). Samples with no detectable target DNA were 
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assigned a load of zero and reported as a negative. Samples with DNA loads within the 
quantifiable range were reported as positive and with ‘x’ DNA load. Samples with DNA 
loads below the quantifiable range were considered detectable for target DNA but 
unquantifiable. 
 
 2.2.14 Data normalisation: β-globin qPCR assay 
For The Ausimmune Study, viral DNA loads were normalised using the internal reference 
gene, human β-globin, for expression in DNA copies/µg. This was done following the 
design and development of a qPCR assay for the detection and quantification of β-globin 
DNA. Assuming that one microgram of human cellular DNA is derived from 1.5 x 10
5
 
cells, and that each cell contains two copies of β-globin DNA, viral DNA loads were 
normalised using the following algorithm (25, 26): 
  
       DNA copies/µg =   (3 x 10
5
)     x     Viral DNA copy number 
 
Amount of amplified β-globin DNA 
  
Normalisation against the β-globin gene was done following confirmation that the PCR 
assays had similar amplification efficiencies. That is, the slope of the standard curve for 
each target assay was parallel to the β-globin assay. The design, development and 
verification of the β-globin qPCR assay are described in section 3.2. 
 
2.3 DNA sequencing 
 2.3.1 PCR product clean-up and sequencing 
Clean-up of PCR products was carried out using 96-well PCR racks (Scientific Specialties 
Incorporated, Astral Scientific Pty. Ltd, Gymea, NSW, Australia) placed on ice. 
Sequencing reactions were prepared by pipetting 9 µL PCR product and 2 µL ExoSAP-IT
®
 
PCR Clean-up Kit (USB Corporation, GE Healthcare Bio-Sciences Pty. Ltd., Rydalmere, 
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NSW, Australia) into a PCR-certified colourless 200 µL flat capped tube. The reaction 
mixture was pulse centrifuged and subjected to a single cycle at 37°C for 50 min and 80°C 
for 20 min on the Eppendorf Mastercycler
®
 gradient instrument (Eppendorf South Pacific). 
Following this, 1 µL 1 µM sense primer was added to the cleaned product and sequenced 
using the Applied Biosystems 3730xl capillary sequencer at the Australian Genome 
Research Facility (AGRF), Sydney, Australia. This automated system employed the Big 
Dye Terminator chemistry version 3.1 (Applied Biosystems, Foster City, USA).  
 
 2.3.2 Thermal cycling conditions 
Thermal cycling conditions for DNA sequencing of EBV and HHV-6 targets are outlined 
in Chapter 6. 
 
 2.3.3 DNA sequence alignment, BLAST and phylogenetic analysis 
DNA sequences were generated as a chromatogram in .ab1 format for analysis. Alignments 
were generated using ClustalW Multiple Alignment tool using BioEdit Sequence 
Alignment Editor, version 7.0.90 (27). Nucleotide sequences were subjected to a Basic 
Local Alignment Search Tool (BLAST) (28) for species and strain confirmation. The 
neighbour-joining method (Kimura-2 parameter) with 1000 bootstrap replicates using 
Mega5, Beta 3, and a maximum parsimony tree using Mega4, Beta 3 were used for 
phylogeny studies (29, 30). Figure 15 shows screenshots of manipulated settings for 
phylogenetic analysis. 
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(i)  (ii)      
  
Figure 15. Phylogenetic tree analysis screenshots 
Software settings used for (i) neighbour-joining method and; (ii) maximum parsimony method. 
 
2.4 Serology 
 2.4.1 Cell culture 
2.4.1.1 Growth medium and maintenance 
The EBV Raji cell line was grown in 500 mL Roswell Park Memorial Institute (RPMI) 
1640 + 20% media containing 10 mL of Penicillin-Streptomycin solution (Sigma-Aldrich) 
plus 100 mL of Foetal Calf Serum (FCS) (Bovogen Biologicals Pty. Ltd, DKSH, Hallam, 
Victoria, Australia). The B95-8 cell line was maintained in 500 mL RPMI 1640 modified + 
10% media containing 10 mL of Penicillin-Streptomycin solution (Sigma-Aldrich) plus 50 
mL of FCS. All media were checked for sterility and mycoplasma contamination by PCR 
before use. No cell line was required for HHV-6 serology. MRC-5 cells were subcultured 
weekly using Eagle’s Minimum Essential Medium + 10% FCS. 
 
  
 
 
118 
 
2.4.1.2 Cell harvest and slide preparation 
Flasks containing the cell lines were knocked 3 to 4 times by hand to detach overgrown 
cells. Approximately 27 mL of suspension was removed and set aside, leaving 3 mL in the 
flask. For Raji and B95-8 cell lines, 27 mL of fresh RPMI 1640+20% FCS and RPMI 1640 
modified +10% FCS were added, respectively. For expression of the EBV early antigen 
components, restricted and diffuse, B95-8 cells were treated with 0.4 mM phosphonoacetic 
acid (PAA) (Sigma-Aldrich) to inhibit DNA production in virus synthesising cells. 
Suspensions were used either to make slides or were archived in liquid nitrogen.  
 
EBV slides were prepared by centrifuging 50 mL of cell suspension at 1,000 rpm for 10 
min. After removal of the supernatant, 10 mL of phosphate buffered saline (PBS; Sigma-
Aldrich) plus 10% FCS were added to the pellet, mixed and spun at 1,000 rpm for 10 min. 
This was repeated twice more, without the final spin procedure. One drop of the B95-8 
suspension was added to the top row of a 10-well slide, one drop of the early antigen 
suspension to the four cells on the bottom row and a drop of Raji suspension to the last 
well. Slides were air dried and fixed in acetone. From the Raji cell line, negative B95-8 
and early antigen slide controls were made. For EBV IgG assays, the B95-8 cell line was 
used. 
 
 2.4.2 Epstein-Barr virus serology  
2.4.2.1 Viral capsid antigen IgG 
The detection of VCA antibodies was achieved using an in-house indirect 
immunofluorescence method developed at CIDMLS, ICPMR, Westmead Hospital. On a 
microtitre plate, 180 µL PBS was added to each well. In the first well, 20 µL of positive 
control (a previously positive patient serum) was pipetted and diluted at 1:10 and then 
titrated four-fold at 1:40, 1:160 and 1:640 (50 µL of sample diluted with 150 µL PBS). 
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This was followed by a four-fold titration of the patient serum using the same titration 
series. Slides were then incubated in a moist chamber containing PBS and washed gently 
with some agitation for 5 min. After drying, one drop of anti-human IgG (γ-chain specific), 
F(ab’)2 fragment-FITC antibody produced in goat (Sigma-Aldrich) was added to each well 
and incubated in a moist chamber at 37ºC for a further 30 min. Following this, slides were 
placed in a wash chamber containing PBS for 5 min and air-dried. Slides were mounted in 
10% buffered glycerol and examined at 400X magnification using a fluorescence 
microscope. 
 
2.4.2.2 Early antigen components 
Discrimination between the two early antigen components, restricted and diffuse, was 
achieved by methods previously described (31). Positive control slides were prepared by 
inoculating patient serum onto a slide and air dried for approximately 1 hour. This was 
followed by further aeration using a hair dryer for 10 min and acetone (Fronine Laboratory 
Supplies, Lomb Scientific, Kensington, Victoria, Australia) fixation for another 10 min. 
For expression of the diffuse component, smears were fixed in methanol (LabServ
®
, 
ThermoFisher Scientific Pty. Ltd., Scoresby, Victoria, Australia) for 10 min. The slides 
were dried and stored at -70ºC for up to 12 months. The same in-house IFA method 
described above for VCA detection was used to detect early antigen antibodies.  
 
2.4.2.3 EBV-nuclear antigen 
Anti-complement immunofluorescence (ACIF) procedure using the EBV-NA Test kit 
(Merifluor
®
, Oxoid Australia Pty. Ltd., Thebarton, South Australia, Australia) was used for 
EBV nuclear antigen detection. Each kit contained EBNA substrate slides, guinea pig 
complement (C’), complement diluent, anti-guinea pig C3, PBS powder, positive and 
negative control sera and mounting fluid. Serum samples were diluted two-fold using PBS 
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and heated for 30 min at 56ºC to inactivate endogenous complement. Fifteen microliters of 
diluted serum was added to each reaction site on the slide and placed in a moist chamber 
for incubation at 37ºC for 30 min. Slides were then kept moist throughout the whole 
preparation. Prior to the end of incubation, an aliquot of thawed guinea pig complement 
was immediately added with the specified volume of cold complement diluent and kept on 
ice. After incubation, slides were gently washed three times with PBS, avoiding direct 
streaming into the wells. To remove excess solution, slides were flicked between rinses, 
washed again and left to sit in a moist chamber for 5 to 10 min. Where necessary, a clean 
paper towel was used to remove excess PBS. Approximately 15 µL of cold working 
complement was added to each reaction site and incubated in a moist chamber at 37ºC for 
30 min. Following this, slides were then gently washed three times with PBS, flicked 
between rinses and washed again. Excess PBS on slides was removed by gentle flicking of 
the wrist. After the addition of 15 µL anti-guinea pig C3 to each reaction site, slides were 
incubated in a moist chamber at 37ºC for 30 min once again. Slides were then rinsed gently 
three times with a stream of PBS and air-dried standing on end on an absorbent paper 
towel. Mounted slides were examined immediately at 200X magnification or stored in a 
dark place for up to 24 hours.  
 
 2.4.3 Human herpesvirus-6 serology  
Human herpesvirus-6 IgG and IgM antibodies were detected using Indirect Fluorescence 
Assay for Human Herpesvirus-6 (HHV-6) IgG Antibody and Indirect Fluorescence Assay 
for Human Herpesvirus-6 (HHV-6) IgM Antibody, respectively (Inverness Medical 
Innovations Pty. Ltd., Sinnamon Park, Queensland, Australia), according to the 
manufacturer’s instructions. Each kit contained HHV-6 antigen slides, HHV-6 IgG or 
HHV-6 IgM positive and negative controls, fluorescein conjugate, coverslip mounting 
media, PBS solution and special blotters. Additional materials not supplied by the kit such 
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as microtitre plates, a moist chamber, slide holder and coverslips are listed in the Table 34, 
Appendix 8A.  
 
2.4.3.1 Human herpesvirus-6 IgG 
According to the package insert for HHV-6 IgG antibody determination, one well 
containing a PBS conjugate control and wells containing a positive and negative control 
diluted in 1:20 were used for each day’s test run. For quantitative titration, four-fold serial 
dilutions of the serum sample were prepared in PBS commencing at 1:10 dilution. This 
was followed by the addition of equal volumes of diluted serum and PBS for each 
consecutive dilution. Approximately one drop (20 µL) of the diluted test sample(s) was 
pipetted onto the antigen slides containing HHV-6-infected human lymphocytes. Slides 
were incubated in a moist chamber for 30 min at 37ºC and then gently rinsed with PBS. 
Following this, slides were washed for 5 min, followed by another 5 min wash in fresh 
PBS solution, and dried with the special blotter. One drop of the fluorescein conjugate was 
added to each test well and, once again, incubated, rinsed, washed and blotted. Slides were 
then mounted in glycerol mounting media with a 22 x 50 mm glass coverslip for viewing 
under 200-500X magnification. Slides were examined immediately for optimum results but 
could be stored at 2-8ºC for a maximum of three days.  
 
2.4.3.2 Human herpesvirus-6 IgM 
The methods described above were used to detect HHV-6 IgM antibodies except that a 
1:10 dilution of IgM fluorescein conjugate and positive and negative HHV-6 IgM controls 
was used. For removal of IgG antibodies, 90 µL of Gullsorb IgG Inactivation Reagent 
(Meridian Biosciences Incorporated, Oxoid Australia Pty. Ltd., Thebarton, South 
Australia, Australia) was mixed with 10 µL of serum. After a 15 min incubation at room 
temperature, samples were spun at 11,000 rpm for 5 min. HHV-6 IgM antibody titres were 
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determined using the supernatant. Test samples were serially diluted two-fold using PBS 
and screened at dilutions commencing at 1:10.  
 
 2.4.4 Result interpretation  
Results were interpreted according to the relevant package insert. Test samples showing no 
discernible fluorescence of the infected cells found at screening dilutions were interpreted 
as antibody negative (titres reading less than 1:10 dilutions). Test samples showing specific 
fluorescence of the infected cells were interpreted as positive (titres more than or equal to 
1:10). 
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Chapter 3 
Establishment of Novel qPCR Assays for EBV 
and HHV-6 DNA: Assay Design, Development 
and Validation  
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3.1 Establishment of novel qPCR assays for EBV and 
HHV-6 DNA: qPCR assay design, development and 
validation 
 3.1.1 Oligonucleotides primer design and target  
The first step in qPCR assay development involved target selection and where necessary, 
the design of new primers. Oligonucleotide primers were constructed according to 
published guidelines (1). Targets selected for EBV qPCR included two gene targets: 
EBNA-1 and BHRF-1 (refer to Table 4 in section 1.2.2 for gene function). The EBNA-1 
primer set was from a published source (2); BHRF-1 primers were originally designed in-
house by VM Ratnamohan in our laboratory and modified by the author. Other target 
regions that were considered for qPCR but not used due to lack of sensitivity and/or 
showed evidence of non-specific priming, included BamHI-W, LMP-2 and other EBNA-1 
and BHRF-1 primer combinations. 
 
Primers for HHV-6 and β-globin qPCR were originally designed in-house by VM 
Ratnamohan. The HHV-6 U67 gene was selected for PCR amplification as it is highly 
conserved, contains one copy per virus genome and has been used successfully in other 
quantification studies (3, 4). The TAL57 target was chosen for β-globin quantification as it 
is found in all Homo sapiens and is commonly used as an internal reference gene (5, 6). 
Upon testing, the HHV-6 primers failed to detect both HHV-6 species while the β-globin 
primers generated primer dimers (Figure 16). New HHV-6 primers were designed, targeted 
at the same gene, that were able to detect both HHV-6 species in samples from the 2008 
European Quality Control for Medical Diagnostics (QCMD) External Quality Assessment 
for Human Herpes Virus 6. To overcome the primer dimers observed with the β-globin 
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qPCR, new primers were designed also targeted at the same gene. All oligonucleotide 
primers, including newly designed and old primers, are listed in Table 19.  
 
For genotypic analysis of EBV and HHV-6, EBNA-2 and U67 targets were selected for 
sequencing, respectively. Both regions contain a high number of single nucleotide 
polymorphisms (SNP) capable of differentiating between EBV genotypes (A from B) and 
HHV-6 species (A and B) (5, 7). Other sequencing regions considered for genotyping but 
not used due to poor sensitivity by endpoint PCR included EBNA-1 (EBV), U95 (HHV-6) 
and U86 (HHV-6). 
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(i)                                                           (ii) 
        
 
 
 
 
 
 
(iii)                                                           (iv)   
 
 
 
 
 
 
 
 
 
 
 
Figure 16. HHV-6 and β-globin primers: old versus new 
(i) Original HHV-6 primers only amplified HHV-6 genotype A in the Quality Control for Medical 
Diagnostics (QCMD) External Quality Assessment for Human Herpes Virus 6 (HHV-6DNA08): melting 
curves showing amplification of a single product only (HHV-6A); Red arrow showing flat lines indicating nil 
amplification of genotype B (HHV-6B); (ii) Re-designed HHV-6 primers showing specific amplification of 
both HHV-6 genotypes A and B (i.e. HHV-6A and HHV-6B) as evidence by the two melting curves; (iii) β-
globin primer dimers (and high background) as seen on melting curve analysis using original primers (250 
bp) with black arrows indicating secondary peaks; (iv) Re-designed β-globin primers (247 bp) showing 
specific amplification of the TAL57 target as evidenced by a single melting curve peak and no secondary 
peaks. Red arrow showing nil amplification of negative samples. Note: X-axes display degrees in Celcius and 
Y-axes display derivative of fluorescence with respect to temperature (dF/dT). 
 
Key: 
 
 
Nil amplification (negative sample) 
 
Secondary peaks (primer dimers) 
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Table 19. List of oligonucleotide primer sequences 
All primers were reconstituted using PCR-grade water to a working stock of 10 µM and stored at -20°C in 50 µL aliquots. 
 
Detection and quantification 
Target Primer Name GenBank Accession (Position) Oligonucleotide Primer Sequence 5’-3’ 
Amplicon 
Length (bp) 
Reference 
      
EBV EBNA-1 QP-1F AJ507799 (97174 – 97386) GCC GGT GTG TTC GTA TAT GG  213 (2) 
 QP-2R  CAA AAC CTC AGC AAA TAT ATG AG   
EBV BHRF-1 
 
EA-1F 
 
AJ507799 (42105 – 42312) 
 
GGA GAT ACT GTT AGC CCT G 
 
208 
 
Custom (VMR) 
 
 EA-2R 
 
 
 
GTG TGT TAT AAA TCT GTT CCA AG 
 
  
 
EBV plasmid construct 
(randomised primers in bold) 
 
EA-F 
 
 
N/A 
 
 
CTA TAT GTC TGC TTA CTC CGG CG 
/ G GAG ATA CTG TTA GCC CTG 
 
554 
 
 
Custom 
 
  EB-R  CGC CGG AGT AAG CAG ACA TAT AG / CAA 
AAC CTC AGC AAA TAT ATG AG 
  
HHV-6 U67 (new) 
 
U67-1F 
 
X83413 (102949 – 103056) 
 
CGA TGT GCG TGA TCT TGA AT 
 
108 
 
Modified from HHV-6 U67 (old) 
 
 U67-2R 
 
 
 GCG GCA TTA TAT CCC GTC TT 
 
 
 
 
  
HHV-6 plasmid construct 
 
U6-7F 
 
X83413 (102911 – 103133) 
 
CTC GAG TAT GCC GAG ACC CCT AAT C 
 
223 
 
Custom 
 
 U6-6R  AAG CTT GCA CAA TGC CAA AAA ACA G   
HHV-6 U67 (old) U67-F X83413 (102917 – 103061) TAT GCC GAG ACC CCT  AAT C 145 Custom (VMR) 
 U67-R  GAA AYG CGG CAT TAT ATC C   
β-globin TAL57 (new) BG-1F EU760960 (173 –  417) TAG CAA CCT CAA ACA GAC ACC A 247 Modified from β-globin (old) 
 BG-1R  CAG CCT AAG GGT GGG AAA AT   
β-globin plasmid construct 
 
 
PC03-F 
 
 
EU760960 (130 – 428) 
 
 
CAT CTA TTG CTT ACA TTT GCT TCT GAC 
ACA ACT GTG TTC ACT AGC 
 
299 
 
 
Custom 
 
  PC04-R  TAG ACC ACC AGC AGC CTA AGG GTG GGA 
AAA TAG ACC AAT AGG C 
  
β-globin TAL57 (old) BetaF EU760960 (155 – 404) ACACAA CTGTGTTCAC TAGC 250 Custom (VMR) 
 BetaR  GGA AAA TAG ACC AAT AGG C   
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Abbreviations: BHRF-1; BamHI fragment H rightward open reading frame-1, EBV; Epstein-Barr virus, EBNA-1; Epstein-Barr virus nuclear antigen-1; HHV-6; human herpesvirus 6, M; 
degenerate base sequence coding for the nucleotide bases adenine and cytosine (according to IUPAC), MLL; primers designed by Meav-Lang Jesse Lay, VMR; primers designed by Mala 
Ratnamohan, CIDMLS. 
Genotyping and sequencing 
Target Primer Name GenBank Accession (Position) Oligonucleotide Primer Sequence 5’-3’ 
Amplicon 
Length (bp) 
Reference 
      
EBV EBNA-2 
 
 
 
 
 
EBNA-2 
Seq1F 
 
 
 
 
AJ507799 (37746-38228) 
DQ279927 (37632-38219) 
 
TGA CMC GCC TGT CAT TCT AT 
 
 
 
 
483 
 
 
588 
Custom (MLL) 
 
 
 
 EBNA-2 
Seq1R 
 
 CCG GCC CTG TAC ACT ACA CT 
 
  
HHV-6 U67 
 
 
 
U67 Seq1F 
 
 
 
X83413 (102459-103056) 
AF157706 (103757-104354) 
TGT GGG TTA TGT CGC AGG TA 
 
 
598 
 
 
598 
Custom (MLL) 
 
 
 
 U67 Seq6R 
 
 GCG GCA TTA TAT CCC GTC T 
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 3.1.2 Primer sensitivity 
Theoretical and practical primer sensitivity was determined by end-point PCR using ten-
fold serial dilutions of DNA extracted from the cell lines B95-8, U1102 and MRC-5. 
Primers that were able to detect target DNA at the higher dilutions (i.e. samples containing 
low copy numbers, e.g. ~ 2.0 x 10
2
 copies/mL or 2 copies per PCR reaction) with good Cq 
values and single melt peaks were chosen for qPCR (see Figure 14 for examples of single 
melting curves for each qPCR target). 
 
 3.1.3 PCR chemistry/detection format 
Intercalating dyes were chosen over fluorogenic probes for real-time qPCR due to cost 
constraints and suitability to large-scale studies. Dyes tested included LC Green Plus+ 
Melting Dye (Idaho Technology Incorporated, Chatswood, NSW, Australia), EvaGreen
TM
 
Dye (Biotium Incorporated, Dural, NSW, Australia) and SYBR
®
 Green I Nucleic Acid Gel 
Stain (Invitrogen Australia Pty. Ltd., Mulgrave, Victoria, Australia). When results from all 
three dyes were compared, SYBR Green I provided the best results based on Cq values, 
melting curves and PCR reaction efficiency. LC Green produced non-discrete bands and 
was too expensive. EvaGreen
TM
 Dye twice failed to detect target DNA. Although good 
results were generated, SYBR Green I Nucleic Acid Gel Stain in combination with the 
AmpliTaq Gold
® 
kit was not economical for large-scale qPCR as the enzyme was 
continually exhausted before the other reagents. For this reason, the commercially 
available LightCycler
®
 FastStart DNA Master incorporating SYBR Green I dye (Roche 
Applied Science, Castle Hill, NSW, Australia) was investigated. This combination proved 
highly sensitive and was cheaper compared with the other dyes. This kit also offered a 
more straightforward approach and minimised the number of master mix preparation steps. 
While this kit was designed for the LightCycler
®
 systems (Roche Applied Science), quality 
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results were generated on the Rotor-Gene
TM
 6000 (Qiagen Pty. Ltd., Doncaster, VIC, 
Australia).  
 
 3.1.4 Master mix and enzyme 
Different combinations of master mixes and enzymes were investigated by endpoint PCR. 
These included Platinum Taq
®
 DNA Polymerase (Invitrogen) and AmpliTaq Gold
®
 DNA 
Polymerase, 6 x 250 units with Gold Buffer and MgCl2 solution (Invitrogen). Non-specific 
products were observed with Platinum Taq
® 
but not AmpliTaq Gold
®
 (data not shown). 
Thus, AmpliTaq Gold
® 
was used for subsequent qualitative PCR
 
experiments. When the 
assay progressed to real-time qPCR analysis, the LightCycler
®
 FastStart DNA Master 
SYBR Green I kit (Roche Applied Science) showed greater specificity and sensitivity than 
AmpliTaq Gold
®
. Preliminary results showed that the LightCycler
®
 FastStart DNA Master 
SYBR Green I kit produced higher fluorescence signals (~40) compared to a combination 
of the AmpliTaq Gold
®
 DNA Polymerase 6 x 250 units with Gold Buffer and MgCl2 
solution and the SYBR Green I Nucleic Acid Gel Stain (diluted 1:2500) (Invitrogen) (<10) 
(data not shown), though this effect could have been due to differences in the polymerase 
enzyme and not the detection chemistry. Positive samples peaked at a derivative of 
fluorescence with respect to temperature (dF/dT) of ~ 3.5 for the LightCycler
®
 FastStart 
DNA Master SYBR Green I kit, whereas the AmpliTaq Gold
®
 DNA Polymerase kit 
peaked at a dF/dT of 0.8. Furthermore, positive samples generated between 3 to 5 Cq 
values lower with the LightCycler
®
 FastStart DNA Master SYBR Green I kit than the 
AmpliTaq Gold
®
 DNA Polymerase kit (data not shown). Positive samples also generated 
(on average) higher amplification efficiencies using the LightCycler
®
 FastStart DNA 
Master SYBR Green I kit (1.68 versus 1.50). 
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 3.1.5 Nucleic acid purification 
Automated and manual methods for nucleic acid extraction were compared to determine 
which provided the best DNA recovery. EDTA whole blood samples from five randomly 
selected hospitalised patients were extracted in parallel using the automated NucliSens 
EasyMag instrument (BioMérieux Australia Pty. Ltd., Baulkham Hills, NSW, Australia) 
and the manual GenElute™ Mammalian Genomic DNA MiniPrep Kit (Sigma-Aldrich Pty. 
Ltd). In four of the five samples, β-globin DNA loads were higher following manual 
extraction compared with the automated method (data not shown). This finding was 
consistent with other studies (8-12), which also favoured manual extraction techniques 
over automated procedures for a higher NA yield. While automated methods are faster and 
suited to high-throughput laboratories, robotic handling of samples has been known to 
cause DNA damage, leading to decreased PCR sensitivity and efficiency (8). In a study of 
manual versus automated NA extraction, manual extraction owed better sensitivity for the 
detection of samples containing low DNA concentrations (13), and thus, was chosen for 
this project.   
 
 3.1.6 Standard curves design  
To minimise costs and to save on labour and time, importation of the standard curve was 
considered. Although simplistic in theory, this method carried a high risk of error as it 
assumed that PCR reaction efficiencies were constant for each assay. After numerous 
attempts, importation of the standard curve proved inconsistent and yielded unpredictable 
DNA loads. As such, a standard curve was constructed for each qPCR assay. Viral DNA 
loads were calculated using the auto-find threshold function that automatically scanned the 
range of threshold levels to obtain the line of best fit. The manual setting adjusted to an 
arbitrary threshold was also tested, but was not reproducible.  
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 3.1.7 PCR optimisation 
PCR cycling conditions were modified and adapted for each target. Modifications included 
addition of 2-10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) and increasing the initial 
denaturation temperature to 97°C. Addition of DMSO appeared to decrease the band 
intensity formed by secondary products (still evidenced in melting curves) while an 
increase in denaturation temperature eliminated non-specific binding (evidenced by single 
peaks in the melting curve). Figure 17 (i) and (ii) show amplicons before and after these 
modifications. Optimised thermal cycling conditions for each qPCR are listed in Table 17, 
section 2.2.8. 
 
(i) (ii) 
 
 
 
 
 
 
 
 
Figure 17. BHRF-1 qPCR assay optimisation 
(i) Non-specific priming as seen in the BHRF-1 qPCR assay before PCR modifications were made; (ii) Non-
specific priming eliminated following adjustments to the initial denaturation temperature. Note: Ausimmune 
Study samples were loaded in the top row; ten-fold serial dilutions of EBV plasmids were loaded in the 
bottom row. EBV (BHRF-1) positive amplicons are indicated by an arrow. 
 
 3.1.8 Plasmid Stability 
Initial experiments included the use of serially diluted plasmid stored in single-use 
aliquots. This however, showed poor sensitivity at the higher dilutions (i.e. lower copy 
numbers) after a few months as plasmids began to degrade. Therefore, fresh plasmids were 
diluted from neat stock for each qPCR run. Despite long-term storage at -80°C, 
BHRF-1 amplified product 
EBV plasmid 
Non-specific products 
BHRF-1 amplified 
product 
EBV plasmid 
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experiments carried out over the year showed signs of plasmid degradation, particularly at 
the higher dilutions. As such, plasmids were aliquoted into single-use 12 µL volumes and 
used a maximum of two times to avoid excessive freeze-thaw cycles. If standard curve 
dilutions containing the lowest copy number (i.e. 2.0 x 10
2
 copies/mL) fell below 66.6% 
(i.e. only one of three plasmids were positive), a new plasmid batch was constructed. 
Experimental data showed that at six months, detection of samples containing 2.0 x 10
3
 
copies/mL dropped by 10% versus 62% at 12 months. Therefore, to maintain high 
sensitivity levels, plasmids were made fresh every 6 months.  
 
3.2 β-globin qPCR assay for data normalisation 
 3.2.1 Introduction 
This section describes the design and development of a qPCR assay for the detection and 
quantification of the human β-globin reference gene. This qPCR assay was developed for 
two purposes: (i) to check for the presence of PCR inhibitors and, (ii) to normalise viral 
DNA load results for expression as copies/µg (used in The Ausimmune Study results). 
 
 3.2.2 Materials & Methods 
3.2.2.1 Samples and assay design 
Section 2.1.1, provides a detailed description of the populations tested. For comparative 
purposes, the Ausimmune Study samples were normalised against β-globin so that results 
could be expressed as both copies/mL and copies/µg of DNA. Clinical samples were 
checked for the presence of β-globin to ensure that PCR inhibitors were not present in the 
sample. That is, no standard curve was constructed for the purpose of quantification and 
results were expressed as copies/mL only.  
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3.2.2.2 PCR target  
A 247 bp fragment of the β-globin TAL57 gene (GenBank Accession: EU760960) was 
selected for PCR amplification. The primer sequences are listed in Table 19.  
 
3.2.2.3 Standard curve construction and data extrapolation 
The β-globin standard curve was constructed from a plasmid inserted with the TAL57 gene 
(from reference strain MRC-5) as described in section 2.2.3 (see Appendix 8C for plasmid 
construct). PCR-grade water was used for ten-fold serial dilutions to generate a dynamic 
range from 1.0 x 10
1 
to 1.0 x 10
8
 copies/5 µL in anticipation of the high β-globin 
concentrations in whole blood. Due to the throughput limitations of the Rotor-Gene 
instrument, plasmids containing 1.0 x 10
5
 to 1.0 x 10
8
 copies/5 µL of β-globin DNA were 
tested in duplicates, and later in triplicates. 
 
3.2.2.4 Assay performance 
Assay reproducibility was assessed by testing ten-fold serial dilutions of the β-globin 
plasmid in duplicates or triplicates. Intra-assay and inter-assay coefficients of variation 
were determined as described in Lay et al, 2010 (14). Sensitivity was determined by end-
point PCR using agarose gel electrophoresis. The limit of detection was calculated by 
assaying ten replicates of serially diluted (ten-fold) plasmids from 10
3
 to 10
1
 copies/5 µL 
in three separate runs. Analytical specificity of the primer set was assessed using 
nucleotide BLAST and by PCR amplification of DNA extracted from the human cell line, 
MRC-5. Primers passed theoretical specificity when BLAST percentage match was 100%, 
the expected value (E-value) approached zero, and when there was no evidence of primer 
cross-reactivity. PCR products were also sequenced to confirm region of interest was 
amplified. 
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 3.2.3 Results 
3.2.3.1 Assay performance 
Intra- and inter-assay variability is shown in Table 20. Endpoint PCR showed that the 
qPCR assay detected β-globin DNA in samples containing 10 copies/5 µL (2.0 x 103 
copies/mL). β-globin DNA was detected at concentrations of 103 copies/5 µL at 100% 
positivity. At 1.0 x 10
2
 and 1.0 x 10
1
 copies/5 µL, β-globin was detected at 83.3% and 
26.7%, respectively. BLAST search for the Homo sapiens TAL57 β-globin gene showed 
100% match and 2e-125 E-values (data not shown). No cross-reactivity was observed with 
samples containing CMV, VZV, HHV-6 and EBV DNA. 
 
Table 20. Beta-globin qPCR intra- and inter-assay co-efficient of variation 
DNA Target 
(copies/5 µL) 
Average Cq 
Mean Rotor-Gene 6000TM 
Results (copies/5 µL) 
Average % 
Variation≠ 
COV 
(%) 
Average 
R-value 
Average 
R2- value 
Intra-assay variation (same day) 
1.0 x 108 6.64 ± 0.77 118,940,107 ± 28,143,091 27.97% 23.66 
0.998 0.997 
1.0 x 107 11.15 ± 1.07 8,539,202 ± 168,776 14.62% 1.98 
1.0 x 106 14.97 ± 1.00 934,091 ± 30,337 6.58% 3.25 
1.0 x 105 18.83 ± 0.99 100,479 ± 9,633 8.08% 9.59 
1.0 x 104 22.66 ± 1.16 11,097 ± 2,547 37.70% 22.95 
1.0 x 103 26.81 ± 1.10 1,084 ± 327 25.10% 30.18 
1.0 x 102 31.11 ± 0.59 96 ± 44 36.74% 45.97 
1.0 x 101 34.16 ± 0 17 ± 6 71.09% N/A 
Inter-assay variation (different days) 
1.0 x 108 7.07 ± 1.74 91,879,200 ± 16,892,939 16.72% 18.39 
0.999 0.997 
1.0 x 107 10.90 ± 1.30 9,523,368 ± 1,226,257 12.02% 12.88 
1.0 x 106 14.64 ± 1.33 1,046,531 ± 106,980 7.40% 10.22 
1.0 x 105 18.51 ± 1.42 106,519 ± 8,533 9.48% 8.01 
1.0 x 104 22.30 ± 1.51 11,484 ± 1,932 16.92% 16.82 
1.0 x 103 26.29 ± 1.71 1,136 ± 255 19.86% 22.45 
1.0 x 102 30.73 ± 1.79 88 ± 38 32.65% 43.18 
1.0 x 101 N/A N/A N/A N/A 
     
  
Abbreviations: Cq, quantification cycle; mean % variation, average percentage variation between the calculated 
(Rotor-Gene 6000TM results) and the given concentration (DNA target); COV, co-efficient of variation (ratio of standard 
deviation to the mean); R-value, square root of the correlation co-efficient;  R2-value, correlation co-efficient. 
≠Average % variation as calculated by the Rotor-GeneTM 6000 software. 
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3.2.3.2 Overall β-globin qPCR characteristics 
Of the 29 β-globin qPCR experiments performed on the Ausimmune Study samples, the 
average Cqs for 10
8 
to 10
1
 were: 7.17, 11.15, 14.90, 18.66, 22.57, 26.36, 30.48 and 32.85 
respectively. The average amplification efficiency was 82% (SD: 0.04), and the reaction 
slope was -3.84 (SD: 0.14) (Table 21). The melting curve analysis showed that β-globin 
amplicons melted between 87.0°C to 87.5°C. All β-globin positive samples including 
plasmids had Cq values <40 cycles. Conversely, all negative samples and controls had a Cq 
equal to zero or >40. 
 
Table 21. Optimal qPCR assay statistics versus average experimental data 
 
Statistics Optimal values Average experimental values 
   
R-value 0.99 0.99 
R2-value 0.99 0.99 
M -3.32 -3.84 
Amplification Efficiency 100% 82% 
Abbreviations: R-value, correlation co-efficient; R2-value, square root of the correlation 
coefficient; M, slope. 
Note: Optimal qPCR statistics based on Rotor-GeneTM 6000 Operator Manual, v1.7.34; 
average experimental values calculated based on 29 qPCR runs. 
 
3.2.3.3 β-globin DNA load 
β-globin DNA was detected and quantified in all Ausimmune Study samples; one sample 
was absent for β-globin DNA but was positive using a new sample aliquot. Overall, 
samples had a mean β-globin DNA load of 4.89 x 107 copies/mL (SD: 1.35 x 107 
copies/mL, median: 4.93 x 10
7
 copies/mL, range: 1.19 x 10
7
 to 9.99 x 10
7
 copies/mL). 
 
3.2.3.4 Data normalisation 
For data normalisation, qPCR assays must have comparable amplification efficiencies and 
slope (15). Amplification efficiency and slope for each qPCR run is plotted in Figure 18; 
standard curve dilution points versus quantification cycles for each assay are shown in 
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Figure 19 and the standard curve dilution points versus quantification cycles for all the 
qPCR assays combined in Figure 20. 
 
 
Figure 18. A plot of PCR amplification efficiency and slope of all qPCR assays 
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 Figure 19. Standard curve dilution points versus quantification cycles for each qPCR assay  
 Five random runs were selected to demonstrate amplification efficiency linearity for (i) β-globin; (ii) EBNA-1; (iii) BHRF-1 and (iv) HHV-6 qPCR.
(i) (ii) 
 
 
 
 
 
 
(iii) (iv) 
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Figure 20. Standard curve dilution points versus quantification cycles for all qPCR 
assays combined 
 
3.2.3.5 Normalisation Analysis 
The PCR amplification efficiency and slope of each assay were examined to determine 
whether data could be normalised. While the T-test (unpaired) showed that EBNA-1 and 
HHV-6 amplification efficiencies were statistically different from β-globin, no statistically 
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significant differences were found for the slope (i.e. EBV and HHV-6 standard curve 
slopes were parallel to β-globin) (Table 22). 
 
Table 22. Comparison of PCR amplification efficiency and slope between qPCR 
assays  
 
Abbreviations: β-globin, beta-globin; BHRF-1, BamHI fragment H rightward open reading frame-1; EBNA-1, 
Epstein-Barr virus nuclear antigen-1; HHV-6, human herpesvirus 6; M, slope; n = number of qPCR runs 
analysed, including repeated runs; qPCR, quantitative polymerase chain reaction. 
† T-test (unpaired) statistic calculated using GraphPad Prism 4  
* P < 0.05 = statistically significant.  
 
 3.2.4 Conclusion 
This section showed that the slope of each qPCR assay was similar to that of the β-globin 
qPCR assay, making data normalisation and expression of viral loads in copies/µg 
possible. Furthermore, β-globin DNA was detectable in all clinical samples, confirming the 
presence of cellular DNA and the absence of sample-related PCR inhibition. 
 
 
 
 
 
 
 
 
qPCR n 
PCR amplification 
efficiency 
M 
PCR amplification 
efficiency P-value† 
M P-value† 
BHRF-1 50 0.85 ± 0.06 -3.67 ± 0.20 0.0518 0.0587 
EBNA-1 62 0.86 ± 0.09 -3.73 ± 0.28 0.0321* 0.0539 
HHV-6 48 0.85 ± 0.05 -3.76 ± 0.18 0.0426* 0.0572 
β-globin 30 0.82 ± 0.04 -3.84 ±0.14 N/A N/A 
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4.1 Aims 
Chapter 4 aims included:- 
1. Development of a sensitive real-time qPCR assay using SYBR Green I dye for the 
detection and quantification of EBV DNA  
2. Application of the above qPCR to research and clinical cohorts to determine EBV 
DNA positivity and load.  
 
4.2 Introduction 
This chapter consists of two publications describing a novel EBV qPCR assay and its 
application to clinical and research cohorts. The first publication describes the design and 
development of two real-time qPCR assays for the measurement of EBV DNA. This qPCR 
assay was then applied to two populations: hospitalised patients with EBV-related diseases 
or immune dysfunction (e.g. IM, PTLD, EBVAHS and HIV infection), and a control 
population. This assay design included a novel quantification standard containing two 
separate EBV DNA targets (EBNA-1 and BHRF-1) for absolute quantification. The EBV 
DNA loads obtained using the qPCR assays were compared to EBV DNA loads reported in 
the literature for similar disease conditions. The EBV sero-status of the control population 
was also investigated to determine the correlation between EBV-specific antibody titres 
and DNA load. This work was published in the Virology Journal as “Measurement of 
Epstein-Barr virus DNA load using a novel quantification standard containing two EBV 
DNA targets and SYBR Green I dye” (Publication 2; Lay et al, 2010). The performance of 
our in-house EBNA-1 qPCR assay was also evaluated in the 2008 and 2009 QCMD EBV 
DNA EQA Program (Table 24, Appendix 4A). Compliance with the Minimum 
Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
guidelines is presented in Table 25, Appendix 4B.  
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The second aim was to apply the EBV qPCR to determine if there was an association of 
EBV DNA detection and load with risk of first CNS demyelination. This work was 
undertaken within the Ausimmune Study and contributed to a collaborative publication in 
Neurology as “Current and past Epstein Barr virus infection in risk of initial CNS 
demyelination” (Publication 3; Lucas et al, 2011). This publication also investigated the 
role of past markers of EBV infection (history of IM infection and EBV-specific antibody 
titres) in the risk of first episode of CNS demyelination, and explored possible interactions 
with other known risk factors implicated in MS such as smoking, vitamin D status and past 
sun exposure. Subjects included case participants with an incident first clinical diagnosis of 
CNS demyelination (FCD): those that had presented with classic first demyelinating events 
(FDE), a first diagnosis of PPMS, and those in whom, retrospectively, there had been a 
previous, undiagnosed probable FDE; and control participants without CNS demyelination 
from the general population matched to a case by sex, location and age. Note that in 
preparation of Publication 3, data on EBV qPCR from two independent Australian 
laboratories were submitted, however, only data from one laboratory was published. All 
qPCR and serology results used in Publication 2 and 3 are listed in Table 23, Appendix 4A. 
 
4.3 Publication 2 summary (Lay et al, 2010) 
Lay et al, 2010 demonstrated a working real-time qPCR assay using SYBR Green I that 
was sensitive at detecting and quantifying EBV DNA in a range of specimens and 
population groups. A novel feature of this assay was the design of a single quantification 
standard containing two separate EBV DNA targets (EBNA-1 and BHRF-1). Results from 
Table 23 showed that EBV DNA load in patients hospitalised with various EBV-related 
diseases or immune dysfunction compared well with reported EBV DNA loads in the 
literature for similar diseases. A modest correlation between VCA IgG antibody titre and 
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BHRF-1 DNA load (P = 0.05) in the population samples (The Ausimmune Study controls) 
was also demonstrated. Overall, the assays were considered robust and reliable for clinical 
laboratory use for studies of EBV-related diseases. This work also highlighted the superior 
efficiency of SYBR Green I dye as the detection chemistry for qPCR, making the need for 
commercial kit-based assays redundant for the next part of our aim.  
 
 4.3.1 Publication 2 authorship 
MLL developed the assays, performed the entire DNA work, assisted in data analysis and 
interpretation of results, and wrote the manuscript. On behalf of the Ausimmune 
Investigator group, RML supplied the EDTA whole blood and serum from the population 
sample, and was involved in the data analysis. VMR aided in primer design and JT 
performed the serology testing. MLL, DED, VMR, RML and ALP were involved in the 
design and conception of the study. All authors have read, reviewed and approved the final 
manuscript. 
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Janette Taylor 
 
Dominic E. Dwyer 
 
  
 
4.4 Publication 3 summary (Lucas et al, 2011) 
In a collaborative publication with The Ausimmune Study Investigator Group, Lucas et al, 
2011 showed that there was no significant difference in the proportion of individuals with 
FCD that were EBV DNA positive compared to matched controls (P = 0.28). In addition, 
the risk of being a FCD case did not increase across the full range of EBV DNA load (P = 
0.33). These results reflected testing across three separate EBV gene regions (EBNA-1 and 
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BHRF-1 methods described in this thesis, and BWRF-1 tested at The Queensland Institute 
of Medical Research, Herston, QLD, Australia). Cases also reported significantly higher 
EBNA IgG, VCA IgG and EA-R IgG antibody titres than matched controls (P < 0.001, 
0.01 and 0.02, respectively). These EBV-specific antibody titres did not vary across the 
different types of FDE presentation; however, EBNA IgG antibody titres were associated 
with a 28% increase in the odds of being a FCD case. Furthermore, this study also 
confirmed that markers of past EBV infection (e.g. EBV IgG antibodies and a history of 
IM) were associated with an increased risk of being a FCD, and there was an interaction 
with HLA susceptibility genes, such that the FCD risk markedly increased in the presence 
of both. Current markers of EBV infection (e.g. DNA positivity and load) in whole blood 
were not associated with increased risk of FCD, nor were there interactions between 
environmental risk factors of MS such as smoking, vitamin D status or past sun exposure.  
 
 4.4.1 Publication 3 authorship 
RML coordinated data collection, undertook data cleaning and analysis and prepared the 
manuscript. ALP was involved in the study design, data collection, analysis and 
preparation of the manuscript. KD was involved in the study design and analysis, and 
provided comment on the manuscript. PV was involved in data collection and provided 
comment on the manuscript. MPP was involved in the study design and data collection, 
and provided comment on the manuscript. MLL and DED (from laboratory 1) and JMB 
and SRB (from laboratory 2) performed viral laboratory analyses and provided comment 
on the manuscript. CC was involved in the study design and data collection, and provided 
comment on the manuscript. AC was involved in data collection and provided comment on 
the manuscript. TD, TK, AJM, BVT, IAFvdM and DW were involved in the study design 
and data collection and provided comments on the manuscript. 
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4.5 Chapter Conclusion 
The in-house SYBR Green I-based qPCR assay developed in this Chapter proved sensitive 
and accurate at detecting and quantifying EBV DNA. Consistent with the literature, our 
methods assisted in showing that markers of past EBV infection were associated with an 
increased risk of early CNS demyelination, but more importantly, that current EBV 
infection or reactivation (as evidenced by EBV DNA in blood), may not be of major 
clinical importance in the pathogenesis of early MS.  
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4.6 Appendix 4A 
 4.6.1 EBV molecular and serology results 
Table 23. Summary of EBV qPCR results  
Viral loads are expressed in copies/mL and copies/µg following normalisation against the reference gene, 
human β-globin where possible. The population sample in Lay et al, 2010 is derived from the Ausimmune 
Study controls.  
Clinical Group: Individuals hospitalised with EBV-related Disease or Immune 
Dysfunction (Lay et al, 2010).  
 N = patients,  
n = samples 
EBV DNA Load in 
this study 
(copies/mL) 
EBV DNA load in the 
literature 
(copies/mL) 
References 
EBV related post-transplant 
lymphoproliferative disease  
N = 5, n = 40 8.0 x 102 – 1.3 x 108 
(Days +32 to +63 
post-transplantation) 
2.2 x 102 – 2.0 x 107 
(~3 weeks before 
death: 106 – 109) 
(1-4) 
Infectious mononucleosis N = 7, n = 7 zero – 2.0 x 105 3.8 x 101 – 6.0 x 105 (5-9) 
EBV-associated 
haemophagocytic syndrome 
N = 1, n = 1 7.5 x 104 – 1.1 x 105 zero – 5.5 x 107 (10-12) 
HIV infection N = 12, n = 12 zero – 5.6 x 103 3.4 x 102 – 1.3 x 105 (7, 13, 14) 
Healthy controls  N = 218, n = 218 2.0 × 102  – 9.1 × 104   < 1.0 x 102 – 5.5 x 105 (7, 9, 15-18) 
Research Group: The Ausimmune Study Participants  
 Cases with first CNS 
demyelination 
Controls without CNS 
demyelination 
Number of participants  213 218 
Average age Males 38 years, females 39 years  Males 39 years, females 40 years 
Sex 47 males : 166 females 46 males : 172 females 
Region 
 Brisbane 73 78 
 Newcastle 28 28 
 Western districts of Victoria and 
Geelong 
45 45 
 Tasmania 67 67 
EBV DNA  
 Cases with first CNS 
demyelination 
Controls without CNS 
demyelination 
EBV DNA detected (both targets %) 26.3% (56/213) 22.5% (49/218) 
EBV DNA load range (both targets) 2.0 x 102 - 1.4 x 104 copies/mL 
(1.0 – 88.5 copies/µg) 
2.0 × 102  – 9.1 × 104  copies/mL 
(1.0 – 533.9 copies/µg) 
 EBNA-1 DNA detected  % 12.2% (26/213) 11.0% (24/218) 
 EBNA-1 DNA load  2.0 x 102 – 1.4 x 104 copies/mL 
(2 – 71.8 copies/µg) 
2.0 × 102 – 9.1 × 104 copies/mL 
(1.1 – 533.9 copies/µg) 
 BHRF-1 DNA detected % 20.2% (43/213) 21.6% (47/218) 
 BHRF-1 DNA load  2.0 x 102 – 8.8 x 103 copies/mL 2.0 × 102 – 3.3 × 104 copies/mL 
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Abbreviations: BHRF-1, BamHI fragment H rightward open reading frame-1; CNS, central nervous system; DNA, 
deoxyribonucleic acid; EA-D, early antigen-diffuse; EA-R, early antigen-restricted; EBNA, Epstein-Barr virus nuclear antigen; 
EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; IgM, immunoglobulin M; mL, 
millilitres; VCA, viral capsid antigen.  
 
 4.6.2 EBNA-1 EBV qPCR assay evaluation 
Our in-house EBNA-1 EBV qPCR assay was able to correctly identify all of the samples in 
the 2008 and 2009 QCMD EBV DNA EQA Program (n = 20/20; 100%). These qualitative 
results suggest that our qPCR assay was competent at detecting EBV DNA. All but one 
sample was quantifiable for EBV DNA: sample 2 from 2009; 2.66 x 10
2
 copies/mL. This 
sample contained EBV DNA approaching the assay’s lower limit of detection (2.00 x 102 
copies/mL). This sample was assayed twice but failed to amplify EBV DNA within the 
linear range. However, samples containing low levels of target DNA (i.e., 5.0 x 10
2
 to 5.0 
x 10
3
 copies/mL) are difficult to detect, and re-amplification in repeated assays from the 
same of different specimens may yield different results (19, 20). Nonetheless, this sample 
was still reported as positive (i.e. ‘detected’ for EBV DNA). 
 
A comparison of the consensus EBV QCMD DNA load for both 2008 and 2009 versus our 
EBNA-1 EBV DNA load showed that our assay “over-quantified” in 72.2% of cases by 
approximately log10 0.34 (SD: 0.30). Conversely, EBV DNA load underestimation 
occurred in 22.2% of positive samples by log10 0.22 (SD: 0.14). One sample (5.6%) had 
(1.0 – 88.5 copies/µg) (1.0 – 195.3 copies/µg) 
 β-globin DNA load  Average: 5.0 x 107 copies/mL 
(2.2 x 107 – 10.0 x 107 copies/mL) 
Average: 4.9 x 107 copies/mL 
(1.2 x 107 – 9.0 x 107 copies/mL) 
EBV Serology 
 Cases with first CNS 
demyelination 
Controls without CNS 
demyelination 
VCA IgG antibody detected % 98.1% (209/213) 95.9% (209/218) 
Median VCA IgG antibody titre  1:640 (<1:10 – 1: 5120) 1:640 (1:10 – 1:5120) 
EA-D IgG antibody detected % 77.5% (165/213) 76.1% (166/218) 
Median EA-D IgG antibody titres 1:40 (<1:10 – 1:640) 1:10 (<1:10 – 1:640) 
EA-R IgG antibody detected  % 86.4% (184/213) 82.6% (180/218) 
Median EA-R IgG antibody titres 1:40 (<1:10 – 1:640) 1:40 (<1:10 – 1:640) 
EBNA IgG antibody detected % 96.7% (206/213) 91.3% (199/218) 
Median EBNA IgG antibody titres 1:160 (<1:10 – 1:2560) 1:160 (<1:10 – 1:2560) 
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EBV DNA equal to the consensus QCMD DNA load (Sample 6 from 2009; log10 4.43). 
Approximately 83.3% (15/18) of EBV DNA loads obtained from our qPCR assay were 
within the QCMD log10 SD; 16.7% (3/18) of samples had EBV DNA loads above the 
consensus QCMD log10 SD by a mean of 0.24. Overall, our performance in the 2008 and 
2009 QCMD EBV DNA EQA Program suggested that our assay was accurate at detecting 
EBV DNA. The sensitivity of our assay was comparable to the levels generally accepted 
for other herpesvirus assays (i.e. 2.0 x 10
2
 copies/mL) (21). 
 
 4.6.3 BHRF-1 EBV qPCR assay evaluation 
Our in-house BHRF-1 EBV qPCR assay was designed one year following development of 
the EBNA-1 qPCR assay; hence, no results were generated for the 2008 QCMD EBV 
DNA EQA Program. Retrospective testing of the samples however, showed that the overall 
performance of our BHRF-1 EBV qPCR assay compared well with our EBNA-1 EBV 
qPCR assay. There was a tendency for the BHRF-1 qPCR assay to underestimate EBV 
DNA loads (88.9%), with overestimation occurring in 11.1% of positive samples. All but 
one sample had EBV DNA loads within the acceptable log10 SD range (88.9%; 8/9). This 
sample (Sample 10 from 2009) was detectable for EBV DNA, but could not be quantified 
within the assay’s linear range. A possible explanation is DNA degradation that may have 
occurred with repeated freeze-thaw cycles (22).  
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Table 24. EBV qPCR assay performance in the 2008 and 2009 QCMD Program  
2008 Quality Control for Molecular Diagnostics for EBV (EBNA-1 qPCR) 
Sample 
number§ 
Consensus 
QCMD load 
(copies/mL)Ω 
Consensus 
QCMD load 
Log10 (SD) 
% 
Qualitative 
correct¥ 
In-house real-
time qPCR 
Log10 (SD)
X 
Our assay 
(copies/mL) 
Our 
assay 
Log10 
Result 
EBV  08-01 2.48 x 102 2.39 (0.64) 60.9 2.53 (0.74) 1.80 x 103 3.26 √ 
EBV  08-02 1.50 x 103 3.18 (0.58) 97.8 3.23 (0.64) 1.07 x 104 4.03 √ 
EBV  08-03 2.77 x 103 3.44 (0.50) 98.9 3.47 (0.56) 3.30 x 103 3.52 √ 
EBV  08-04 1.44 x 104 4.16 (0.54) 100.0 4.20 (0.63) 2.55 x 104 4.41 √ 
EBV  08-05 5.09 x 102 2.71 (0.61) 87.0 2.78 (0.69) 3.40 x 103 3.53 √ 
EBV  08-06 Not detected N/A 95.7 N/A Not detected N/A √ 
EBV  08-07 7.19 x 103 3.86 (0.53) 100.0 3.88 (0.62) 2.26 x 104 4.35 √ 
EBV  08-08 1.35 x 105 5.13 (0.48) 100.0 5.15 (0.55) 1.12 x 105 5.05 √ 
EBV  08-09 2.59 x 104 4.41 (0.48) 100.0 4.43 (0.56) 3.65 x 104 4.56 √ 
EBV  08-10 4.48 x 102 2.65 (0.62) 84.8 2.53 (0.72) 2.00 x 102 2.30 √ 
2009 Quality Control for Molecular Diagnostics for EBV (EBNA-1 qPCR) 
Sample 
number§ 
Consensus 
QCMD load 
(copies/mL)Ω 
Consensus 
QCMD load 
Log10 (SD) 
% 
Qualitative 
correctδ 
In-house real-
time qPCR 
Log10 (SD)
Y 
Our assay 
(copies/mL) 
Our 
assay 
Log10 
Result 
EBV  09-01 Not detected N/A 96.8 N/A Not detected N/A √ 
EBV  09-02 2.66 x 102 2.42 (0.53) 72.3 2.55 (0.63) Detected 
(<LOD) 
<2.30 √ 
EBV  09-03 5.24 x 102 2.72 (0.55) 92.6 2.80 (0.63) 1.20 x 103 3.08 √ 
EBV  09-04 8.30 x 103 3.92 (0.46) 100.0 4.05 (0.51) 1.28 x 104 4.11 √ 
EBV  09-05 1.65 x 104 4.22 (0.48) 100.0 4.34 (0.53) 2.88 x 104 4.46 √ 
EBV  09-06 2.70 x 104 4.43 (0.45) 100.0 4.54 (0.50) 2.72 x 104 4.43 √ 
EBV  09-07 1.58 x 105 5.20 (0.46) 98.9 5.28 (0.50) 2.53 x 105 5.40 √ 
EBV  09-08 5.41 x 102 2.73 (0.48) 89.4 2.87 (0.51) 8.33 x 102 2.92 √ 
EBV  09-09 2.58 x 103 3.41 (0.50) 100.0 3.45 (0.54) 1.23 x 103 3.09 √ 
EBV 09-10 2.07 x 103 3.31 (0.51) 100.0 3.36 (0.54) 2.73 x 103 3.44 √ 
2009 Quality Control for Molecular Diagnostics for EBV (BHRF-1 qPCR) 
Sample 
number§ 
Consensus 
QCMD load 
(copies/mL)Ω 
Consensus 
QCMD load 
Log10 (SD) 
% 
Qualitative 
correctδ 
In-house real-
time qPCR 
Log10 (SD)
Y 
Our assay 
(copies/mL) 
Our 
assay 
Log10 
Result 
EBV  09-01 Not detected N/A 96.8 N/A Not detected N/A √ 
EBV  09-02 2.66 x 102 2.42 (0.53) 72.3 2.55 (0.63) 6.33 x 102 2.80 √ 
EBV  09-03 5.24 x 102 2.72 (0.55) 92.6 2.80 (0.63) 5.00 x 102 2.70 √ 
EBV  09-04 8.30 x 103 3.92 (0.46) 100.0 4.05 (0.51) 3.37 x 103 3.53 √ 
EBV  09-05 1.65 x 104 4.22 (0.48) 100.0 4.34 (0.53) 1.41 x 104 4.15 √ 
EBV  09-06 2.70 x 104 4.43 (0.45) 100.0 4.54 (0.50) 1.70 x 104 4.23 √ 
EBV  09-07 1.58 x 105 5.20 (0.46) 98.9 5.28 (0.50) 1.08 x 105 5.03 √ 
EBV  09-08 5.41 x 102 2.73 (0.48) 89.4 2.87 (0.51) Detected <2.30 √ 
EBV  09-09 2.58 x 103 3.41 (0.50) 100.0 3.45 (0.54) 9.33 x 102 2.97 √ 
EBV 09-10 2.07 x 103 3.31 (0.51) 100.0 3.36 (0.54) Detected <2.30 √ 
Abbreviations: BHRF-1, BamHI fragment H rightward open reading frame-1; EBNA-1, Epstein-Barr nuclear antigen-1; 
EBV, Epstein-Barr virus; mL, millilitre; N/A, not applicable; QCMD, quality control for molecular diagnostic; qPCR, quantitative polymerase chain 
reaction; SD, standard deviation. 
Note: Viral loads and standard deviation rounded to two decimal places; percentages rounded to one decimal place. 
§ QCMD sample matrix is viral transport medium comprising Dulbecco's modified eagle’s medium and foetal calf serum 
Ω Consensus values calculated from all of the data returned by participants, once outliers were removed 
¥ Qualitative correct results calculated based on the number of participating laboratories using in-house real-time PCR (n = 92) 
X Consensus quantitative result by real-time in-house qPCR (n = 79) 
δ Qualitative correct results calculated based on the number of participating laboratories using in-house real-time PCR (n = 94) 
Y Consensus quantitative result by real-time in-house qPCR (n = 75). 
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4.7 Appendix 4B 
Table 25. MIQE checklist for EBV qPCR assays 
(E) denotes essential information necessary for submission with manuscript; (D) indicates desirable 
information that should be submitted if available.  
 
ITEM TO CHECK IMPORTANCE CHECKLIST 
EXPERIMENTAL DESIGN   
Definition of experimental and control  groups E Cases: individuals with a first clinical diagnosis of demyelination and 
individuals with EBV-associated diseases or immune dysfunction 
such as PTLD, IM, EBVAHS and HIV infection. Controls: individuals 
without evidence of demyelination 
Number within each group E Defined by n 
Assay carried out by core lab or investigator's 
lab 
D Yes; assays performed at the Centre for Infectious Diseases & 
Microbiology, Westmead Hospital, Westmead, NSW, Australia 
Acknowledgement of authors' contributions D Noted after main body of manuscript 
SAMPLE   
Description E EDTA Whole blood, plasma, PBMC and CSF 
Volume/mass of sample processed D 200 µL 
Microdissection or macrodissection E N/A 
Processing procedure E N/A 
If frozen - how and how quickly? E Ausimmune Study samples were collected and aliquoted within 4 
hours (kept at room temperature or refrigerated after 8 hours) and 
frozen at -80°C before processing. Samples were thawed at room 
temperature for 15 to 30 min and extracted immediately 
If fixed - with what, how quickly? E N/A 
Sample storage conditions and duration 
(especially for FFPE samples) 
E DNA extracts were stored at -80°C in 12 µL single-use aliquots. 
Testing was performed within one week following extraction 
NUCLEIC ACID EXTRACTION   
Procedure and/or instrumentation E Manual extraction using a commercial kit 
Name of kit and details of any modifications E For EDTA, plasma and CSF; GenElute™ Mammalian Genomic DNA 
Miniprep Kit® (Sigma-Aldrich), for PBMC; QIAamp DNA mini kit 
(Qiagen) 
Source of additional reagents used D N/A 
Details of DNase or RNAse treatment E N/A. Note: There is a possibility that CSF DNA extracts were treated 
with DNase following extraction by other laboratories 
Contamination assessment (DNA or RNA) E PCR-grade water used as contamination controls during DNA 
extraction, PCR set-up and post-PCR manipulations known as 
specimen no DNA controls (sndc) and no template controls (NTC) 
Nucleic acid quantification E DNA load measured by absolute quantification; standard curves 
generated from plasmid DNA containing known concentrations of 
target DNA 
Instrument and method E Rotor-GeneTM 6000 (Qiagen) using the 36-well rotor 
Purity (A260/A280) D Purity measured by the Beckman DU® 530 Life Science UV/Vis 
spectrophotometer. Acceptable purity absorbance ratios (A260/A280) 
were between 1.8 and 2.0 
Yield D Plasmid concentration measured by Beckman DU® 530 Life Science 
UV/Vis spectrophotometer. 
RNA integrity method/instrument E N/A 
RIN/RQI or Cq of 3' and 5' transcripts E N/A 
Electrophoresis traces D Product checked using agarose gel electrophoresis 
Inhibition testing (Cq dilutions, spike or other) 
 
 
 
 
E Reference gene human β-globin was tested for all samples 
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REVERSE TRANSCRIPTION   
Complete reaction conditions E N/A 
Amount of RNA and reaction volume E N/A 
Priming oligonucleotide (if using GSP) and 
concentration 
E N/A 
Reverse transcriptase and concentration E N/A 
Temperature and time E N/A 
Manufacturer of reagents and catalogue 
numbers 
D N/A 
Cqs with and without RT D* N/A 
Storage conditions of cDNA D N/A 
qPCR TARGET INFORMATION   
If multiplex, efficiency and LOD of each assay. E N/A 
Sequence accession number E Lay et al, 2010, Table 1 
Location of amplicon D Lay et al, 2010, Table 1 
Amplicon length E Lay et al, 2010, Table 1 
In silico specificity screen (BLAST, etc) E BLAST, agarose gel electrophoresis, QCMD external QA program, 
melt curve profile, DNA sequencing, absence of cross-reactivity with 
other Herpesviruses 
Pseudogenes, retropseudogenes or other 
homologs? 
D N/A 
Sequence alignment D Primers were checked by DNA sequencing and nucleotide BLAST 
search. Theoretical specificity obtained if percentage match was 
100% and E-value approached zero (see Figure 29, Appendix 8F) 
Secondary structure analysis of amplicon D Checked for secondary structures using FastPCR program 
Location of each primer by exon or intron (if 
applicable) 
E N/A 
What splice variants are targeted? E N/A 
qPCR OLIGONUCLEOTIDES   
Primer sequences E Lay et al, 2010, Table 1 
RTPrimerDB Identification Number D N/A. EBNA-1 primers were obtained from Stevens et al, 1999, 
BHRF-1 primers were designed by VM Ratnamohan, human β-globin 
primers were modified from VM Ratnamohan (Chapter 3, section 
3.1.1,Table 19) 
Probe sequences D** N/A 
Location and identity of any modifications E Chapter 3, section 3.1.1 
Manufacturer of oligonucleotides D Designed by OligoPerfectTM Designer by Invitrogen Life 
Technologies 
Purification method D PAGE purification by manufacturer 
qPCR PROTOCOL   
Complete reaction conditions E Lay et al, 2010: DNA extraction and molecular assay design 
Reaction volume and amount of cDNA/DNA E 5 µL DNA template, 25 µL total reaction volume 
Primer, (probe), Mg++ and dNTP 
concentrations 
E 0.5 μL 0.2 mM sense and antisense primers, 0.8 μL 25 mM MgCl2 
Polymerase identity and concentration E FastStart Taq DNA Polymerase 
Buffer/kit identity and manufacturer E LightCycler® FastStart DNA Master SYBR Green 1 dye (Roche 
Diagnostics) 
Exact chemical constitution of the buffer D Unknown 
Additives (SYBR Green I, DMSO, etc.) E SYBR Green I, no additives 
Manufacturer of plates/tubes and catalog 
number 
D Table 34, Chapter 8, Appendix 8A 
Complete thermocycling parameters E Lay et al, 2010, Table 1 
Reaction setup (manual/robotic) D Manual 
Manufacturer of qPCR instrument E Rotor-GeneTM 6000 (Qiagen; formerly known as Corbett Research) 
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qPCR VALIDATION   
Evidence of optimisation (from gradients) D Chapter 3, section 3.1 
Specificity (gel, sequence,  melt, or digest) E Agarose gel, melting curve analyses and DNA sequencing 
For SYBR Green I, Cq of the NTC E Approximate Cqs for NTC not included but conditions for data 
rejection specified (NTC = zero, any Cqs > 40 should be ignored 
and considered negative) 
Standard curves with slope and y-intercept E Average slope not specified in publication but calculated to be 3.73 
and -3.67 for EBNA-1 and BHRF-1, respectively. The y-intercept was 
intentionally omitted as this value varies from run-to-run 
PCR efficiency calculated from slope E Average amplification efficiency for EBNA-1 and BHRF-1; 86% and 
85% (reported as 0.86 and 0.85 on the Rotor-GeneTM 6000 
software; theoretical maximum of 1.0 for 100% amplification 
efficiency). Published as 1.74 (average sample comparative 
quantitation efficiency in Lay et al, 2010) 
Confidence interval for PCR efficiency or 
standard error 
D Standard deviation for PCR efficiency was not specified in Lay et al, 
2010 but calculated to be 0.09 and 0.06 for EBNA-1 and BHRF-1, 
respectively 
R2 of standard curve E Lay et al, 2010; Table 2 
Linear dynamic range E 1.0 x 101 to 1.0 x 105 copies/5 µL 
Cq variation at lower limit E Lay et al, 2010; Table 2 
Confidence intervals throughout range D N/A 
Evidence for limit of detection E Lay et al, 2010: Product identification, reproducibility, sensitivity, 
limit of detection and specificity 
If multiplex, efficiency and LOD of each assay E N/A 
DATA ANALYSIS   
qPCR analysis program (source, version) E Rotor-GeneTM 6000  Software 1.7 (Build 90) 
Cq method determination E Auto-find threshold 
Outlier identification and disposition E Chapter 2, section 2.2.9, Table 18 
Results of NTCs E Not mentioned in Lay et al, 2010 but NTC included in assays 
Justification of number and choice of reference 
genes 
E Chapter 3, section 3.1 
Description of normalisation method E Chapter 3, section 3.2 
Number and concordance of biological 
replicates 
D Not mentioned 
Number and stage (RT or qPCR) of technical 
replicates 
E Study samples tested in duplicate; plasmid standards tested in 
triplicates 
Repeatability (intra-assay variation) E Lay et al, 2010; Table 2 
Reproducibility (inter-assay variation, %CV) D Lay et al, 2010; Table 2 
Power analysis D Performed during project design 
Statistical methods for result significance E Spearman’s (rho) correlation co-efficient was used to assess the 
correlation between EBV DNA load and VCA IgG antibody titres 
Software (source, version) E SPSS version 17 
Cq or raw data submission using RDML D Raw data not submitted 
Abbreviations: BHRF-1, BamHI fragment H rightward open reading frame-1; BLAST, basic local alignment search tool; Cq, 
quantification cycle; CSF, cerebrospinal fluid; DNA, deoxyribonucleic acid; EBNA-1, Epstein-Barr virus nuclear antigen-1; EBV, 
Epstein-Barr virus; EBVAHS, Epstein-Barr virus-associated haemophagocytic syndrome; EDTA, ethylenediamine tetraacetic acid; HIV, 
human immunodeficiency virus; IM, infectious mononucleosis; n, number; N/A, not applicable; NSW, New South Wales; NTC, no 
template control; PAGE, polyacrylamide gel electrophoresis; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain 
reaction; PTLD, post-transplant lymphoproliferative disease/disorder; QA, quality assurance; QCMD, quality control for molecular 
diagnostics; VCA, viral capsid antigen.  
 
* Assessing the absence of DNA using a no RT assay is essential when first extracting RNA. Once the sample has been validated as 
RDNA-free, inclusion of a no-RT control is desirable, but no longer essential. 
** Disclosure of the probe sequence is highly desirable and strongly encouraged. However, since not all commercial pre-designed 
assay vendors provide this information, it cannot be an essential requirement. Use of such assays is advised against. 
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Chapter 5 
Development and Application of a Quantitative 
PCR Assay for the Detection and Measurement 
of Human Herpesvirus-6 DNA 
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5.1 Aims  
Chapter 5 aims included:- 
1. Development of a sensitive real-time qPCR assay using SYBR Green I dye for the 
detection and quantification of HHV-6 DNA  
2. Application of the above qPCR to research and clinical cohorts to determine HHV-6 
DNA positivity and load. 
 
5.2 Introduction  
The risk of HHV-6 infection complication in immunocompromised individuals and 
involvement in neurological disorders has prompted the need for rapid, sensitive and 
specific diagnostic tests. In particular, viral load monitoring as a means for detecting and 
measuring virus burden has become essential for early intervention for those at risk of 
disease complications and progression (1, 2). This chapter describes the development of a 
real-time qPCR assay using SYBR Green I dye for the detection and quantification of 
HHV-6 DNA in research and clinical groups.  
 
5.3 Materials and methods    
 5.3.1 Study groups  
Samples tested for HHV-6 DNA and HHV-6-specific antibodies were derived from 
research and clinical groups. Samples were obtained from two research studies, The 
Ausimmune Study (3) and the Southern Tasmanian Multiple Sclerosis Longitudinal Study 
(MSL) (4). The Ausimmune Study samples consisted of EDTA whole blood and serum 
from case participants with a first clinical diagnosis of CNS demyelination (FCD; Group 1, 
number of subjects, N = 213; number of samples, n = 213); and control individuals without 
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evidence of CNS demyelination case-matched by sex, location of residence (postcode) and 
age (within two years) (Group 2, N = 218, n = 218). Group 3 comprised PBMC and serum 
from a selection of RRMS subjects enrolled in the MSL Study (N = 5); two subjects had 
multiple samples collected at six monthly intervals between 2002 and 2005 (Australian 
winter and summer; note summer 2002 and winter 2005 samples could not be obtained) (n 
= 24). All subjects previously tested HHV-6 DNA positive by PCR. The clinical group 
(Group 4, N = 15) comprised liver tissue from liver transplant recipients (n = 3), and 
plasma from HIV-infected individuals (n = 12) who had been admitted to Westmead 
Children’s Hospital and Westmead Hospital, (Westmead NSW, Australia), respectively, 
between 2006 and 2009. All liver transplant recipients tested HHV-6 qualitative PCR 
positive at their respective laboratories and all HIV-infected individuals had HIV RNA 
loads between 1.3 x 10
4 
to 1.0 x 10
7
 copies/mL. Samples from Groups 1 to 4 were 
quantified for HHV-6 DNA; serology was performed on serum from Groups 1 to 3; no 
serum could be obtained for Group 4. The author performed all DNA work; serology was 
done by Janette Taylor and V. Mala Ratnamohan. Table 26 shows the study groups tested. 
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Table 26. Study groups investigated for HHV-6 DNA and IgG and IgM antibodies 
 
Abbreviations: CNS, central nervous system; DNA, deoxyribonucleic acid; EDTA, ethylenediamine tetraacetic acid; F, female; HIV, human immunodeficiency virus; M, male; MS, multiple 
sclerosis; RRMS, relapsing-remitting multiple sclerosis. 
*Two subjects had between 5 and 6 samples. Each subject also had between 4 to 6 sera samples collected at 6 monthly intervals (winter and summer months) after the initial (baseline) sera. 
Study 
group 
Derivation (collected) Underlying disease condition 
Number of 
subjects (N) 
Number of 
samples (n) 
Sex 
(M, F) 
 
 
 
Specimen Test 
        
1 Cases from the Ausimmune Study 
(2003–2006) 
First clinical diagnosis of CNS 
demyelination 
213 213 47, 166 EDTA whole blood, serum qPCR, serology 
2 Controls from the Ausimmune Study 
(2003–2006) 
No evidence of CNS 
demyelination  
218 218 45, 173 EDTA whole blood, serum qPCR, serology 
3 The Southern Tasmanian Multiple 
Sclerosis Longitudinal Study  
(2002–2005) 
RRMS 5* 24 
 
1, 4 PBMC, serum qPCR, serology 
4 Westmead Children’s Hospital  
(2006–2009) 
 
Westmead Hospital 
(2006-2009) 
Liver transplant recipient  
 
 
HIV infection  
3 
 
 
12 
3 
 
 
12 
1, 2 
 
 
unknown 
liver tissue 
  
 
plasma 
qPCR  
 
Total DNA studies 451 470 95, 345 
  
 
Total serology studies 436 436  
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 5.3.2 Molecular testing 
5.3.2.1 Primers and controls 
A 108 bp segment of U67 ORF (also known as 13r) was selected for HHV-6 qPCR (primer 
sequences are shown in Chapter 3, Table 19). The function of the U67 gene is unknown 
(5), but the gene is highly conserved, contains one copy per virus genome (6), and has been 
the target used in other HHV-6 qPCR studies (7-9). Positive HHV-6 controls included 
DNA extracted from the HHV-6A U1102 cell line. The human β-globin gene targeted at 
the TAL57 region was used as a reference gene to screen for PCR inhibitors, ensure DNA 
integrity and to normalise data. Contamination controls consisting of molecular grade H2O 
shadowed test samples during DNA extraction and PCR set-up.  
 
5.3.2.2 DNA extraction and standard curve construction  
Viral DNA was extracted from EDTA whole blood, plasma, PBMC and liver tissue as 
described in section 2.2.1. Quantification standards were constructed from a plasmid 
inserted with the U67 gene (from reference strain U1102) as described in section 2.2.3 (see 
Appendix 8C for plasmid construct). A standard curve was generated for each qPCR assay 
using fresh plasmid. Standard curves encompassed five dilution points and consisted of 
three replicates (1.0 x 10
1 
to 1.0 x 10
5
 copies/5 μL). Samples with high HHV-6 DNA loads 
(i.e. >1.0 x 10
5 
copies/mL) were repeated using standard curves spanning six logarithms 
(1.0 x 10
1
 to 1.0 x 10
6
 copies/5 μL).  
 
5.3.2.3 Product identification and viral load calculation  
Samples positive for HHV-6 DNA were identified by amplification curves (Cq <40), a 
melting curve analysis (81°C to 82°C) and by agarose gel electrophoresis. HHV-6 DNA 
copy number was determined by the Rotor-Gene 6000
TM
 instrument using software version 
1.7 (Build 90) and final DNA loads, expressed as copies/mL, were calculated according to 
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the initial sample volume extracted, final elution volume and number of PCR replicates 
using the formula in section 2.2.13.  
 
5.3.2.4 Assay performance  
Human herpesvirus-6 qPCR assay sensitivity was assessed by real-time and endpoint PCR; 
samples were diluted ten-fold to contain 2.0 x 10
0
 to 2.0 x 10
6
 copies/mL and assayed to 
determine the minimum target amount that could be detected. The limit of detection (LOD) 
as defined by the least amount of target DNA that could be measured with ≥95% certainty 
(10), was determined by three separate assays comprising ten plasmid replicates spanning 
2.0 x 10
0
 to 2.0 x 10
2
 copies/mL (i.e. higher dilutions). Primer specificity was checked 
using nucleotide BLAST search and by PCR for cross-reactivity with the EBV strain, B95-
8, and the CMV strain, AD169. Primers passed theoretical specificity if the BLAST 
percentage match was 100% and the E-value approached zero. Practical specificity was 
achieved if the primer pair failed to amplify EBV and CMV DNA sequences. HHV-7 
positive samples were unfortunately not available for cross-checking our HHV-6 primers. 
Instead, practical and theoretically specificity served to ensure that there was no cross-
reactivity between the two genetically similar (but distinct) herpesviruses. Reproducibility 
was assessed by amplifying triplicates of each standard curve dilution points from 2.0 x 
10
1 
to 2.0 x 10
5
 copies/mL. Intra-assay variation was determined by running three separate 
assays within a 24-hour period and over three consecutive days. Inter-assay variation 
involved testing three different LightCycler
®
 FastStart DNA Master SYBR Green I 
(Roche) mix kits. The qPCR assay performance was (informally) assessed using samples 
from the 2008 and 2009 QCMD External Quality Assessment for Human Herpesvirus 6 
(HHV-6DNA08 and HHV-6DNA09). 
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 5.3.3 Serology 
5.3.3.1 HHV-6 IgG and HHV-6 IgM antibody detection and result interpretation 
Serum from Groups 1 to 3 was tested to quantify HHV-6 IgG and HHV-6 IgM antibodies 
using the commercial kits described in section 2.4.3. Measurement of HHV-6 IgM 
antibodies were undertaken only if HHV-6 IgG antibody titres were >1:10. HHV-6 IgG 
and IgM antibody results were reported according to the manufacturer’s instructions as 
follows: 
 HHV-6 IgG antibody titres <1:10 were reported as a negative  
 HHV-6 IgG antibody titres  ≥1:10 were reported as a positive 
 HHV-6 IgM antibody titres <1:20 were reported as a negative  
 HHV-6 IgM antibody titres ≥1:20 were reported as a positive  
 
 5.3.4 Statistical calculations  
Descriptive statistics using Microsoft Excel were undertaken by the author, and included 
mean, median, range and the proportion positive. Additional statistical analysis on the 
Ausimmune Study samples (Groups 1 and 2) was undertaken using Stata by Dr Robyn M 
Lucas. Data analysis was performed on The Ausimmune Study participants in accordance 
with the PhD Collaboration Framework Agreement (see Appendix 8E). Adjustments for 
possible confounders, such as HLA-DRB1*15 positivity and smoking habits, were not 
done as this was beyond the scope of the project and restricted by the PhD Collaborative 
Framework Agreement. These data are currently being analysed with the aim to submit for 
publication in 2013, in collaboration with the author of this thesis. Statistical analysis was 
not performed on Groups 3 and 4 given the small sample size.  
 
In the Ausimmune Study, Spearman’s rank correlation was used to assess the link between 
HHV-6 antibody titres and HHV-6 DNA load in the Ausimmune Study controls (Group 2). 
This group consisted of non-diseased participants (i.e. no CNS demyelination) and was 
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therefore more likely to reflect viral loads and antibody titres typical of a non-diseased 
population. Variation in HHV-6 DNA positivity and load according to sex, study location 
and age within the Ausimmune Study controls was assessed using the Kruskal-Wallis test. 
Conditional logistic regression was used to evaluate whether there was an increased odds 
of being a case (compared to being a control) in relation to HHV-6 DNA (positivity or 
load) and antibody titre. Interpretation of all results was the responsibility of the thesis 
author.  
 
5.4 Results 
 5.4.1 Assay performance  
The average Cqs for 10
5
,
 
10
4
, 10
3
, 10
2
 and 10
1
 copies/5 µL were: 16.0, 19.4, 22.9, 26.4 and 
30.0, respectively. All HHV-6 DNA positive samples, including plasmid controls, had Cqs 
<40. Conversely, all negative samples had Cqs equal to zero or >40. Melting curve 
analyses showed that amplicons melted at temperatures identical to the positive and 
plasmid HHV-6 controls (between 81°C and 82°C). Table 27 shows the average 
amplification efficiency and reaction slope values. Figure 21 shows an example of a typical 
qPCR experiment with amplification, melting and standard curves.  
 
Table 27. Optimal HHV-6 qPCR assay statistics 
Optimal qPCR assay statistics as specified by the Rotor-GeneTM 6000 Operator Manual, v1.7.34, versus 
average experimental data collected from 46 HHV-6 qPCR runs. 
 
Abbreviations: R2-value, correlation coefficient; R-value, square root of the correlation 
coefficient. 
 
 
 
 
Statistics  
 
 
 
Optimal values 
 
 
 
 
Average experimental values 
 R-value 0.99 0.99 
R2-value 0.99 0.99 
Slope  -3.32 -3.76 ± 0.18 
Amplification Efficiency 100% 85% ± 0.05 
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A. 
 
 
 
 
 
 
B. 
 
 
 
 
 
C. 
                            
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. HHV-6 qPCR assay curves 
A. Amplification curves of serially (ten-fold) diluted plasmids spanning six logarithms in triplicates; B. Melt 
curves showing HHV-6 dsDNA dissociating between 81°C and 82°C; C. Standard curve for HHV-6 qPCR 
assay spanning six dilution points (10
6 
to 10
1
 copies/5 µL).  
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The sensitivity limit of the assay was 2.0 x 10
2
 copies/mL and LOD was ≥2.0 x 103 
copies/mL. There was no evidence of primer cross-reactivity with EBV or CMV DNA. All 
PCR products were confirmed by visualisation of a single band (108 bp) following agarose 
gel electrophoresis (data not shown). Nucleotide BLAST showed 100% maximum 
sequence identities and E-values of 1e-48 for the HHV-6A strains: GS and U1102, and 
HHV-6B strains: Z29 and HST (see Appendix 8F for examples of BLAST search results). 
Table 28 shows the HHV-6 qPCR intra-assay and inter-assay performance.  
 
Table 28. HHV-6 qPCR inter- and intra-assay variation 
Abbreviations: COV, co-efficient of variation; Cq, quantification cycle; R
2-value, correlation coefficient. 
 ≠Average % variation as calculated by the Rotor-GeneTM 6000 software. 
 
Our HHV-6 qPCR assay was able to correctly identify HHV-6 DNA in all but one QCMD 
sample for 2008 and 2009 (n = 21/22; 95.5%), which had a DNA load below the assay’s 
sensitivity limits (sample 3 from 2009; 1.7 x 10
2
 copies/mL). A comparison of the 
consensus QCMD DNA load for both 2008 and 2009 versus our DNA load results showed 
that our assay over-quantified in 68.7% of cases by approximately log10 0.14 (SD: 0.18). 
DNA target 
(copies/5 µL) 
Average Cq 
Average Rotor-gene TM  
6000 results (copies/5 µL) 
Average 
variation 
(%)≠ 
COV 
(%) 
Average 
R2-value 
Intra-assay variation (within 24 hours) 
1.0 x 105 17.41 ± 2.19 104,516 ± 7,877 7.00 7.54 
0.998 
1.0 x 104 20.88 ± 2.06 10,076 ± 956 7.84 9.49 
1.0 x 103 24.74 ± 2.26 995 ± 110 8.85 11.06 
1.0 x 102 28.21 ± 2.14 108 ± 25 18.95 23.15 
1.0 x 101 32.42 ± 2.06 10 ± 4 34.23 40.00% 
Intra-assay variation (3 consecutive days) 
1.0 x 105 15.01 ± 2.56 89,591 ± 6,500 10.40 7.26 
0.993 
1.0 x 104 18.41 ± 2.62 9,375 ± 428 6.25 4.57 
1.0 x 103 21.52 ± 2.78 1,203 ± 88 20.25 7.32 
1.0 x 102 24.23 ± 2.15 108 ± 10 11.12 9.26 
1.0 x 101 27.74 ± 2.34 10 ± 4 32.89 40.00 
Inter-assay variation (3 different kits) 
1.0 x 105 17.85 ± 2.09 99,814 ± 7,448 5.94 7.46 
0.995 
1.0 x 104 21.53 ± 2.21 9,782 ± 1,252 9.37 12.80 
1.0 x 103 25.24 ± 2.10 1,048 ± 64 5.99 6.11 
1.0 x 102 28.72 ± 2.27 108 ± 32 26.84 29.63 
1.0 x 101 32.91 ± 2.01 11 ± 6 50.91 54.55 
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Conversely, HHV-6 DNA load underestimation occurred in 31.3% of samples by log10 
0.08 (SD: 0.22). Over 95% of HHV-6 DNA loads obtained from our qPCR assay were 
within the QCMD log10 SD (shown in brackets in Table 29), with the exception of one 
sample that was under-quantified by a logarithm (sample 11 from 2008: QCMD log10 3.40 
(SD: 0.55) versus our qPCR assay log10 2.44). 
 
Table 29. HHV-6 qPCR performance in 2008 and 2009 QCMD Program 
2008 Quality Control for Molecular Diagnostics for HHV-6 
Sample 
number§ 
Consensus 
QCMD load 
(copies/mL)Ω 
Consensus 
QCMD load 
Log10 (SD) 
% 
Qualitative 
correct¥ 
In-house real-
time qPCR 
Log10 (SD)
X 
Our assay 
(copies/mL) 
Our 
assay 
Log10 
Result 
HHV-6 08-01 1.15 x 103 3.06 (0.58) 97.1 3.04 (0.50) 2.50 x 103 3.40 √ 
HHV-6 08-02 5.68 x 102 2.75 (0.72) 94.3 2.90 (0.49) 1.53 x 103 3.19 √ 
HHV-6 08-03 9.77 x 102 2.99 (0.61) 97.1 2.99 (0.56) 1.30 x 103 3.11 √ 
HHV-6 08-04 7.43 x 103 3.87 (0.62) 100.0 3.99 (0.50) 3.30 x 103 3.52 √ 
HHV-6 08-05 Not detected N/A 100.0 N/A Not detected N/A √ 
HHV-6 08-06 Not detected N/A 97.1 N/A Not detected N/A √ 
HHV-6 08-07 6.52 x 103 3.81 (0.46) 100.0 3.79 (0.43) 9.50 x 103 3.98 √ 
HHV-6 08-08 Not detected N/A 100.0 N/A Not detected N/A √ 
HHV-6 08-09 2.58 x 104 4.41 (0.46) 100.0 4.39 (0.48) 3.34 x 104 4.52 √ 
HHV-6 08-10 2.42 x 102 2.38 (0.56) 85.7 2.39 (0.53) 7.00 x 102 2.85 √ 
HHV-6 08-11 2.50 x 103 3.40 (0.55) 97.1 3.51 (0.44) 2.74 x 102 2.44 √ 
HHV-6 08-12 Not detected N/A 100.00 N/A Not detected N/A √ 
2009 Quality Control for Molecular Diagnostics for HHV-6 
Sample 
number§ 
Consensus 
QCMD load 
(copies/mL)Ω 
Consensus 
QCMD load 
Log10 (SD) 
% 
Qualitative 
correctδ 
In-house real-
time qPCR 
Log10 (SD)
Y 
Our assay 
(copies/mL) 
Our 
assay 
Log10 
Result 
HHV-6 09-01 1.00 x 105 5.0 (0.46) 100.0 5.12 (0.47) 8.5 x 104 4.93 √ 
HHV-6 09-02 1.02 x 103 3.01 (0.49) 98.0 3.13 (0.46) 1.60 x 103 3.20 √ 
HHV-6 09-03 1.66 x 102 2.22 (0.68) 44.0 2.33 (0.74) Not detected N/A X 
HHV-6 09-04 2.47 x 103 3.39 (0.66) 100.0 3.57 (0.55) 3.20 x 103 3.51 √ 
HHV-6 09-05 Not detected N/A 98.0 N/A Not detected N/A √ 
HHV-6 09-06 9.35 x 103 3.97 (0.43) 100.0 4.12 (0.39) 8.00 x 103 3.90 √ 
HHV-6 09-07 1.33 x 103 3.12 (0.46) 98.0 3.23 (0.44) 8.00 x 102 2.90 √ 
HHV-6 09-08 2.09 x 102 2.32 (0.60) 50.0 2.51 (0.67) 6.00 x 102 2.78 √ 
HHV-6 09-09 6.85 x 102 2.84 (0.50) 94.0 2.97 (0.74) 1.00 x 103 3.00 √ 
HHV-6 09-10 9.12 x 102 2.96 (0.55) 98.0 3.08 (0.48) 2.80 x 103 3.45 √ 
Abbreviations: HHV-6, human herpesvirus 6; mL, millilitres; N/A, not applicable; QCMD, quality control for molecular 
diagnostic; SD, standard deviation. 
Note: Viral loads and standard deviation rounded to two decimal places; percentages rounded to one decimal place. 
§ QCMD sample matrix is comprised of plasma 
Ω Consensus values calculated from all of the data returned by participants, once outliers had been removed 
¥ Qualitative correct results calculated based on the number of participating laboratories using in-house real-time PCR (n = 35) 
X Consensus quantitative result by real-time in-house qPCR (n = 23) 
δ Qualitative correct results calculated based on the number of participating laboratories using in-house real-time PCR (n = 50) 
Y Consensus quantitative result by real-time in-house qPCR (n = 30). 
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 5.4.2 HHV-6 DNA detection and load 
5.4.2.1 Groups 1 and 2: The Ausimmune Study cases and controls 
Of the 431 Ausimmune Study participants, 10.4% (45/431) were positive for HHV-6 
DNA; 13.6% (29/213) were cases and 7.3% (16/218) were controls. HHV-6 qPCR results 
ranged from zero to 8.5 x 10
6
 copies/mL (median = zero copies/mL). Of the HHV-6 DNA 
positive samples, 84.4% (38/45) had HHV-6 DNA loads equal to the sensitivity limit of the 
assay (i.e. 2.0 x 10
2
 copies/mL). Seven samples (7/45, 15.6%) had HHV-6 DNA loads >1.0 
x 10
6
 copies/mL (ranging from 2.7 x 10
6
 to 8.5 x 10
6
 copies/mL), which yielded similar 
results upon repeat. All seven were female; six were FCD cases; and one was a control. All 
Ausimmune Study samples were positive for β-globin DNA. HHV-6 qPCR results for all 
study groups are presented in Table 30. 
 
Table 30. HHV-6 DNA loads results 
Abbreviations: CNS, central nervous system demyelination; HHV-6, human herpesvirus 6; HIV, human 
immunodeficiency virus; mL, millilitres; MS, multiple sclerosis; N, number of subjects tested; RRMS, relapsing-remitting 
multiple sclerosis. 
Note: Given the skewed distribution of HHV-6 DNA load, median and range are presented. 
 
 
5.4.2.2 Group 3: MSL Study RRMS subjects  
All five RRMS subjects were HHV-6 DNA positive (5/5, 100%); HHV-6 DNA loads 
ranged from detected to 8.7 x 10
6
 copies/mL (median 4.1 x 10
6
 copies/mL; Table 30). The 
Study group and underlying disease condition  
HHV-6 DNA load 
range (copies/mL) 
HHV-6 DNA 
load median 
(copies/mL) 
Proportion 
HHV-6 DNA 
positive (%) 
    
Group 1: The Ausimmune Study Cases: first clinical 
diagnosis of CNS demyelination (N = 213) 
 
Nil – 5.8 x 106 
 
 
Nil 
 
 
29/213 (13.6) 
 
 
Group 2: The Ausimmune Study Controls: no CNS 
demyelination (N = 218) 
 
 
Nil – 8.5 x 106 
 
 
Nil 
 
 
16/218 (7.3) 
 
 
Group 3: The Southern Tasmanian MS Longitudinal 
Study: RRMS (N = 5) 
 
Detected – 8.7 x 106 
 
 
 
 
4.1 x 106 
 
 
 
 
 
5/5 (100.0) 
 
 
 
 
Group 4: Clinical samples (hospitalised patients) 
 
 
 
 
 
  
 
 
 
Liver transplant (N = 3) 
 
 
8.2 x 102 – 1.3 x 105 
 
 
3.3 x 103 
 
 
3/3 (100.0) 
 
  
 
 
HIV infection (N = 12) 
 
 
N/A 
 
 
2.0 x 102 
 
1/12 (8.3) 
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two subjects with multiple samples had HHV-6 DNA loads >10
6
 copies/mL: Subject 1 had 
a mean HHV-6 DNA load of 5.4 x 10
6 
copies/mL; Subject 2 had a mean HHV-6 DNA load 
of 4.0 x 10
6
 copies/mL. All samples were β-globin DNA positive. 
 
5.4.2.3 Group 4: Liver transplant recipients and HIV-positive individuals 
HHV-6 DNA was detected in all liver transplant recipients (n = 3/3; 100%) and one HIV-
infected individual (n = 1/12; 8.3%; Table 30). Overall, Group 4 had a median HHV-6 
DNA load of 2.1 x 10
3
 copies/mL. HHV-6 DNA load was higher in the liver transplant 
recipients (range: 8.2 x 10
2 
to 1.3 x 10
5 
copies/mL) compared with the HIV-infected 
individual (2.0 x 10
2
 copies/mL). All samples were β-globin DNA positive. 
 
 5.4.3 HHV-6 serology  
5.4.3.1 Groups 1 and 2: The Ausimmune Study cases and controls  
HHV-6 IgG antibody titres could not be determined in one case and two control sera due to 
non-specific staining and/or anti-nuclear antibodies, and these were excluded from the 
analyses. Of the remaining 428 Ausimmune Study samples, HHV-6 IgG antibodies were 
detected and quantified in 96.3% of individuals (n = 412/428,): 98.1% of cases (n = 
208/212) and 94.4% of controls (n = 204/216). Of the original 431 Ausimmune Study case 
and control samples, HHV-6 IgM antibody titres were not measured in 16 sera; HHV-6 
IgG antibody titres were ≤1:10 for three cases and 12 controls; and one case had anti-
nuclear antibodies. Of the remaining 415 samples, 22 were positive for HHV-6 IgM 
antibodies (22/415, 5.3%); 4.8% were cases (n = 10/209) and 5.8% were controls (n = 
12/206). Antibody titres ranged from ≤1:10 to 1:2560 for HHV-6 IgG and ≤1:10 to 1:40 
for HHV-6 IgM. In the seven samples with HHV-6 DNA loads >10
6
 copies/mL, HHV-6 
IgG antibody titres ranged from 1:40 to 1:60; all were negative for HHV-6 IgM antibodies. 
Summarised HHV-6 serology results for Groups 1 to 3 are shown in Table 31. 
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Table 31. HHV-6 IgG and IgM serology results  
Abbreviations: CNS, central nervous system demyelination; HHV-6, human herpesvirus 6; HIV, human immunodeficiency 
virus; IgG, immunoglobulin G; IgM, immunoglobulin M; mL, millilitres; MS, multiple sclerosis; N, number of subjects tested; 
RRMS, relapsing-remitting multiple sclerosis 
 
5.4.3.2 Group 3: MSL Study RRMS subjects  
All five RRMS subjects were positive for HHV-6 IgG antibodies and negative for HHV-6 
IgM antibodies (Table 31). HHV-6 IgG anti body titres ranged from 1:40 to 1:160. The 
two RRMS subjects with multiple samples had a median HHV-6 IgG antibody titre of 1:40 
(Subject 1) and 1:160 (Subject 2). No increases in HHV-6 IgG antibody titres on the serial 
samples were found. 
 
 5.4.4 Group 2: The Ausimmune Study controls  
5.4.4.1 Variation by sex, study region and age group  
There were no differences by sex, study region or age group for either HHV-6 DNA 
positivity (2 = 0.91, P = 0.34 with 1 d.f.; 2 = 3.35, P = 0.34 with 3 d.f.; 2 = 3.37, P = 
0.34 with 3 d.f.) or DNA load (P = 0.34, 0.35 and 0.34, respectively). There were also no 
differences in HHV-6 IgG and IgM antibody titres by sex (P = 0.41 and 0.25, respectively), 
study region (P = 0.14 and 0.19, respectively), or age group (P = 0.98 and 1.00, 
respectively). 
 
Study group and underlying disease 
condition  
HHV-6 IgG 
antibody 
titre range 
HHV-6 IgG 
positive (%) 
HHV-6 IgM 
antibody 
titre range 
HHV-6 IgM 
positive (%) 
Group 1: The Ausimmune Study Cases: first 
clinical diagnosis of CNS demyelination (N = 213) 
≤1:10 to 
1:2560 
 
208/212 (98.1) 
 
1:20 to 1:40 
 
10/209 (4.8) 
 
Group 2: The Ausimmune Study Controls: no 
CNS demyelination (N = 218) 
 
≤1:10 to 
1:2560 
 
 
204/216 (94.4) 
 
 
1:20 to 1:40 
 
 
12/206 (5.8) 
 
 
Group 3:  The Southern Tasmanian MS 
Longitudinal Study: RRMS (N = 5) 
 
 
 
1:40 to 1:160 
 
 
 
 
 
 
 
 
5/5 (100.0) 
 
 
 
 
 
N/A 
 
 
 
 
 
 
0/5 (0.0) 
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 5.4.5 Group 1 versus Group 2: The Ausimmune Study case-control analyses  
5.4.5.1 HHV-6 DNA detection and load 
A higher proportion of cases compared with controls had detectable HHV-6 DNA: 13.6% 
(n = 29/213) versus 7.3% (n = 16/218). In a conditional logistic regression model without 
adjustment for possible confounders, cases were more likely to be HHV-6 DNA positive 
and have a higher DNA load compared with controls (P = 0.02 and 0.02, respectively). The 
OR for DNA positivity was 2.17 (95% CI 1.12 to 4.21), indicating that cases were twice as 
likely to be HHV-6 DNA positive compared with controls. There was also an 8% increase 
in the odds of being a case for each doubling of HHV-6 DNA load (OR = 1.08, 95% CI 
1.01 to 1.16). It is important to note that these results were driven entirely by the small 
proportion of cases who had a DNA load >10
6
 copies/mL. Figure 22 shows the HHV-6 
DNA load in cases versus controls. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. HHV-6 DNA load in Ausimmune Study cases versus controls 
 
N = 29/213 (13.6%) N = 16/218 (7.3%) 
HHV-6 DNA Load in The Ausimmune Study
Cases and Controls
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5.4.5.2 HHV-6 IgG and IgM antibody titres 
In a conditional logistic regression analysis (without adjustment for possible confounders), 
there were no differences in either HHV-6 IgG or HHV-6 IgM antibody titres between 
cases and controls (P = 0.28 and 0.69, respectively). Figure 23 shows the distribution of 
HHV-6 IgG and IgM antibodies in The Ausimmune Study cases and controls. 
 
Figure 23. Distribution of HHV-6 IgG and IgM antibody titres in Ausimmune Study 
cases versus controls   
 
 5.4.6 DNA load versus antibody titres  
There was a significant positive correlation between increasing HHV-6 DNA load and 
HHV-6 IgG antibody titre (Spearman’s rho = 0.11; P = 0.02). In an ordinal logistic 
regression model, the odds of having detectable HHV-6 DNA doubled with each HHV-6 
IgG antibody titre increment (1:10, 1:40, 1:160, 1:2560, 1:6400) (odds ratio (OR) = 2.01, 
95% CI 1.13 to 3.58, P = 0.02). There was no association between HHV-6 IgM antibody 
titres and HHV-6 DNA load (Spearman’s rho = -0.01; P = 0.81).  
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 5.4.7 HHV-6 DNA load stability over time  
Multiple samples were collected from Group 3 RRMS participants to examine stability of 
viral load over time. Figure 24 shows HHV-6 DNA load in the two subjects over a three-
year period from samples taken during winter and summer. In Subject 1, HHV-6 DNA 
loads peaked in winter 2003 (8.7 x 10
6 
copies/mL), dramatically decreased in summer that 
same year (1.7 x 10
6
 copies/mL) and steadied between 4.6 x 10
6
 to 6.2 x 10
6
 copies/mL 
thereafter. Samples from Subject 2 showed a gradual rise in HHV-6 DNA load for two 
years before peaking in summer 2004 (5.8 x 10
6 
copies/mL). This was then accompanied 
by a sharp fall one year later in summer 2005 (1.5 x 10
6 
copies/mL).  
 
Figure 24. HHV-6 DNA load in two RRMS subjects at six monthly intervals 
Note: HHV-6 DNA loads are expressed as exponential notation; samples for summer 2002 and winter 2005 
could not be obtained. DNA loads were calculated as an average based on duplicate PCR reactions in a single 
run only. No statistical testing could be done; data presented for interest only. 
 
5.5 Discussion  
Given the success of the EBV qPCR assay described in Lay et al, 2010 (11), a similar 
approach was undertaken to develop a HHV-6 qPCR assay. The performance of our real-
time HHV-6 qPCR assay was comparable to that of other laboratory in-house assays. It 
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was able to correctly identify 95% of samples from the QCMD HHV-6 Proficiency 
Programs for 2008 and 2009. The single sample that could not be positively identified 
(sample 3, QCMD 2009) had a DNA load below the sensitivity limit of our assay (i.e. 1.66 
x 10
2
 copies/mL). A follow-up summary report by QCMD found that this sample was 
correctly identified by only 44% of participating laboratories (n = 50) using similar 
methods (i.e. an in-house real-time platform). Real-time qPCR assays using commercial 
kits performed only slightly better, identifying this sample correctly at 47.4%.  
 
In another QCMD follow-up review, HHV-6 assays enrolled in the 2008 QCMD program 
were found to be more sensitive compared with other herpesvirus assays (12). For 
example, in-house assays were able to detect HHV-6 DNA containing ~2.0 x 10
2
 
copies/mL at 86% compared with 61.3% and 77.8% for CMV and EBV DNA in-house 
assays, respectively. Our assay was able to detect QCMD samples from 2008 and 2009 
containing ~2.0 x 10
2
 copies/mL, which is comparable to the sensitivity level generally 
accepted for other herpesviruses assays.  
 
It is uncertain whether healthy adults have detectable circulating HHV-6 DNA in plasma. 
The Ausimmune Study control participants provided the means to determine the frequency 
and level of HHV-6 DNA in healthy adults. Overall, HHV-6 DNA was found in 7.3% of 
whole blood samples from the control participants (Group 2). While this prevalence is low, 
it is consistent with previous studies that have found HHV-6 DNA in 2.2% to 16.5% of 
blood from healthy donors (8, 13, 14). A higher HHV-6 DNA prevalence (ranging from 
15% to 95%) has also been found in healthy adults, but from saliva samples (15-18). This 
most likely reflects viral DNA being shed from the mucosal membranes, a heralded source 
for HHV-6 transmission (19). HHV-6 DNA loads were also low in the controls, with 
nearly 85% of participants having DNA loads at the sensitivity limit of the assay (~2.0 x 
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10
2
 copies/mL). One study found an average of 8.1 x 10
1
 copies/mL in whole blood, with 
fractionated blood samples yielding slightly lower DNA loads (e.g. PBMC had 6.2 x 10
1
 
copies/mL and polymorphonuclear leucocytes had 3.5 x 10
1
 copies/mL) (13). HHV-6 
DNA loads as high as 10
4
 to 10
5
 copies/mL (median: 2.4 x 10
4
 copies/mL) have been 
found in healthy adults, but again these were from saliva (15). Lastly, similar to previous 
studies (20, 21), no correlation was found between HHV-6 DNA load and HHV-6-specific 
IgM antibody titres. 
 
In a population-based study of primary HHV-6 infection, acquisition was correlated with 
the female sex (adjusted hazard ratios = 1.7, 95% CI 1.2 to 2.4), with 77% of subjects 
infected by 24 months of age (22). While direct comparisons cannot be made (primary 
infection versus absence of primary infection; children versus adults), we found no 
variation in HHV-6 DNA positivity or DNA load by age, sex or study region in control 
participants. Further investigations in adult samples are required for validation of these 
results. 
 
In the Ausimmune Study case participants (Group 1), the prevalence of HHV-6 DNA 
positivity (13.6% versus 7.3%) and the DNA load were higher compared with the controls. 
While these differences were statistically significant, it is important to note that 
adjustments for possible confounders such as smoking, history of past IM, UV radiation 
exposure etc, were not made and therefore, the results should be interpreted with some 
caution. Given that this study was the first to examine HHV-6 DNA positivity and DNA 
load in those with a first diagnosis of CNS demyelination, comparisons with other studies 
are not yet possible. 
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Seven Ausimmune Study samples had HHV-6 DNA loads above 1.0 x 10
6 
copies/mL: one 
control participant, and six case participants. It is uncertain whether these high HHV-6 
DNA loads were disease-related (e.g. CNS demyelination in the case participants), or the 
result of HHV-6 genomic integration into host chromosomes, a rare phenomenon that 
generates high HHV-6 DNA loads (i.e. above ~10
6
 copies/mL), and is seen in 0.21% to 
0.8% of healthy blood donors (8, 13, 23). In individuals with chromosomally integrated 
HHV-6 DNA, high viral DNA loads persist over time and do not respond to therapy. 
HHV-6 DNA loads are generally much higher when compared with individuals with non-
integrated latent HHV-6 infections (e.g. >10
6 
copies/mL versus ~10
2
 copies/mL in whole 
blood) (24, 25). Given that all seven subjects were HHV-6 IgM sero-negative, active or 
primary HHV-6 infection could be excluded. Reactivation of (latent) HHV-6 infection may 
be a possibility, but this could not be established, as multiple sera were unavailable to 
demonstrate increases in antibody titre. Also, as fluorescence in-situ hybridisation (FISH) 
was not performed, the occurrence of chromosomal integration in these seven subjects 
could not be dismissed, and as such, may be deemed as a possible contributor to the high 
DNA loads. FISH, a widely accepted technique for demonstrating chromosomal 
integration (26), was unavailable at the testing site. This method involves tagging the target 
of interest with a fluorescent probe matched with the chromosomal region of interest. The 
probes are tagged with a dye that fluoresces when dsDNA is formed to reveal the location 
of the integration within the chromosome. Other means for identifying the occurrence of 
chromosomal integration but was also unavailable; includes qPCR testing of multiple sera 
to demonstrate persistently high viral loads over a period of time (6, 24), chromosome 
specific PCR sequencing (27) or Gardella gel techniques (28). 
 
In studies of RRMS patients, a number of authors have shown that HHV-6 DNA activity 
are more pronounced during active MS compared with disease remission. For example, a 
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higher HHV-6 DNA prevalence has been found more frequently in patients experiencing 
relapses versus those recovering from MS symptoms (29-32). In our study, all RRMS 
patients (Group 3) were positive for HHV-6 DNA. This figure however, does not reflect 
the true HHV-6 DNA prevalence in RRMS subjects, as only a small fraction of the total 
MSL Study subjects were tested (n = 5/200). In addition, as subjects were chosen based on 
preliminary HHV-6 DNA investigations (i.e. were HHV-6 DNA positive), no further 
comments on prevalence can be made. Viral DNA loads in the RRMS subjects however, 
were interesting and ranged from detected, to low but quantifiable (<1.0 x 10
3 
copies/mL) 
in two subjects, to persistently high (>10
6 
copies/mL) in two subjects. While one study 
found high HHV-6 DNA loads in patients with active MS (33), others have found non-
significant increases in DNA load between MS patients and controls (34, 35). In RRMS, 
SPMS and PPMS patients, studies have found HHV-6 DNA burdens range between 1.3 x 
10
2
 to 1.5 x 10
3
 copies/mL in serum and CSF (33, 36, 37). Once more, it is difficult to 
comment on whether the high HHV-6 DNA loads (>1.0 x 10
6
 copies/mL) in the two 
RRMS subjects were the result of the clinical status of the individual (e.g. RRMS), or 
caused by chromosomal integration. Given that all RRMS subjects were HHV-6 IgM 
negative, active infection could be excluded. Reactivation of HHV-6 infection could also 
be discounted, as HHV-6 IgG antibodies titres remained constant over the three-year study 
(i.e. no changes from the baseline levels). Chromosomal integration is a plausible 
explanation, but would require FISH confirmation.  
 
In Group 4, HHV-6 DNA loads from liver tissue in the liver transplant recipients were 
similar to the DNA loads reported in the literature (38-40). In the HIV-infected individuals, 
high HHV-6 DNA loads were anticipated in light of the high HIV RNA loads (>1.0 x 10
4
 
HIV RNA copies/mL), but only one individual was positive for HHV-6 DNA. HHV-6 
DNA load in this patient was low (2.0 x 10
2 
copies/mL), but was comparable with another 
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study examining asymptomatic HIV infection (41). Higher HHV-6 DNA loads, up to 1.3 x 
10
5 
copies/mL
 
have also been reported, but again, these were from saliva of HIV-infected 
persons (42).  
 
Overall, the number of HHV-6 DNA positive samples was lower than anticipated. Whether 
this was a reflection of the clinical status of the groups tested or due to the specimen type is 
unknown. As for testing of EBV DNA load, there currently is no consensus as to which 
specimen type should be measured for HHV-6 DNA load, with studies to date having used 
bloods (whole blood, plasma, PBMC, serum) (40, 43), CSF (39), saliva (15) and tissue (44, 
45). There has been a recent push for standardisation of all qPCR assays (10), with some 
authors putting forward the use of unfractionated blood (i.e. whole blood) for HHV-6 
qPCR testing rather than plasma or PBMC (40, 46). However, we speculate that HHV-6 
DNA loads vary depending on the specimen type and propose that measurement of HHV-6 
DNA loads should be done using symptom relevant disease-associated samples. For 
example, in neurological conditions such as MS, examination of CSF or brain tissue for 
evidence of HHV-6 infection would be more suitable than blood. In primary HHV-6 
infection, blood or saliva would be more appropriate than other sample types as HHV-6 
infects B and T cells (47), and infectious virions are shed from the salivary glands (19). 
Correlation of HHV-6 DNA in symptom relevant disease-associated samples with HHV-6 
DNA in blood needs to be determined. 
 
Low HHV-6 DNA prevalence may also have been attributed to the PCR target selected for 
qPCR and time of sampling relative to onset of clinical symptoms. Amplification of dual 
targets rather than a single target may perhaps have led to higher HHV-6 DNA positivity. 
While this was done for the EBV qPCR assay, this design was withheld for HHV-6 due to 
time constraints and costs of testing multiple targets (i.e. this would require performing 
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two separate qPCR assays or designing a multiplex assay). Time of sampling relative to the 
onset of clinical symptoms may provide a good explanation for the low DNA positivity. 
For example, our study tested samples from subjects who had had their first clinical 
diagnosis of CNS demyelination (Group 1), versus those with clinically definite MS (i.e. 
RRMS subjects from Group 3), where median HHV-6 DNA loads were much higher. 
Perhaps, if participants with clinically definite disease were tested, the HHV-6 prevalence 
and DNA load may have increased, that is, assuming that HHV-6 infection causes MS. 
 
5.6 Chapter conclusion 
A sensitive real-time HHV-6 qPCR assay using SYBR Green I dye was developed for the 
detection and quantification of HHV-6 DNA. The qPCR assay developed in this chapter 
was comparable in performance with other laboratory developed in-house assays and 
generated HHV-6 DNA loads similar to the DNA loads reported in the literature for 
respective diseases. Furthermore, our assay was compliant with the Minimum Information 
for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines (see Table 
32, Appendix 5). Our results also showed that those with first CNS demyelination were 
more likely to be HHV-6 DNA positive and have a higher DNA load compared to controls 
without CNS demyelination, but this analysis was not adjusted for possible confounders. 
Though further analyses are required, these results suggest that HHV-6 DNA may be 
clinically important in early MS. 
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5.7 Appendix 5  
Table 32. MIQE checklist for HHV-6 qPCR assay  
(E) denotes essential information necessary for submission with manuscript; (D) indicates desirable 
information  that should be submitted if available. 
 
ITEM TO CHECK IMPORTANCE CHECKLIST  
EXPERIMENTAL DESIGN    
Definition of experimental and control  groups E Ausimmune Study Controls: individuals without evidence of 
demyelination. Ausimmune Experimental Cases: individuals with a 
first clinical diagnosis of demyelination. Clinical patients: liver 
transplant recipients and HIV-infected individuals.  
Number within each group E Defined by n  
Assay carried out by core lab or investigator's 
lab 
D Yes; Assay performed at the Centre for Infectious Diseases & 
Microbiology, Westmead Hospital, NSW, Australia 
Acknowledgement of authors' contributions D Noted after main body of manuscript 
SAMPLE    
Description E Whole blood, plasma, PBMC and tissue 
Volume/mass of sample processed D 200 µL  
Microdissection or macrodissection E N/A 
Processing procedure E N/A 
If frozen - how and how quickly? E Ausimmune Study samples were collected and aliquoted within 4 
hours (kept at room temperature or refrigerated after 8 hours) 
and frozen at -80°C before processing. Samples were thawed at 
room temperature for 15 to 30 min and extracted immediately  
If fixed - with what, how quickly? E N/A 
Sample storage conditions and duration 
(especially for FFPE samples) 
E DNA extracts were stored at -80°C in 12 µL single-use aliquots. 
Testing was performed within one week following extraction  
NUCLEIC ACID EXTRACTION    
Procedure and/or instrumentation E Manual extraction using a commercial kit 
Name of kit and details of any modifications E For EDTA, plasma and CSF; GenElute™ Mammalian Genomic DNA 
Miniprep Kit® (Sigma-Aldrich), for PBMC; QIAamp DNA mini kit 
(Qiagen) 
Source of additional reagents used D N/A 
Details of DNase or RNAse treatment E N/A. There is a possibility that CSF DNA extracts were treated 
with DNase following extraction by other laboratories 
Contamination assessment (DNA or RNA) E PCR-grade water used as contamination controls during DNA 
extraction, PCR set-up and post-PCR manipulations known as 
specimen no DNA controls (sndc) and no template controls (NTC) 
Nucleic acid quantification E DNA load measured by absolute quantification; standard curves 
generated from plasmid DNA containing known concentrations of 
target DNA 
Instrument and method E Rotor-GeneTM 6000 (Qiagen) using the 36-well rotor 
Purity (A260/A280) D Purity measured by the Beckman DU® 530 Life Science UV/Vis 
spectrophotometer. Acceptable purity absorbance ratios 
(A260/A280) were between 1.8 and 2.0 
Yield D Plasmid concentration measured by Beckman DU® 530 Life 
Science UV/Vis spectrophotometer 
RNA integrity method/instrument E N/A 
RIN/RQI or Cq of 3' and 5' transcripts E N/A 
Electrophoresis traces D Product checked using agarose gel electrophoresis  
Inhibition testing (Cq dilutions, spike or other) E Reference gene human β-globin was tested for all samples 
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REVERSE TRANSCRIPTION    
Complete reaction conditions E N/A 
Amount of RNA and reaction volume E N/A 
Priming oligonucleotide (if using GSP) and 
concentration 
E N/A 
Reverse transcriptase and concentration E N/A 
Temperature and time E N/A 
Manufacturer of reagents and catalogue 
numbers 
D N/A 
Cqs with and without RT D* N/A 
Storage conditions of cDNA D N/A 
qPCR TARGET INFORMATION    
If multiplex, efficiency and LOD of each assay E N/A 
Sequence accession number E Chapter 3, section 3.1.1, Table 19 
Location of amplicon D U67 gene (also known as 13r) 
Amplicon length E 108 bp 
In silico specificity screen (BLAST, etc) E BLAST, agarose gel electrophoresis, QCMD external QA program, 
melt curve profile, DNA sequencing, absence of cross-reactivity 
with other 
Pseudogenes, retropseudogenes or other 
homologs? 
D N/A 
Sequence alignment D Primers were checked by DNA sequencing and nucleotide BLAST 
search. Theoretical specificity obtained if percentage match was 
100% and e-value approached zero 
Secondary structure analysis of amplicon D Checked for secondary structures using FastPCR 
Location of each primer by exon or intron (if 
applicable) 
E N/A 
What splice variants are targeted? E N/A 
qPCR OLIGONUCLEOTIDES    
Primer sequences E Chapter 3, section 3.1.1, Table 19 
RTPrimerDB Identification Number D N/A. HHV-6 U67 primers were modified from VM Ratnamohan’s 
original primers. Refer to Chapter 2  
Probe sequences D** N/A 
Location and identity of any modifications E Chapter 3, section 3.1.1 
Manufacturer of oligonucleotides D Designed by OligoPerfectTM Designer by Invitrogen Life 
Technologies  
Purification method D PAGE purification by manufacturer 
qPCR PROTOCOL    
Complete reaction conditions E Chapter 2, section 2.2.4 
Reaction volume and amount of cDNA/DNA E 5 µL DNA template, 25 µL total reaction volume 
Primer, (probe), Mg++ and dNTP 
concentrations 
E 0.5 μL 0.2 mM sense and antisense primers, 0.8 μL 25 mM MgCl2 
Polymerase identity and concentration E FastStart Taq DNA Polymerase 
Buffer/kit identity and manufacturer E LightCycler® FastStart DNA Master SYBR Green 1 dye (Roche 
Diagnostics) 
Exact chemical constitution of the buffer D Unknown  
Additives (SYBR Green I, DMSO, etc.) E SYBR Green I, no additives 
Manufacturer of plates/tubes and catalog 
number 
D PCR-certified colourless 200 μL flat-capped tubes by Integrated 
Sciences, Australia. Catalogue numbers in Chapter 8, Table 34,  
Appendix 8A  
Complete thermocycling parameters E Chapter 2, section 2.2.8, Table 17 
Reaction setup (manual/robotic) D Manual set-up  
Manufacturer of qPCR instrument 
 
 
E Rotor-GeneTM 6000 (Qiagen; formerly known as Corbett 
Research) 
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qPCR VALIDATION    
Evidence of optimisation (from gradients) D Chapter 3, section 3.1 
Specificity (gel, sequence,  melt, or digest) E Agarose gel, melting curve analyses and DNA sequencing 
For SYBR Green I, Cq of the NTC E Approximate Cqs for NTC not included but conditions for data 
rejection specified (NTC = zero, any Cqs > 40 should be ignored 
and considered negative) 
Standard curves with slope and y-intercept E Average slope not specified in publication but calculated to be -
3.76. The y-intercept was intentionally omitted as this value 
varies from run-to-run 
PCR efficiency calculated from slope E Average amplification efficiency = 85% (Note: reported as 0.85 
on the Rotor-Gene 6000TM software; maximum of 1.0 for 100% 
amplification efficiency) 
Confidence interval for PCR efficiency or 
standard error 
D Standard deviation error = 0.05 
r2 of standard curve E 0.99 
Linear dynamic range E 1.0 x 101 to 1.0 x 106 copies/5 µL 
Cq variation at lower limit E 30.0 
Confidence intervals throughout range D N/A 
Evidence for limit of detection E Chapter 5, section 5.4.1 
If multiplex, efficiency and LOD of each assay E N/A 
DATA ANALYSIS    
qPCR analysis program (source, version) E Rotor-Gene6000TM  Software 1.7 (Build 90) 
Cq method determination E Auto-find threshold  
Outlier identification and disposition E Chapter 2, Table 18 
Results of NTCs E Chapter 5, section 5.4.1 
Justification of number and choice of reference 
genes 
E Chapter 3, section 3.1  
Description of normalisation method E Chapter 3, section 3.2 
Number and concordance of biological 
replicates 
D Not mentioned  
Number and stage (RT or qPCR) of technical 
replicates 
E Study samples tested in duplicate; plasmid standards tested in 
triplicates 
Repeatability (intra-assay variation) E Chapter 5, section 5.4.1, Table 28 
Reproducibility (inter-assay variation, %CV) D Chapter 5, section 5.4.1, Table 28 
Power analysis D Performed during project design 
Statistical methods for result significance E Spearman’s (rho) correlation co-efficient was used to assess the 
correlation between HHV-6 DNA load and HHV-6 antibody titres 
Software (source, version) E Stata version 17 
Cq or raw data submission using RDML D Raw data not submitted 
Abbreviations: BLAST, basic local alignment search tool; Cq, quantification cycle; CSF, cerebrospinal fluid; DNA, deoxyribonucleic 
acid; EDTA, ethylenediamine tetraacetic; HHV-6, human herpesvirus 6; HIV, human immunodeficiency virus; n, number; N/A, not 
applicable; NSW, New South Wales; NTC, no template control; PAGE, polyacrylamide gel electrophoresis; PBMC, peripheral blood 
mononuclear cells; PCR, polymerase chain reaction; QA, quality assurance; QCMD, quality control for molecular diagnostics.  
 
* Assessing the absence of DNA using a no RT assay is essential when first extracting RNA. Once the sample has been validated 
as RDNA-free, inclusion of a no-RT control is desirable, but no longer essential. 
** Disclosure of the probe sequence is highly desirable and strongly encouraged. However, since not all commercial pre-designed 
assay vendors provide this information, it cannot be an essential requirement. Use of such assays is advised against. 
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6.1 Aims  
Chapter 6 aims included:- 
1. Identification of the EBV genotypes and strains in various research and clinical 
groups studied in Chapter 4 (section 6.3) 
2. Identification of the HHV-6 species and strains in various research and clinical 
groups studied in Chapter 5 (section 6.4). 
 
6.2 Introduction 
Epstein-Barr virus and HHV-6 are divided into two distinct genotypes: EBV genotype A 
and B; and HHV-6 species A and B, based on sequence polymorphisms within certain 
ORFs (e.g. EBNA-2, EBNA-3A, 3B and 3C; and between U86 and U100, respectively). 
These sequence mutations separate the viruses into distinct biological genotypes (or 
species), which are known to differ by disease association, geography and cellular tropism. 
Chapter 6 comprises two main sections: section 6.3 describes the EBV genotypes and 
strains isolated from subjects in Chapter 4 (described in Publication 4; Lay et al, 2012); 
section 6.4 describes the HHV-6 species and strains isolated from subjects in Chapter 5 
(Manuscript 6, in preparation).  
 
6.3 EBV genotypting: Publication 4 summary (Lay et 
al, 2012) 
Lay et al, 2012 describes the EBV genotypes and strains isolated from the Ausimmune 
Study participants: cases with and controls without an incident first diagnosis of CNS 
demyelinating disease, and patients with various EBV-related diseases in Australia. The 
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most prevalent EBV genotype found at 98.2% was genotype A. The predominant EBV 
genotype A strain was GD1 (77.7%), followed by the wild-type B95-8 strain (16.7%) and 
the M-ABA strain (5.6%). EBV genotype B was found in one subject only and was 
identified as the AG876 strain. Overall, there was no evidence of disease-specific EBV 
genotypes or strains in the groups examined. 
 
 6.3.1 Publication 4 authorship 
MLL performed all the DNA work which included primer design and assay evaluation, 
sequence alignment and comparison, data analyses and manuscript writing. On behalf of 
the Ausimmune Investigator group, RML supplied the blood samples and epidemiological 
data, was involved in the data analysis and manuscript editing. CT and VMR supervised all 
virology work and provided technical support. All authors were involved in the design and 
conception of this study, have read, reviewed and approved the final manuscript.  
 
 6.3.2 Publication 4 postscript 
The number of samples/subjects tested differs between Publication 3 and Publication 5 due 
to specimen limitations (inadequate sample volume) and availability of new samples. For 
example, 24 Ausimmune Study controls were positive for EBNA-1 by qPCR in Chapter 4, 
but only 21 were genotyped in Chapter 6 (Note: only EBNA-1 qPCR positivity was 
considered, as genotyping targeted the EBNA gene). This was also the case for IM and 
HIV-infected individuals. A number of new samples became available post-qPCR studies 
including four LPD individuals and one individual with hepatitis. 
Meav-Lang J. Lay 
 
Robyn M. Lucas 
Cheryl S. Toi V. Mala Ratnamohan 
Anne-Louise Ponsonby 
 
Dominic E. Dwyer 
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6.4 HHV-6 genotyping: Materials and methods 
 6.4.1 Study groups 
Sixty-five samples (n) from 54 subjects (N) positive for HHV-6 by qPCR (from Chapter 5) 
were investigated for HHV-6 species and strain type. This included four groups: Group 1 
(N = 29), case participants from The Ausimmune Study (EDTA whole blood, n = 29); 
Group 2 (N = 16), controls (EDTA whole blood, n = 16); Group 3 (N = 3), RRMS subjects 
from the Southern Tasmanian Multiple Sclerosis Longitudinal Study (MSL, n = 13, 
PBMC); and Group 4, a clinical group comprising hospitalised paediatric liver transplant 
recipients (including two patients that were not previously described in Chapter 5, N = 5; 
liver tissue, n = 6) and an individual with HIV infection (N = 1; plasma, n = 1). Group 4 
liver transplant recipients were HHV-6 DNA positive by qualitative PCR at their referring 
hospital. Viral load testing was not done due to insufficient specimen. Multiple samples 
were available for three subjects: two RRMS patients each had six samples collected at two 
yearly intervals (winter and summer) over three consecutive years (2002 to 2005); one 
liver transplant recipient had two samples collected six months apart (2009). These 
samples were investigated for species and strain persistence. 
 
 6.4.2 Molecular testing 
6.4.2.1 Primers and controls 
Positive HHV-6 samples were divided into HHV-6A and HHV-6B based on 15 single 
nucleotide mutations spanning a 598 bp segment of the HHV-6 U67 gene (sense 5’-
TGTGGGTTATGTCGCAGGTA - 3’ and anti-sense 5’ – GCGGCATTATATCCCGTCT - 
3’; GenBank accession numbers: X83413, position 102459 to 103056; and AF157706, 
positions 103757 to 104354). This gene has been used as the primary target for HHV-6 
identification (detection and genotyping) at our laboratory and has previously successfully 
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divided HHV-6 into species in other genotyping studies (1, 2). Initial assessment of this 
primer pair by endpoint PCR showed that it was able to detect samples containing HHV-6 
DNA levels of ~2.0 x 10
2
 copies/mL (data not shown). Furthermore, this primer pair also 
served as a second check to confirm that HHV-6 positive samples by qPCR in Chapter 5 
were true positives and not a contaminant. To monitor for contamination, each PCR run 
included NTCs comprising extraction and PCR controls made up of molecular-grade 
water. To ensure DNA integrity and to monitor for PCR inhibition, a β-globin PCR was 
performed prior to qPCR studies (see Chapter 3). HHV-6 laboratory positive reference 
controls consisting of the culture purified HHV-6A (strain GS) and HHV-6B (strain Z29) 
from the 2008 and 2009 HHV-6 QCMD Program, were included for each PCR run.  
 
6.4.2.2 DNA extraction and PCR amplification 
Viral DNA was extracted from EDTA whole blood and plasma, PBMC and liver tissue as 
described in section 2.2.1. PCR was performed on the Rotor-Gene
TM
 6000 analyser using 
0.5 µL 10 mM sense and anti-sense primers, 2 µL 10X LightCycler
®
 FastStart DNA 
Master SYBR Green I dye pre-mixed with hot start LightCycler
®
 FastStart Enzyme, 1.4 µL 
25 mM MgCl2, 15.6 µL molecular-grade water and 5 µL DNA template. As >80% of 
samples contained HHV-6 DNA ~2.0 x 10
2
 copies/mL (see section 5.4.2), samples were 
assayed twice (i.e. two PCR assays were done) and tested in duplicate. Within each PCR, 
two amplification rounds were employed with a 1:100 amplicon dilution between rounds to 
prevent PCR saturation. This ensured adequate concentration of target DNA for 
sequencing. Thermal cycling conditions consisted of initial denaturation at 95°C for 9 min 
and 30 sec, followed by three cycles of 95°C, 68°C, 72°C (40 sec each); 40 cycles of 95°C, 
68°C, 72°C (20 sec each); and a final extension at 72°C for 5 min. Figure 25 shows typical 
PCR amplification curves generated from the Rotor-Gene
TM
 6000. Target amplification 
was confirmed by visualisation of a single band following agarose gel electrophoresis. 
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Figure 25. Example of HHV-6 DNA PCR positive amplification curves 
This HHV-6 PCR run shows amplification curves of samples with high DNA loads (marked with 
parentheses). Ten-fold serial dilutions of plasmid standard curves can also be seen commencing at 10
8
 to 10
2
 
copies/5 µL (left to right). 
 
6.4.2.3 Product clean-up, sequence alignment and phylogenetic analyses 
Amplicons were purified using ExoSAP-IT
®
 PCR Clean-up Kit as described in section 
2.3.1. Sequencing was done on the 3730xl capillary sequencer using the Big Dye 
Terminator chemistry, v3.1. All returned sequences were manually checked and corrected 
for software-related base-calling errors and aligned using the ClustalW Multiple Alignment 
tool on the BioEdit Sequence Alignment Editor (version 7.0.90). Sample sequences were 
aligned by nucleotide BLAST to GenBank reference strains: HHV-6A strain U1102, 
X83413; and HHV-6B strains Z29, AF157706 and HST, AB021506 (see Appendix 8F for 
sequencing and BLAST search examples). A phylogenetic tree was constructed using the 
neighbour-joining method (Kimura-2 parameter, with 1000 bootstrap replicates) on MEGA 
5 to show alignment patterns. Given the high sequence homology (3), human herpesvirus 7 
(HHV-7) strains, JI (U43400) and RK (AF037218) were also included. 
 
N
o
rm
a
lis
e
d
 F
lu
o
re
sc
e
n
ce
 
Cycle 
 222 
  
6.5 Results 
 6.5.1 DNA sequencing and phylogenetic analyses 
All returned sequences were cropped at the ends to remove regions prone to base-calling 
errors and background noise to give a total analytical length of 438 bp. All but one 
chromatogram had little background interference and well-defined nucleotide peaks that 
could easily be interpreted. One chromatogram could not be analysed due to high 
background noise, and was excluded. Two HHV-6 species and strains were identified by 
BLAST (percentage match >99% and e-value approached zero): HHV-6A (U1102 strain) 
and HHV-6B (HST strain) (see Appendix 8F for examples of BLAST search results). 
There was no evidence of HHV-6 co-infection (i.e. no mixed sequences were observed). 
All laboratory HHV-6 control sequences aligned with their respective GenBank reference 
strains (Figure 26). High bootstrapping probabilities (>80) confirmed three distinct 
phylogenetic groupings: HHV-6A, HHV-6B and HHV-7. Phylogenetic alignments 
corresponded 100% with DNA sequencing results.  
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Table 33. HHV-6 species and strain by study group 
Abbreviations: CNS, central nervous system demyelination; FCD, first demyelinating event; HHV-6A, human herpesvirus-6 
species A; HHV-6B, human herpesvirus-6 species B; HIV, human immunodeficiency virus; MSL, multiple sclerosis longitudinal; 
N, number of subjects tested; RRMS, relapsing-remitting multiple sclerosis. 
§ One sample amplified using the HHV-6 sequencing primers but returned sequences that could not be interpreted (high 
background noise) 
† Two HHV-6 PCR positive patients not previously tested in Chapter 5  
* Multiple samples tested; Group 3 (two subjects had six samples each collected at six monthly intervals) and Group 4 (one 
liver transplant recipient had two samples collected 6 months apart)  
Note: Group 2 is a matched study group, thus direct comparisons of other study groups to group 2, without accounting for 
matching, cannot be made. Species have been labelled “strain-like” as sequencing was done on partial gene segments rather 
than the entire genome. 
 
 6.5.2 HHV-6 species and strains by study group 
A total of 59.3% (N = 32/54) of subjects were positive for HHV-6 by PCR, of which 
66.2% (n = 43/65) of samples could be divided into species and strain. HHV-6B was found 
across all four study groups (31/32, 96.9%); HHV-6A was found in one subject only - a 
Group 1 case with a FCD (1/32, 3.1%). These results are shown in Table 33. Each species 
was represented by a single strain: U1102 (HHV-6A) and HST (HHV-6B). In subjects with 
multiple samples (Groups 3 and 4), the same species and strain were detected in all 
samples. There was no evidence of sequence recombination or primer cross-reactivity 
between HHV-6 and HHV-7 as determined by BLAST, DNA sequencing or phylogenetic 
analysis (data not shown). 
 
 
Study Group 
U67 
qPCR 
positive 
U67 
sequencing 
positive 
% 
genotyped 
HHV-6 species (strain) 
HHV-6A 
(U1102-like) 
HHV-6B 
(HST-like) 
      
Group 1: The Ausimmune Study Cases:  first 
clinical diagnosis of CNS demyelination 
29§ 15 51.7 1 14 
Group 2: The Ausimmune Study Controls: no 
CNS demyelination  
16 
 
9 
 
56.3 
 
0 
 
9 
 
Group 3: The Southern Tasmanian MS 
Longitudinal Study: RRMS 
3* 3 100.0 0 3 
Group 4: Clinical samples (hospitalised 
patients) 
Liver transplant recipient 
  HIV infection 
 
 
5†* 
1 
 
 
5 
0 
 
 
100.0 
0.0 
 
 
0 
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Figure 26. Nucleotide-constructed phylogenetic tree of HHV-6 sequences  
Phylogenetic tree generated using Neighbour-joining method (Kimura-2 parameter model with 1000 
bootstrap replicates) from 438 bp sequences showing alignment patterns of study groups and GenBank 
reference strains (HST, Z29, U1102, RK and JI). Replicate samples are denoted by lower-case letters. The 
percentage of 1000 bootstrap replicates are indicated alongside branches, with 0.05 substitutions per site.  
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6.6 Discussion  
Species classification of HHV-6 is diagnostically important as HHV-6 infections differ 
clinically and epidemiologically. In this section, HHV-6 species and strains were 
investigated in the four study groups described in Chapter 5. Overall, HHV-6B was found 
more frequently and across all study groups (96.9%). A similar frequency has been 
reported for the USA, Europe and Japan (4, 5), with high incidences most likely reflected 
by the ease with which HHV-6B is transmitted through saliva. While HHV-6B is 
characteristically associated with ES, it has also been found in solid-organ and stem cell 
transplant recipients (6), HIV-infected individuals (7) and healthy adults (8), indicating 
that HHV-6B infection may not be restricted to specific disease conditions. HHV-6A 
infection was found in one subject only - an individual with a FCD. Given that this finding 
was confined to a single subject, the significance of this result is uncertain. Since this study 
is the first to investigate HHV-6 speciation and strain diversity in those with and without a 
FCD, literature comparisons could not be made.  
 
In contrast with other studies (9-12), we found all RRMS patients were infected with 
HHV6-B; however the small sample size limited any inferences that could be drawn from 
these data. In the paediatric liver transplant recipients, our results were consistent with 
previous studies (13, 14). While HHV-6B infection is common following liver 
transplantation, studies have also shown that the infecting HHV-6 species may differ 
depending on transplant type. For example, HHV-6B infection commonly follows bone 
marrow transplantation (15), but HHV-6A infection occurs more often after renal 
transplantation (16). Nevertheless, these findings for different transplant types were also 
from different geographic locations, so that the importance of the separate influence of 
geography and transplant type requires further investigation. 
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In subjects with multiple samples, the same species and strain was detected, suggesting 
that infection with the same virus can occur for up to three years (although serology results 
from Chapter 5 showed all three subjects were HHV-6 IgM antibody negative, indicating 
that infection was not recent). HHV-6 species persistence has also been found in PBMC 
and saliva of children five years following primary infection (17). Given the high HHV-6 
DNA loads in these subjects (see Chapter 5), chromosomal integration is a likely 
contributor. 
 
More than a hundred HHV-6 strains have been isolated from various specimens and 
clinical syndromes (18). However, strain diversity in our study was minimal, with only 
HST-like and U1102-like strains identified. Other studies have found a variety of HHV-6 
strains from patients with different clinical syndromes and geographical locations. For 
example, strains SIE and TAN are derived from the African regions, Ivory Coast and 
Congo respectively, whereas strains BOU, MAR, BLE and MBE have been isolated from 
children with HIV-seropositive mothers (19). Originally found in an AIDS patient from 
Uganda (20), the presence of the HHV-6A strain U1102 in our study was unexpected given 
the low global prevalence of HHV-6A infections (between 2 to 3%) (21). The most 
frequently detected HHV-6B strain was HST, a strain first isolated from an ES patient in 
Japan (22). This finding was to be expected, as primary HHV-6 infection occurs early in 
life and is responsible for high HHV-6 seropositivity among children and adults 
worldwide. The abundance of the HST-like strain in our study may be explained by the 
relative proximity of Japan and Australia. Despite also having associations with ES (23), 
the prototype Z29 strain was not found. First isolated from an AIDS patient in Zaire (24), 
the Z29 strain was perhaps, not detected in our study due to the large physical separation 
between Australia and Africa. Physical proximity to Australia as an explanation for 
genotype spread is, however a naïve assumption, as international travel has become 
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increasingly common. The lack of strain diversity may be mostly due to the small sample 
size, skewed ethnicity of the Ausimmune Study participants (i.e. mostly Caucasians), or 
perhaps, influenced by differences in infectivity and transmissibility between HHV-6 
strains, though this cannot be determined from our data. 
 
Overall, the proportion of HHV-6 DNA positive samples sequenced was low. Less than 
60% of previously HHV-6 positive samples by qPCR could be re-amplified. Three 
possible explanations include insensitivity of the primers to amplify low-levels of target 
DNA, difficulties in repeat detection of samples with low-levels of target DNA, and 
degradation of sample DNA extract. Primer insensitivity was excluded, as preliminary 
trials showed that the sequencing primers were capable of detecting samples containing 2.0 
x 10
2 
copies/mL of HHV-6 DNA. Sensitivity was also confirmed by endpoint PCR using 
ten-fold serial dilutions of known HHV-6 positive laboratory control reference strains (data 
not shown). However, given that >80% of HHV-6 qPCR positive samples contained ~2.0 x 
10
2
 copies/mL, the most plausible explanation is difficulty in repeat detection of samples 
with low-level target NA. In qPCR studies (25, 26) and other disciplines (27), high 
variability has been documented at low DNA concentrations, which has major implications 
for assay reliability and result interpretation. In one study, it was shown that PCR results 
may not be reproducible if detected in repeated assays from the same or different sample 
due to low copy levels of target NA (e.g. 5.0 x 10
2
 to 5.0 x 10
3
 copies/mL) (28). Here, 
measures were taken to maximise target NA detection (e.g. two PCR assays, duplicate 
samples and 2 separate PCR amplification rounds), but despite this, a proportion of 
samples that originally detected as positive, could not be amplified using the sequencing 
primers. Lastly, degradation of DNA extract, which may occur over time and with 
excessive freeze-thaw, could also have contributed to re-amplification difficulties. In our 
study, PCR was done on DNA extracts 6 to 12 months following initial qPCR 
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investigations, with some extracts stored for up to three years. Previous works have shown 
that DNA stored over extended periods can be successfully amplified by PCR (29, 30), but 
for optimal results, testing should occur within 60 days (31).  
 
In summary, this study provides valuable data on HHV-6 speciation and strain diversity 
across different study groups in Australia.  Both HHV-6A and HHV-6B were found, but at 
very different frequencies. HHV-6B, strain HST was far more common than HHV-6A 
strain U1102, and was isolated from all study groups.  
 
6.7 Chapter conclusion 
The most frequently detected genotypes were EBV genotype A, and HHV-6B, 
respectively. Four EBV strains were identified: GD1, B95-8, M-ABA and AG876 at 
different frequencies, whereas only two HHV-6 strains, HST and U1102, were found. EBV 
and HHV-6 genotypes and strains did not appear to be associated with a specific disease or 
manifestation of early MS.  
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Chapter 7 
General Discussion, Summary and Future 
Directions  
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7.1 General discussion 
Epstein-Barr virus and HHV-6 cause infection in both healthy and immunocompromised 
individuals. EBV mainly causes disease in children and young adults, whereas HHV-6 
typically affects infants and young children. In healthy adults, EBV infection is generally 
asymptomatic (1); acute HHV-6 infection, while rare in immunocompetent adults, often 
manifests as mononucleosis-like syndromes (2, 3). Both viruses have the ability to cause 
recurrent infection through reactivation by persisting in various host cells (e.g. B or T 
cells). During primary infection, lytic replication causes a surge in virus levels which may 
be correlated with either symptomatic infection and/or worsening of disease. During 
latency, viral replication is ceased or occurs at low levels (4, 5), and infection is generally 
asymptomatic or causes disease of little consequence (6). However, in periods of 
compromised cellular immunity (e.g. acquired immunosuppression: stress, sunlight, 
medication and other infections; and inherited immunosuppression: X-linked 
lymphoproliferative disease and haemophagocytic syndrome), EBV and HHV-6 infection 
may reactivate by re-entering into the lytic cycle to produce new infectious virions (7, 8). 
Reactivation of EBV and HHV-6, particularly in the immunocompromised (e.g. 
individuals with HIV/AIDS and transplants recipients), is associated with high morbidity 
and mortality (1, 8). Sensitive and accurate tests are therefore important in diagnosing and 
quantifying EBV and HHV-6 infection. 
 
Serology enables the quantitative detection of virus-specific antibodies for determination 
of infection status in healthy individuals (9). However, in those with immune dysfunctions 
and/or malignancies, sero-diagnosis has a lower predictive value and may be complicated 
by unpredictable (delayed, masked or enhanced) virus production (10-13). NAT using PCR 
is the gold standard for the diagnosis of many viral infections (14-16) and is suitable for 
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use in immunocompromised populations (17, 18). Using the standard curve method, qPCR 
enables both the detection and quantification of viruses as a prognostic marker of 
pathology/disease activity (19). Viral load monitoring by qPCR is already used routinely 
for screening, diagnosing and managing treatment regimens for a number of viruses (e.g. 
Hepatitis C, HIV, CMV etc) (17, 20-22). This thesis describes the development of in-house 
qPCR assays for the detection and quantification of EBV and HHV-6 DNA using SYBR 
Green I dye. All qPCR assays were evaluated using external QAP samples and by 
comparing DNA loads for specific diseases in the literature. Standardisation was achieved 
through adherence to the MIQE guidelines by full disclosure of essential and desirable 
information where possible.  
 
 7.1.1 Detection and quantification of viral DNA 
7.1.1.1 EBV DNA detection and quantification 
The first major component of this project was the design and application of an in-house 
real-time qPCR assay for the detection and measurement of EBV DNA. Previous works 
targeted single genes (23, 24), used commercial kits with sequence-specific detection 
formats (e.g. hydrolysis probes) (25-29), or applied techniques such as semi-quantitation 
(26, 30), quantitative-competitive PCR (31, 32), end-point PCR (33) or southern 
hybridisation (34). At the time of project conception, commercial assays for quantifying 
EBV DNA were few and expensive, with most unsuitable for undertaking high sample 
volume research projects. Given the number of samples for testing, a more cost-effective 
approach was to use the intercalating fluorescent dye, SYBR Green I, which is comparable 
to fluorogenic probes in sensitivity (35-37). Chapter 4 centred on assay evaluation and 
application of the qPCR assay to EBV-related disease groups, and The Ausimmune viral 
sub-study – to examine the role of EBV DNA in early CNS demyelination, a precursor of 
MS. 
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First, the qPCR was designed, developed and optimised for accurate and sensitive EBV 
DNA detection and quantification (Chapter 3). Second, the qPCR assay was evaluated to 
assess the working capabilities. Results from the 2008 and 2009 QCMD EBV DNA EQA 
Program confirmed that our in-house (EBNA-1 and BHRF-1) qPCR assays generated 
100% correct qualitative PCR results (Appendix 4A). When compared to the consensus 
QCMD EBV DNA loads, the EBNA-1 qPCR assay overestimated EBV DNA in 72.2% of 
cases, whereas our BHRF-1 qPCR assay underestimated EBV DNA in 88.9% of cases. 
Over 80% of the EBV DNA loads obtained from our assays were within the acceptable 
Log10 SD range. Our EBV qPCR failed to quantify EBV DNA in one QAP sample 
containing low EBV DNA, but other studies have reported similar difficulties in measuring 
DNA loads below log10 3.0 copies/mL (18, 19, 25, 38, 39). This suggested that the 
sensitivity of our EBV qPCR assays could have been improved slightly; however, the 
overall performance in the QCMD EBV Program indicated that our results were acceptable 
and comparable with other laboratories. This made inter-laboratory comparisons (with the 
literature) somewhat easier. 
 
Application of our EBV qPCR assays included to samples from individuals with various 
EBV-related illnesses including PTLD, EBV-associated haemophagocytic syndrome 
(EBVAHS), HIV and IM. EBV DNA loads obtained for each respective group compared 
well with the reported EBV DNA loads for similar diseases in the literature (25, 40-44). 
That is, EBV DNA loads generated from our qPCR assays were within the expected ranges 
for the similar disease groups (Publication 2). This instilled confidence in using the assays 
on participant samples from The Ausimmune Study (Publication 3), where high sensitivity 
(for detecting low copy numbers) was required.  This work was the first to describe the 
prevalence of EBV DNA (detection/positivity) and load in individuals with a FCD and 
their matched controls. This work was complemented with EBV serology and DNA load 
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results (performed on the same samples) from a separate laboratory at a later date. 
Combined laboratory findings showed that there were no significant case-control 
differences in the proportion with detectable EBV DNA (P = 0.28) or EBV DNA load (P = 
0.33). Similar to previous studies (45-51), the risk of being an FCD case was shown to 
increase with past (manifesting as IM and high EBV IgG antibody titres) rather than 
current and active EBV infection (DNA positivity and load), particularly when combined 
with HLA-DRB1*1501 positivity.  
 
7.1.1.2 HHV-6 detection and quantification 
Given the success of the application of the EBV qPCR assays, a similar in-house assay was 
developed for the detection and quantification of HHV-6 DNA (Chapter 5). The HHV-6 
qPCR assay was first evaluated using samples from the 2008 and 2009 QCMD EQA 
Program for HHV-6, and was >95% accurate at detecting HHV-6 DNA. In one instance,  
the qPCR assay failed to detect HHV-6 DNA in s sample containing <2.0 x 10
2 
copies/mL, 
but others have described similar difficulties in reliably measuring DNA in samples with 
low HHV-6 DNA burdens (2.0 x 10
2
 to 1.0 x 10
3
 copies/mL) (5, 44, 52). Over-
quantification occurred in 68.7% of cases by approximately log10 0.14 (SD: 0.18), but 
overall, viral load results were comparable with other laboratory developed real-time qPCR 
assays.  
 
Application of the HHV-6 qPCR assay to the clinical group consisting of hospitalised 
HIV-infected individuals and paediatric liver transplant recipients showed that results were 
concordant with the HHV-6 DNA loads in the literature for liver transplant recipients (17, 
44, 53) and HIV-infected individuals (54). In the RRMS subjects, HHV-6 DNA loads 
varied from nil, to detectable, to persistently high, but were comparable with the viral load 
ranges for those previously reported in people with MS (55-57). In the Ausimmune Study 
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control participants, no significant differences in HHV-6 DNA positivity or load, or HHV-
6 IgM and IgG antibody titres were found by sex, study region or age (P > 0.05). In crude 
analyses, a higher HHV-6 DNA prevalence was noted in case participants with FCD 
compared with their matched controls (13.6% versus 7.3%), and cases were twice as likely 
to be HHV-6 DNA positive (OR = 2.17, CI 1.12 to 4.21, P = 0.02), suggesting that primary 
HHV-6 infection or reactivation of the virus could be involved in early CNS 
demyelination. This finding, however, requires further investigation in multivariate 
analyses and in other cohorts for confirmation. 
 
In The Ausimmune Study cases and controls, a significant positive correlation between 
increasing HHV-6 DNA load and HHV-6 IgG antibody titre (Spearman’s rho = 0.11; P = 
0.02) was also found, with the odds of having detectable HHV-6 DNA doubling with each 
HHV-6 IgG antibody titre increment (OR=2.01, 95% CI 1.13 to 3.58, P = 0.02). The 
detection of HHV-6 DNA in those with previous HHV-6 infection (i.e. HHV-6 IgG 
antibody positive) were also as expected, given that HHV-6 persists (either as free virions 
or integrated into host chromosomes) after primary infection and may be detectable in the 
blood (6), saliva (6) and CSF (58). Also, given that nearly all Ausimmune Study 
participants were previously infected with HHV-6 (as defined by high proportion of HHV-
6 IgG antibody positivity (96.3%), the presence of both DNA and HHV-6 IgG antibodies 
was not unusual. The clinical significance of the results in first CNS demyelination has yet 
to be established, with formal case-control analyses currently underway and a manuscript 
in preparation.  
 
 7.1.2 Genotyping 
For viruses to establish infection, they must first invade and overcome the host immune 
system. Although most of the time an effective response is mounted, some viruses are 
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capable of adjusting their genetic material by means of mutation, recombination, inversion 
and re-assortment, to circumvent the immune system and cause infection. Some mutations 
confer selective advantages and allow the virus to evade the cellular immune response 
(59), circumvent apoptosis (60) or replicate in the presence of antiviral drugs (61). Other 
mutations are neutral and do not induce phenotypic changes. Nonetheless, mutational 
studies are important as they provide valuable epidemiological data on viral evolution (e.g. 
lineage studies) and cellular function (e.g. protein synthesis) (62). 
 
Within the EBV and HHV-6 genomes, prominent sequence mutations divide the species 
into two distinct genotypes: EBV genotype A and B; and HHV-6 species A and B, each of 
which have been recognised to differ by geography (63, 64), disease association (54, 65, 
66), cellular and tissue tropism (67-70) and virulence (71, 72). In Chapter 6, the common 
EBV and HHV-6 genotypes and strains circulating in the clinical and research populations 
from previous chapters were explored.  
 
7.1.2.1 EBV genotyping 
In Publication 4, two EBV genotypes were described at different frequencies: genotype A 
(98.2%) and genotype B (1.8%). EBV genotype A was found in all study groups: The 
Ausimmune Study case and control participants, and those with various EBV-related 
infections (e.g. IM, EBVAHS, hepatitis, HIV and LPD). Genotype B was found in a single 
Ausimmune Study case participant. Three EBV genotype A strains were found at different 
frequencies: GD1 at 77.7%, followed by B95-8 at 16.7% and M-ABA at 5.6%. EBV 
genotype B was represented by the AG876 strain. EBV genotypes and strains were 
randomly disseminated amongst the different study groups (with the exception of genotype 
B, which was found in one FCD case), and thus, were speculated not to be restricted to a 
particular disease (73, 74).  
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7.1.2.2 HHV-6 genotyping 
In section 6.4, HHV-6 speciation and strain were investigated in The Ausimmune Study 
case and control participants, RRMS subjects from the Southern Tasmanian MSL Study 
and paediatric liver transplant recipients. Both HHV-6A and HHV-6B were isolated, each 
represented by a single strain, at different frequencies: HHV-6B HST (96.9%) and HHV-
6A U1102 (3.1%). The HST strain was found in all groups; strain U1102 was found in a 
single Ausimmune Study case participant. Similar to EBV genotypes, HHV-6 species and 
strains were widely distributed amongst the different study groups, and thus, were assumed 
not to be disease-specific. Detection of HHV-6B in the liver transplant recipients was in 
accordance with the literature (75, 76), but isolation of HHV-6B from the MSL RRMS 
subjects was unexpected compared with some studies (77, 78). However, given the small 
number of participant samples, the significance of this finding is uncertain. 
 
 7.1.3 Chapters 4 and 5 limitations 
There were difficulties comparing viral loads with other publications owing to the lack of 
qPCR standardisation and differences in methodologies. A review by Bustin et al, showed 
that most qPCR experiments in the literature were improperly validated and were not 
reproducible, and culminated in misleading and technically inadequate publications (79, 
80). In a concerted effort to safeguard qPCR as a robust, accurate and reliable technology, 
the MIQE guidelines were developed (81). Standardisation of qPCR work in this thesis 
was achieved through adherence to these guidelines. There is some controversy 
surrounding the adoption of the MIQE guidelines as there is reluctance to embrace the 
guidelines without agreement from the wider scientific community (79). The MIQE 
guidelines continue to evolve today as new recommendations are made (82, 83), and 
remain the only formal directive for qPCR publications.  
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Before standardisation can occur, variations inherent to qPCR including technical (e.g. 
specimen type, qPCR method, PCR target and reporting unit, pipetting errors) and 
biological (e.g. sequence polymorphism and stochasticity) variability must be addressed 
(84). Since biological variability is difficult to control, the focus must be on the regulation 
of technical variability such as specimen type, unit of measurement and the choice of 
qPCR target.  
 
The most suitable specimen type for qPCR testing has yet to be determined, and varies 
depending on the pathogen of interest as well as the disease. For EBV and HHV-6, 
unfractionated whole blood appears to be the most appropriate candidate given that blood 
is the site of viral persistence (85, 86). For EBV, EDTA whole blood is the most widely 
used sample type (87-90) and has been considered as the most reliable for qPCR, but for 
HHV-6, there is still uncertainty as to the preferred sample type. While HHV-6 infects 
epithelial and T cells (91), the virus also infects neuronal cells (92-94). Whether the low 
HHV-6 DNA prevalence in this study reflected the nature of pathology of the test subjects 
or the specimen type, is unknown. Thus, in Chapter 5, we proposed the investigation of 
pathology-appropriate specimens for future work (e.g. CSF for investigation of CNS 
demyelination). 
 
Adding to the controversy is the quantification of nucleic acids in tissue. Despite 
publications that have quantified viruses in biopsied tissue (21, 95-104), it has been 
articulated by some authors that this is not possible as quantification may be confounded 
by sampling error (105). Tissue samples are dynamic systems that are subject to spatial 
variability and heterogeneity, thus the amount of virus may vary depending on the location 
tested. That is, cross-sections from different parts of the same tissue may yield dissimilar 
viral loads. Often, initial volume of extracted tissue is not taken into consideration and 
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viral load is reported as copies per mL of sample. In such cases, it has been suggested that 
copies/µg of sample is more appropriate, but formal clarifications have yet to be made. In 
this thesis, tissues were quantified for HHV-6 DNA (and reported in copies/mL) in Chapter 
5, as it was the only sample accessible for analyses. 
 
While copies/mL is the most common reporting unit for EBV (25, 89) and HHV-6 DNA 
load (52, 106), qPCR data have also been expressed as copies/µg, copies/10
5
 PBMC cells 
and copies/10
6
 PBMC cells (89, 107). This made viral load comparisons across studies 
difficult in Chapters 4 and 5. This, however, is anticipated to change in the near future to 
reporting of International Units/mL with the introduction of the “International Biological 
Reference Preparations” or International Standards (IS) by the World Health Organisation 
(WHO) (108). Currently, IS provided by the WHO are available for hepatitis C (109), 
hepatitis B (110), HIV (111), parvovirus B19 (112) and human papilloma virus (113), and 
more recently, for CMV, polyoma (BK) virus and EBV by the U.S.A. National Institute of 
Standards and Technology (114).  
 
The choice of qPCR target is also important: viral load results and PCR sensitivity vary 
depending on the amplified gene target (98). However, the choice of qPCR target is 
difficult to regulate, as different laboratories have different perceptions as to which target 
is suitable. For the EBV work in this thesis, a previously published primer set was used 
(EBNA-1), coupled with the design of a novel qPCR target (BHRF-1). EBNA-1 has been 
the target of many qPCR studies (23, 98, 115), and thus provided a means to compare viral 
load results with the literature. In Chapter 4, selective drop out of gene targets was 
demonstrated, and highlighted the benefits of using two separate assays targeting two 
different genes (98). While the detection of a single gene was sufficient, it is unfortunate 
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that the same design was not applied for the HHV-6 qPCR assay. Again, it is hoped that 
implementation of IS will provide a resolution to this technical variability. 
Challenges also exist in quantifying samples with low-level viraemia, with the clinical 
significance of low viral burdens contributing to much uncertainty (116, 117). In a report 
by Smith et al, samples containing low-levels of target NA may not be reproducible if 
detected in repeated assays from the same or different sample (118). This is particularly 
common if the viral load is close to the limit of detection of the assay. For example, a 
patient sample may be a low positive (e.g. 2.0 x 10
2
 copies/mL), but when re-tested may be 
negative using the same or different sample. In such cases, confusion arises as low-levels 
of detected virus are indicative of true viraemia, but the absence of viral DNA cannot be 
considered as evidence of full viral suppression (119). While there were no data presented 
in this thesis, reproducibility of our assays was investigated in a sub-study of 15 duplicate 
Ausimmune Study samples (mix of cases and controls). Two separate qPCRs using the 
same or re-extracted sample generated different results (i.e. either positive or negative); 
concordance was only 8.3% (1 of 12 samples). In addition, subsequent qPCRs on the same 
sample yielded different DNA loads (e.g. 4.0 x 10
2
 versus 1.2 x 10
3
 copies/mL). This was 
attributed to low-level viraemia and was not explored further.  
 
While the in-house molecular assays developed in this thesis have proven useful and 
relevant for the investigation of EBV and HHV-6 DNA, they are expected to remain 
largely a research tool given the upcoming NPAAC guideline for in-house assays 
(‘Requirements for the Development and Use of In-House In Vitro Diagnostic Devices’) 
(120). At present, the guideline is under discussion and is in an initial draft form, but it is 
foreseeable that a number of laboratories will rely on using commercial kit-based in-vitro 
diagnostic assays given the many validation requirements (e.g. design, production, 
analytical and clinical etc.) and peer-reviewed scrutiny that will accompany in-house 
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assays. Thus, while the application of in-house assays may be limited in clinical diagnostic 
laboratories, there is undoubtedly (as demonstrated in our study) still a need for them in 
particular applications where high sensitivity is required for the detection of low-level 
virus, such as the project described in this thesis. 
 
 7.1.4 Chapter 6 limitations 
Limitations in Chapter 6 were mostly confined to the reference sequences used in our 
analyses. Accurate sequencing is dependent on chromatograph interpretation of nucleotide 
base peaks using specialised software. However, manual intervention for checking for 
base-calling errors is still necessary. As this involves a degree of subjectiveness, sequence 
determination may vary and in turn, lead to the deposition of inaccurate sequences into 
shared public domains (e.g. GenBank). As submitted sequences are not subject to peer-
scrutiny and deposition is open freely to all researchers, the accuracy of our analyses is 
dependent on the accuracy of the sequences deposited into GenBank, which are known to 
contain errors (121, 122). Thus, the EBV and HHV-6 genotypes presented in this thesis are 
a reflection of the current sequences in GenBank, and are subject to potential change as 
new strains become available (e.g. EBV HKNPC1 strain, GenBank accession: JQ009376, 
submitted  in November 2011) (123). Moreover, as genotyping studies sequence different 
gene regions and lengths, comparisons across studies may be difficult (124). In our study, 
gene targets were selected based on the literature. This may have somewhat limited our 
ability to define the full spectrum of virus diversity. However, diversity within DNA 
viruses (such as EBV or HHV-6) is less than that seen with RNA viruses (mostly owing to 
their superior proof-reading and repair capabilities of the polymerase enzymes) (62). Most 
genotyping studies target specific gene segments (66, 73, 125, 126). As sequencing 
technologies improve and costs decrease, analyses of whole genomes will become 
standard. Lastly, investigation of EBV and HHV-6 sequence mutations is often considered 
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less significant than for RNA viruses, but the expanded recognition of EBV and HHV-6-
associated diseases suggests an ongoing need for molecular studies (123, 124, 127, 128). 
  
7.2 Summary 
The molecular work produced in this thesis demonstrated that there was little evidence for 
an association between current markers of EBV infection (detection and load of EBV DNA 
in blood) and initial CNS demyelination. The HHV-6 DNA work suggested that HHV-6 
infection may be a risk factor for early CNS demyelination, but these findings require 
further investigations. Genotype characterisation contributed to an understanding of the 
circulating EBV and HHV-6 genotypes and strains, and provided an insight into the 
molecular diversity of the viral strains in Australia, of which there was little data. Overall, 
the work described here were achieved using sensitive and accurate methods that aligned 
with peer-reviewed guidelines. 
 
7.3 Future directions 
Future directions from the work undertaken in this thesis include examining EBV and 
HHV-6 DNA activity (positivity and load) using specimen types that are pathology-
appropriate (e.g. CSF for HHV-6). Investigation of multiple gene targets to maximise 
detection and overcome false negatives due to selective target drop out, should also be 
considered, particularly in individuals with low-level viraemia. In addition, ensuring that 
assays used in research studies meet the same level of performance, reliability and quality 
control as assays used for patient diagnosis, would improve comparisons between studies 
and laboratories. This requires consensus and adherence to a set of guidelines such as the 
MIQE and/or the use of an IS for all qPCR assays. To better assess the common EBV and 
HHV-6 genotypes and strains circulating in Australia, investigations into non-biased 
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samples from the general population (and from a wider geographic spread) would provide 
a more accurate detailed assessment. In those with CNS demyelination, genotyping of 
EBV and HHV-6 in other research groups, in large-scale studies and multi-centre 
evaluations would better define the genotypes. For example, genotyping EBV and/or 
HHV-6 in RRMS persons participating in The Southern Tasmanian MSL Study. If disease-
specific genotypes or strains are identified, then investigations into modes of cell entry (i.e. 
initiation of infection), pathogenesis and treatment responses would be warranted. The role 
of other herpesviruses (e.g. VZV and HSV) in first CNS demyelination should also be 
explored, as the literature shows mixed associations or little or no data. Part of this work 
has already been commenced through collaboration with Cheryl Toi (Senior Research 
Fellow at CIDM-PH, ICPMR, Westmead Hospital), with the examination of the role of 
another herpesvirus, VZV, in similar population groups to those examined in this thesis 
(Publication 5, Appendix 8G). Preliminary evidence suggests a lack of association between 
VZV DNA and initial CNS demyelination (Ausimmune Study cases versus controls: VZV 
positivity (P = 0.06) and VZV DNA load (P = 0.11)). Similar approaches with other 
viruses may better delineate the role of viruses in MS and related conditions. For example, 
a new potential candidate for exploration is the RNA virus, human endogenous retrovirus 
(HERV). To date, there is evidence linking different HERVs (e.g. HERV-W, HERV-K18, 
HERV-Fc1) with MS (129-131), but associations are mixed, laboratory techniques differ 
and data unreliable (132-134).  
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8.1 Appendix 8A: Products, reagents and solutions 
Table 34. List of product manufacturers and distributers  
(In ascending alphabetical and numerical order)  
 
Product     Cat #   Manufacturer     Distributor  
 
0.2 mL Flat Cap Tubes (Natural) AB-0620  ABgene
® 
Nucleic Acid   Integrated Sciences Pty. Ltd. 
        Amplification    54 Gibbs Streets 
             Chatswood, NSW, 2067 
 
100 bp DNA Ladder   15628-019   Life Technologies by Invitrogen™   Invitrogen Australia Pty. Ltd. 
             30-32 Compark Circuit 
             Mulgrave, VIC 3170 
 
1 mL Transfer Pipette Graduated 232-20S   Samco Scientific Corporation  LOMB Scientific    
Large Bulb Sterile Sleeves          26 Atkinson Road 
(Pastuer pipette)            Taren Point, NSW 2229    
         
50 bp DNA Ladder   10416-014  Life Technologies by Invitrogen™   Invitrogen Australia Pty. Ltd. 
30-32 Compark Circuit 
             Mulgrave, VIC 3170   
 
96-Position PCR Work-UP  5230-29   Scientific Specialties Incorporated  Astral Scientific Pty. Ltd 
              PO Box 232 
             Gymea, NSW 2227 
          
96-Well Microplate U/ Well    650101   Greiner Bio-One    Interpath Services Pty. Ltd. 
P = 100            80 Woodfield Boulevard 
Caringbah, NSW 2229 
 
Acetone (4 L)    JJ004   Fronine
 
Laboratory Supplies  Lomb Scientific 
             4/313-317 Arden Street 
             Kensington, VIC, 3031    
  
Agarose I™    0710-500G  Amresco® Incorporated   Austral Scientific Ptd. Ltd. 
             PO Box 232 
             Gymea, NSW 2227 
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Product     Cat #   Manufacturer     Distributor  
  
Ampicillin    10835269001  Boehringer Mannheim Biochemicals   Roche Diagnostics Pty. Ltd 
31 Victoria Avenue 
Castle Hill, NSW 2154 
 
AmpliTaq Gold
®
 DNA Polymerase 4311814   Life Technologies by Invitrogen
TM
  Invitrogen Australia Pty. Ltd. 
6 x 250 units with Gold Buffer and          30-32 Compark Circuit 
MgCl2 solution           Mulgrave, Victoria 3170 
          
Anti-human IgG (γ-chain specific), F1641   Sigma-Aldrich Pty. Ltd   Sigma-Aldrich Pty. Ltd 
F(ab’)2 fragment-FITC antibody         PO Box 970 
produced in goat           Castle Hill, Australia   
 
Axygen Filter Barrier Pipette Tips 10 µL TF-400-L-R-S  Axygen Scientific Inc.   Pacific Laboratory Products Pty. Ltd. 
             20 Highgate Street 
             Auburn, NSW 2144    
          
Barrier Tips, 20 µL, Racked,   BT20   Neptune™     Pathtech Pty. Ltd. 
Pre-sterilised, 960 Tips/pack          46 Swanston Street 
Neptune™ Barrier Tips          Preston, VIC 3072 
 
Barrier Tips, 200 µL, Racked,   BT200    Neptune™     Pathtech Pty. Ltd. 
Pre-sterilised, 960 Tips/pack          46 Swanston Street  
Neptune™ Barrier Tips           Preston, VIC 3072    
      
Barrier Tips, 1000 µL, Racked,  BT1000   Neptune™     Pathtech Pty. Ltd. 
Pre-sterilised, 480 Tips/pack          46 Swanston Street 
Neptune™ Barrier Tips          Preston, VIC 3072 
 
Beckmans DU 530 Spectrophotometer N/A   Beckman Coulter    Beckman Coulter Australia Pty. Ltd. 
(12.5 mm x 12.5 mm x 53 mm cuvette)         Unit D, 24 College Street  
               Gladesville, NSW, 2111 
 
Blue Max™ 50 mL Polypropylene  352070   Becton Dickinson   Becton Dickinson 
Conical (Falcon) Tube           Macquarie University Research Park 
North Ryde, NSW, 2113 
 
Blue/Orange Loading Dye 6x  G1881   Promega Corporation   Promega Corporation 
37 Nelson Street 
             Annandale, NSW 2038 
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Coverslips    CS256010  Menzel-Gläser    Lomb Scientific 
             26 Atkinson Road 
             Taren Point, NSW, 2229 
 
Dimethyl sulfoxide (DMSO)   D9170   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd 
             PO Box 970 
Castle Hill, NSW 1765 
 
Eagle’s Minimum Essential Medium M0275   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd 
+ 10% FCS             PO Box 970 
             Castle Hill, NSW 1765 
 
EBV NA IgG ACIF   GEN100  Merifluor
®    
Oxoid Australia Pty. Ltd. 
20 Dalgleish Street 
             Thebarton, SA 5031    
   
eLine Single Channel   73002X   Biohit Oyj    Biolab Australia 
0.2-10 µL Pipettor           2 Clayton Road 
             Clayton, VIC 3168 
 
eLine Single Channel   73006X   Biohit Oyj    Biolab Australia 
10-300 µL Pipettor           2 Clayton Road 
             Clayton, VIC 3168 
 
Eppendorf 5810R Centrifuge   5811000010  Eppendorf South Pacific Pty. Ltd.  Eppendorf South Pacific Pty. Ltd. 
             Unit 4, 112 Talavera Road 
             North Ryde, NSW 2113 
 
Eppendorf Mastercycler
®
 Gradient  5331000010  Eppendorf South Pacific Pty. Ltd.  Eppendorf South Pacific Pty. Ltd. 
Instrument            Unit 4, 112 Talavera Road 
             North Ryde, NSW 2113 
 
Ethanol Absolute Univar  0901212   Ajax Finechem    Crown Scientific Pty. Ltd. 
             Unit 1, 21 Huntsmore Road  
Minto, NSW 2566 
 
EvaGreenTM Dye, 20X in water 31000/31000-T  Biotium Incorporated   Gene Target Solutions Pty Ltd 
Unit 33a 280 New Line Rd 
Dural, NSW, 2158 
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ExoSAP-IT
®
 For PCR Product Clean-Up US70995  USB Corporation    GE Healthcare Bio-Sciences Pty. Ltd.   
             Building 4B, 21 South Street 
             Rydalmere, NSW 2116 
                
FITC conjugated and    F1641   Sigma-Aldrich Pty. Ltd   Sigma-Aldrich Pty. Ltd 
human IgG (γ chain)            PO Box 970 
Castle Hill, NSW 1765 
 
Foetal Bovine (Calf) Serum  SFBS   Bovogen Biologicals Pty. Ltd.  DKSH 
             14-17 Dansu Court 
             Hallam, VIC 3803 
 
GenElute™ Mammalian Genomic G1N350   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd.  
DNA MiniPrep Kit            PO Box 970 
             Castle Hill, NSW 1765 
 
Gull Sorb IgG Inactivation Reagent GXX715  Meridian Biosciences Inc.   Oxoid Australia Pty. Ltd. 
20 Dalgleish Street 
             Thebarton, SA 5031 
 
Human Herpesvirus 6 IgG   I-HV601G  Inverness Medical Innovations  Inverness Medical Innov. Pty. Ltd. 
             532 Seventeen Mile Rocks Road 
Sinnamon Park, QLD 4073  
 
Human Herpesvirus 6 IgM  I-HV601M   Inverness Medical Innovations  Inverness Medical Innov. Pty. Ltd. 
             532 Seventeen Mile Rocks Road 
             Sinnamon Park, QLD 4073 
              
IPTG     15529-019   Life Technologies by Invitrogen™  Invitrogen Australia Pty. Ltd 
             30-32 Compark Circuit 
             Mulgrave, VIC, 3170 
 
Isopropanol Univar   AH410198  Ajax Finechem    Crown Scientific Pty. Ltd. 
             Unit 1, 21 Huntsmore Road 
             Minto, NSW 2566 
 
JM109 Competent Cells, High  L2004   Promega Corporation   Promega Corporation  
Efficiency             37 Nelson Street 
             Annandale, NSW 2038 
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LB (Luria-Bertani) Broth  244510    BD Difco™    Becton Dickinson 
             Macquarie University Research Park 
North Ryde, NSW, 2113   
 
LC Green
®
 Plus+ Melting Dye  BCHM-ASY- 0005 Idaho Technology Inc.   John Morris Scientific 
             61-63 Victoria Avenue 
             Chatswood, NSW 2067 
 
LightCycler
®
 FastStart DNA Master 12239264001  Roche Diagnostics Pty. Ltd   Roche Diagnostics Pty. Ltd. 
SYBR Green I           31 Victoria Avenue 
Castle Hill, NSW 2154 
 
Methanol    10158 (6B)  LabServ
®
    ThermoFisher Scientific Pty. Ltd.   
             5 Caribbean Drive 
             Scoresby, VIC, 3179 
 
Microscope Slides   R-MIC-024  Menzel-Glasner
®
    PathTec Pty. Ltd. 
             46 Swanston Street 
             Preston, VIC, 3072 
 
Minisart
®
 Single Use Filter  16532   Sartorius Stedim Biotech   Sartorius Stedim Australia Pty. Ltd. 
Sterile-EO, non-pyrogenic hydrophilic         Unit 17/104 Ferntree Gully Road 
             East Oakleigh, VIC 3166    
             
NucliSens EasyMAG   200111   bioMérieux Australia Pty. Ltd.  bioMérieux Australia Pty. Ltd 
Unit 25, Parkview Business Centre 
             1 Maitland Place 
             Baulkham Hills, NSW 2153 
 
Oligonucleotide primers  Custom order  Life Technologies by Invitrogen™  Invitrogen Australia Pty. Ltd 
             30-32 Compark Circuit 
             Mulgrave, VIC, 3170 
 
Penicillin-Streptomycin  P4458   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd. 
50X, liquid, stabilized, sterile-filtered,          PO Box 970 
cell cultured tested           Castle Hill, NSW 1765 
 
pGEM
®
-T and pGEM
®
-T Easy Vector  A1380   Promega Corporation   Promega Corporation 
Systems            PO Box 168 
             Annandale, NSW 2038 
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Phosphate Buffered Saline (PBS) P4417-100TAB   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd. 
             PO Box 970 
             Castle Hill, NSW 176 
 
Phosphonoacetic acid (PAA)  P3523   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd. 
             PO Box 970 
             Castle Hill, NSW 1765 
 
Pipetman
®
 P10   F144802  Gilson Incorporated   John Morris Scientific 
1-10 µL            61-63 Victoria Avenue 
             Chatswood, NSW 2067 
 
Pipetman
®
 P20   F123600  Gilson Incorporated   John Morris Scientific 
2-20 µL            61-63 Victoria Avenue 
             Chatswood, NSW 2067 
 
Pipetman
®
 P200   F123601  Gilson Incorporated   John Morris Scientific 
50-200 µL            61-63 Victoria Avenue 
             Chatswood, NSW 2067 
 
Pipetman
®
 P1000   F123600  Gilson Incorporated   John Morris Scientific 
200-1000 µL            61-63 Victoria Avenue 
             Chatswood, NSW 2067 
 
Platinum
®
Taq DNA Polymerase 10966-018  Life Technologies by Invitrogen
TM
  Invitrogen Australia Pty Ltd. 
             30-32 Compark Circuit  
             Mulgrave, Victoria 3170 
 
Powder Free Textured Latex  PFLMSH-XS  Mediflex Industries Ptd. Ltd.  Mediflex Industries Pty. Ltd. 
Examination Gloves (X-Small)          Unit 1, 97 Banksia Street  
             Botany, NSW 2019 
 
PureYield™ Plasmid Midiprep  A2492   Promega Corporation   Promega Corporation 
System 25 preps            37 Nelson Street 
             Annandale, NSW 2038 
 
QIAamp DNA Mini Kit  51304   Qiagen Pty. Ltd.    Qiagen 
PO Box 641 
Doncaster, Victoria 3108 
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Rotor-Gene 6000
TM
 Instrument  9001656   Qiagen Pty. Ltd.    Qiagen 
(formerly Corbett Research)           PO Box 641 
Doncaster ,Victoria 3108  
                  
RPMI 1640 Medium Modified  51536C   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd. 
With 2.05 mM L-glutamine, with    (previously Fisher Scientific)  PO Box 970  
25 mM HEPES Liquid Medium          Castle Hill, NSW 1765 
 
RPMI 1640 Medium    51501C   Sigma-Aldrich Pty. Ltd.   Sigma-Aldrich Pty. Ltd. 
With 2.05 mM L-glutamine     (previously Fisher Scientific)  PO Box 970  
Liquid Medium           Castle Hill, NSW 1765    
    
Safe-Lock Tubes 1,5 mL  0030 120.086  Eppendorf South Pacific   Eppendorf South Pacific 
Unit 4, 112 Talavera Road 
             North Ryde, NSW 2113 
 
Safe-Lock Tubes 2,0 mL  0030 120.094   Eppendorf South Pacific   Eppendorf South Pacific 
Unit 4, 112 Talavera Road 
             North Ryde, NSW 2113 
 
Sealing Film Parafilm   PM-996   Parafilm
®    
LOMB Scientific 
4 in. X 125 Ft. Roll           26 Atkinson Road 
10 cm x 38 cm           Taren Point, NSW, 2229 
 
Sigma 4K15    N/A   Sigma-Aldrich Pty. Ltd   Sigma-Aldrich Pty. Ltd 
(11150, Swing-out rotor Centrifuge         PO Box 970 
rotors)            Castle Hill, NSW 1765 
 
S.O.C medium   15544-034  Life Technologies by Invitrogen
TM
  Invitrogen Australia Pty. Ltd. 
             30-32 Compark Circuit 
             Mulgrave, Victoria, 3170 
 
Sodium Hypochlorite Solution  6401-OGC  IDL Chemicals Pty. Ltd.   IDL Chemicals Pty. Ltd. 
12.5% w/v (5 L)           80 Hassall Street 
             Smithfield, NSW 2164 
 
Sterile Water for Irrigation  2F7114   Baxter Pty. Ltd.    Baxter Healthcare Pty. Ltd.  
1000 mL, USP, Plastic Pour Bottle          1 Baxter Drive    
Container            Old Toongabbie, NSW 2146 
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Product     Cat #   Manufacturer     Distributor  
                  
SYBR
®
 Safe DNA Gel Stain   S33102   Life Technologies by Invitrogen™  Invitrogen Australia Pty. Ltd. 
10,000X concentrate in DMSO          30-32 Compark Circuit 
             Mulgrave, Victoria, 3170  
 
SYBR Green I Nucleic Acid Gel Stain S7563   Molecular Probes Inc.    Invitrogen Australia Pty. Ltd 
by Invitrogen™            30-32 Compark Circuit 
             Mulgrave, Victoria, 3170  
               
TBE, 5X Liquid Concentrate  J885-4   Amresco
®    
Astral Scientific Pty. Ltd. 
             PO Box 232 
             Gymea, NSW 2227 
 
Trace Klean
TM
 Concentrated Solution 598190    Fisher Scientific    ThermoFisher Scientific Pty. Ltd. 
(previously Beckman Coulter Inc.,         5 Caribbean Drive  
589784)            Scoresby, VIC, 3179  
  
UV Transilluminator   P/UV95-0452-02  PathTec Pty. Ltd.    PathTec Pty. Ltd. 
             46 Swanston Street 
             Preston, VIC, 3072 
 
Water Molecular Biology Reagent W4502   Sigma-Aldrich Pty. Ltd   Sigma-Aldrich Pty. Ltd 
PO Box 970 
             Castle Hill, NSW 1765 
 
X-Gal (100 mg)   15520-034  Life Technologies by Invitrogen™   Invitrogen Australia Pty. Ltd. 
             30-32 Compark Circuit 
             Mulgrave, Victoria, 3170 
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8.2 Appendix 8B: Reagents and solution recipes 
Table 35. List of reagents and solution recipes 
Reagent/solution    Composition  Instructions/storage conditions 
0.25X TBE electrophoresis buffer     25°C (room temperature), made weekly 
TBE, 5X Liquid Concentrate   50 mL  
MQ water     950 mL  
 
1:20 SYBR
®
 Safe DNA Gel Stain       25°C (room temperature), away from direct sunlight, made weekly 
SYBR
®
 Safe DNA Gel Stain   100 µL      
TBE, 5X liquid concentrate   100 mL 
MQ water      900 mL 
 
100 bp DNA ladder       -20°C in 50 µL aliquots 
Blue/Orange Loading Dye 6x   200 µL 
MQ water     800 µL 
 
IPTG stock solution    1.0 g   4°C 
MQ water     50 mL   
     
LB broth with ampicillin       37°C made as needed    
LB agar      40.0 g          
MQ water     1 L  
Ampicillin     200 µL 
 
LB plate with ampicillin       4°C up to 1 month or room temperature for one week 
Agar     8.0 g 
LB medium     200 mL 
100 µg/µL ampicillin    200 µL   
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Reagent/solution    Composition  Instructions/storage conditions 
LB plate with ampicillin/IPTG/X-Gal     Spread IPTG and X-gal over agar surface and allow to 
Agar     8.0 g   absorb for 30 min at 37°C prior to use 
LB medium     200 mL       
100 µg/µL ampicillin   200 µL 
100 mM IPTG    20 µL  
50 mg/mL X-Gal    50 µL  
 
Phosphonoacetic acid (PAA)      -20°C in 20 mL aliquots 
0.4 mM PAA    0.56 g        
MQ water     1 L 
 
RPMI 1640 Medium     500 mL   2 to 8°C 
Foetal bovine serum (20%)   100 mL 
Penicillin-streptomycin   10 mL 
 
RPMI 1640 Medium Modified   500 mL   2 to 8°C 
Foetal bovine serum (10%)   50 mL 
Penicillin-streptomycin   10 mL 
          
SOC medium     3 g   Dissolve and stir SOC medium in MQ water. Autoclave and 
MQ water     97 mL   cool to room temperature. Store at -20°C 
         
X-Gal         
5-bromo-4-chloro-3-indolyl-β-D-galactoside 100 mg   -20°C cover with aluminium foil  
N, N’-dimethyl-formamide   2 mL 
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8.3 Appendix 8C: pGEM®-T Easy Vector Plasmid Map 
and plasmid constructs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. pGEM
®
-T Easy Vector map, sequence and cloning reference points 
(i) Vector map and sequence reference points; (ii) Promoter and multiple cloning sequence sites: top strand 
corresponds to the RNA synthesised by T7 RNA polymerase; bottom strand corresponds to the RNA 
synthesised by SP6 RNA polymerase; (cloned insert) shows site of inserted plasmid construct. 
T7 RNA polymerase transcription initiation site 1 
multiple cloning region 10-128 
SP6 RNA polymerase promoter (-17 to +3) 139-158 
SP6 RNA polymerase transcription initiation site 141 
pUC/M13 Reverse Sequencing Primer binding site 176-197 
lacZ start codon 180 
lac operator 200-216 
β-lactamase coding region 1337-2197 
phage f1 region 2380-2835 
Lac operon sequences 2836-2996, 166-395 
pUC/M13 Forward Sequencing Primer binding site 2949-2972 
T7 RNA polymerase promoter (-17 to +3) 2999-3 
(i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(ii) 
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Figure 28. pGEM
®
-T Easy Vector plasmid constructs for HHV-6 and β-globin qPCR 
(i) HHV-6 plasmid construct with 223 bp product insert; (ii) β-globin plasmid construct with 299 bp product 
insert. EBV plasmid constructs shown in Lay et al, 2010 (Publication 2, page 4, Figure 1).  
Figures 27 and 28 images reproduced and modified from the Promega pGEM
®
-T and pGEM
®
-T Easy Vector 
System Technical Manual (revised 12/2005).
(i) 
 
 
 
 
 
 
 
 
(ii) 
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8.4 Appendix 8D: Programs and software 
Table 36. List of programs and software 
Program/software   Description       Version (year)   Reference  
BioEdit    Biological sequence alignment editor    v7.0.5.3 (2005)   (1) 
    
Endnote   Tool for publishing and managing bibliographies   X5, Build 5478 (1988-2011) (2) 
                 
FastPCR   Program for designing primers for PCR applications   v6.1.63, Beta 3 (2011)  (3-5) 
          
GraphPad Prism 4  Tool for basic biostatistics, curve fitting and scientific graphing  v4.03 (1994-2003)  (6)  
  
MEGA4, MEGA5   Molecular evolutionary genetics analysis tool   M4.1, Beta 3, Build 4153  (7, 8)   
            (1993-2008)  
 
Microsoft Professional   A commercial office suite of inter-related desktop applications  v14.0.5128.5000, 32-bit  (9), Microsoft
® 
 
Plus (Word and Excel)          (2010)       
 
Rotor-Gene
TM 
6000  Real-time rotary analyser      v1.7, Build 87 (1990-1999) Qiagen Pty. Ltd. 
              
SPSS    Statistical Package for the Social Sciences     v17 (2008)   (10), IBM
®
  
  
STATA    Data analysis and statistics software    v9.2 (2006)   STATA
® 
 
References: 1. Hall TA. BioEdit: A user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucleic Acids Symposium Series. 1999;41:95-98. 2. 
Endnote. Available from: http://www.endnote.com/. 3. FastPCR. [updated 15/02/2011; cited 2006-2010]; Available from: http://primerdigital.com/fastpcr.html. 4. Kalendar R, Lee D, Schulman 
AH. FastPCR software for PCR primer and probe design and repeat search. Genes, Genomes and Genomics. 2009;3(1):1-14. 5. Kalendar R, Lee D, Schulman AH. Java web tools for PCR, in 
silico PCR, and oligonucleotide assembly and analysis. Genomics. 2011;98(2):137-144. 6. GraphPad Prism. Available from: http://www.graphpad.com/quickcalcs/index.cfm. 7. Tamura K, 
Dudley J, Nei M, Kumar S. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Molecular Biology and Evolution. 2007;24(8):1596-1599. 8. Tamura K, Peterson D, 
Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular 
Biology and Evolution. 2011;28(10):2731-2739. 9. Microsoft office. [cited 2010]; Available from: http://office.microsoft.com/en-au/. 10. SPSS. Available from: http://www-
01.ibm.com/software/au/analytics/spss/.
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8.5 Appendix 8E: The Ausimmune Study 
Collaborative Framework Agreement 
 
 268 
  
 
 
 269 
  
 
 
 270 
  
 
 
 271 
  
 
 
 272 
  
 
 
 273 
  
 
 
 274 
  
 
 
 275 
  
 
 
 276 
  
 
 
 277 
  
 
 
 278 
  
 
 
 279 
  
 
 
 280 
  
 
 
281 
 
282 
 
8.6 Appendix 8F: Nucleotide BLAST search examples for EBV and HHV-6 strains 
(i) 
 
(ii) 
 
 
 
 
(iii) 
 
 
(iv) 
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(v) 
 
(vi) 
 
 
Figure 29. Examples of nucleotide BLAST searches for EBV and HHV-6 returned sequences 
Sequence strains identified in this thesis include: (i) EBV GD1; (ii) EBV B95-8; (iii) EBV M-ABA; (iv) EBV AG876; (v) HHV-6 HST and (vi) HHV-6 U1102.  
Note: A standard nucleotide BLAST search was completed for each returned sequence at http://blast.ncbi.nlm.nih.gov/Blast.cgi. by selecting the following parameters: Basic 
BLAST > Nucleotide BLAST (Search a nucleotide database using a nucleotide query) > Choose Search Set (Database: Others (nr etc.) > Program Selection (Optimize for: 
Highly similar sequences (Megablast). Top strand (Query) is compared with the bottom strand (Sbject). That is, the unknown nucleotide sequence is compared with submitted 
nucleotide sequences for organisms in the GenBank database to give the closest percentage match.
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8.7 Appendix 8G: Publication 5 (Toi et al, 2013) 
Toi et al, 2013 is a collaborative article that builds on the EBV and HHV-6 DNA work in 
this thesis. By employing similar methods in Chapters 4 and 5, this manuscript describes 
the development of a VZV qPCR assay using EvaGreen
®
 fluorescent dye for the detection 
and quantification of VZV DNA in various sample types. Two populations divided into 4 
groups were tested: Group 1 (VZV symptomatic), hospitalised patients with VZV 
infection; Groups 2, 3 and 4 (VZV asymptomatic): participants with a FCD of CNS 
demyelination, control participants without CNS demyelination (cases and controls from 
the Ausimmune Study viral sub-study), and individuals with HIV infection, respectively. 
The group with the highest proportion of VZV DNA was Group 1 (hospitalised VZV-
infected patients) at 100% (n = 10/10 at 4.6×10
6 
± 1.4×10
7 
copies/mL) followed by Group 
4 (HIV infection) at 12% (n = 6/50 at 7.7×10
1
 ± 2.8×10
2
 copies/mL). Of the Ausimmune 
Study participants, VZV DNA was detected at a higher proportion of samples from the 
control group (Group 3; 8%, n = 17/218 at 1.1×10
3
 ±7.8×10
3
 copies/mL) compared to case 
participants with first CNS demyelination (4%, n = 9/213 at 1.5×10
3
 ± 1.8×10
4
 copies/mL). 
VZV DNA loads were significantly higher in the symptomatic group compared with the 
asymptomatic groups (P<0.001); no statistically significant differences were found 
between the asymptomatic Groups 2, 3 and 4 (P=0.05). Additionally, there was no 
significant correlation between VZV DNA load and VZV IgG antibody titres (measured in 
Group 3). Genotypic analysis of the ORF22 revealed five VZV clades, with clade 1 the 
commonest circulating VZV strain. Overall, this article showed that while VZV was 
detectable in asymptomatic individuals, the frequency and DNA load were lower in 
comparison with symptomatic individuals with VZV infection.  
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 8.7.1 Publication 5 authorship 
Cheryl S. Toi 
 
Meav-Lang J. Lay 
 
 
Robyn M. Lucas Choo Beng Chew 
Janette Taylor Anne-Louise Ponsonby 
 Dominic E. Dwyer   
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